UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): February 24, 2015
REAL GOODS SOLAR, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Colorado |
|
001-34044 |
|
26-1851813 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
833 West South Boulder Road, Louisville, CO 80027-2452
(Address of Principal Executive Offices, Including Zip Code)
Registrants telephone number, including area code: (303) 222-8300
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 |
Entry into a Material Definitive Agreement. |
Public Offering
On February 23, 2015, Real Goods Solar, Inc. (the Company), entered into a Securities Purchase Agreement (the
Purchase Agreement) with one institutional and accredited investor (the Institutional Investor). Pursuant to the terms of the Purchase Agreement, the Company will sell to the Institutional Investor $2,750,000 of units of the
Companys Class A common stock, par value $0.001 per share, (the Common Stock), and warrants (each, a Unit). On the same day, the Company agreed to sell $750,000 of Units to public investors. The purchase price for
each Unit is $0.50.
Each Unit consists of: (i) one share of Common Stock; (ii) a Series A Warrant to purchase share of the
Companys Common Stock equal to 50% of the sum of the number of shares of Common stock purchased as part of the Units plus, if applicable, the number of shares of Common Stock issuable upon exercise in full of the Series E Warrants (without
regard to any limitations on exercise) described below; (iii) a Series B Warrant to purchase shares of the Companys Common Stock for a stated amount (as described below); (iv) a Series C Warrant to purchase up to 50% of
that number of shares of Common Stock actually issued upon exercise of the Series B Warrant; and (v) a Series D Warrant to purchase additional shares of Common Stock in an amount determined on a future reset date after the issuance of the
Series D Warrant.
In addition, in the event that an investor, together with certain attribution parties, would beneficially
own in excess of 4.99% of the number of shares of Common Stock outstanding immediately after the closing of the offering as a result of its purchase of Units, the Company will issue to such investor shares of Common Stock in an amount up to such
4.99% cap and a Series E Warrant to purchase the balance of the shares of Common Stock the investor would have received at closing but for the 4.99% cap.
The closing of the offering is expected to occur on or before February 27, 2015, with respect to the Purchase Agreement, subject to the
satisfaction of certain customary closing conditions.
The Company offered and sold the Units, the shares of Commons Stock and the
warrants issued as part of the Units, and the shares of Common Stock issuable upon exercise of the warrants issued as part of the Units pursuant to an effective registration statement on Form S-3 (File No. 333-193718).
The Company expects to receive net proceeds of approximately $2.7 million at the closing, after deducting commissions to the Placement Agent
and estimated offering expenses payable by the Company associated with the offering.
The Company has agreed to maintain an effective
registration statement covering the issuance of the Common Stock issuable upon exercise of the Series A Warrants, the Series B Warrants, the Series C Warrants, the Series D Warrants and the Series E Warrants (collectively, the Warrants).
The Units will not be issued or certificated. The Warrants will be issued in physical form separately from the Common Stock included in
the Units and may be transferred separately immediately thereafter (other than the Series B Warrants and the Series C Warrants, as described below). The Warrants will not be listed on any national securities exchange or other trading market, and no
trading market for the Warrants is expected to develop.
Terms of the Warrants
Terms of the Series A Warrants
Each Unit contains a Series A Warrant to purchase shares of the Companys Common Stock equal to 50% of the sum of the number of shares of
Common Stock purchased as part of the Units plus, if applicable, the number of shares of Common Stock issuable upon exercise in full of the Series E Warrants (without regard to any limitations on exercise). The Series A Warrants will be exercisable
beginning on the six month anniversary after issuance and will expire five years following the initial exercisability date. The initial exercise price of the Series A Warrants is $0.50, subject to adjustments for stock splits and similar events.
Also, if after issuance of the Series A Warrants the Company publicly announces the issuance or sale, issues or sells, or is deemed to have issued or sold, any shares of Common Stock for consideration per share less than the exercise price in effect
at the time, then the exercise price then in effect shall be reduced to an amount equal to such per share consideration. Under certain circumstances, the holders of the Series A Warrants may elect to exercise them through a cashless exercise, in
which case the holders
will receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in the Series A Warrant and the Company will not receive the
exercise price. Upon the occurrence of certain fundamental transactions (as defined in the Series A Warrants) or if the Company is unable to obtain the shareholder approvals described below, the holders of the Series A Warrants may
request that the Company purchase the Series A Warrants in cash for an amount equal to the Black Scholes value of the remaining unexercised portion of the Series A Warrants.
If all of the Series A Warrants are exercised for cash at the initial exercise price, the Company would receive additional gross proceeds of
approximately $1.75 million. There can be no assurance that the holders of the Series A Warrant will exercise their warrants for cash.
Terms of the Series B Warrants
Each Unit contains a Series B Warrant to purchase shares of Common Stock in a stated amount equal to the investors pro rata share of
$8,000,000 based on the purchase price paid by each investor for the Units. The number of shares of Common Stock initially issuable upon exercise of a Series B Warrant will be equal to the quotient resulting from dividing the stated amount by the
lower of (i) $0.50 per share, and (ii) in the case of (x) a mandatory exercise (as described below), 85% of the lowest volume weighted average price of the Common Stock during the three consecutive trading days immediately following
the date of the investors receipt of a mandatory exercise notice from the Company, and (y) a voluntary exercise by an investor or otherwise, 85% of the lowest volume weighted average price of the Common Stock during the three consecutive
trading days immediately before the date of the applicable exercise notice or other date of determination. The Series B Warrants are immediately exercisable and will expire 12 months after the later of (i) the issuance date, and (ii) the
date as of which (x) the Company has obtained the shareholder approvals described below, and (y) the date the holders may freely sell all the shares underlying the Series B Warrants. At any time after March 30, 2015, the Company may elect
to force a mandatory exercise of the Series B Warrants, subject to certain equity conditions. If a holder does not pay the exercise price to the Company within 4 days after receiving a mandatory exercise notice, the portion of such holders
Series B Warrant subject to the mandatory exercise notice will expire unexercised. Notwithstanding the foregoing, under the terms of the Purchase Agreement, the Institutional Investor has covenanted to honor its obligation to pay the exercise price
upon a mandatory exercise of the Series B Warrants. Under certain circumstances, the holders of the Series B Warrants may elect to exercise them through a cashless exercise, in which case the holders will receive upon such exercise the net
number of shares of Common Stock determined according to the formula set forth in the Series B Warrant and the Company will not receive the exercise price. Upon the occurrence of certain fundamental transactions (as defined in the
Series B Warrants) or if the Company is unable to obtain the shareholder approvals described below, the holders of the Series B Warrants may request that the Company purchase the Series B Warrants in cash for an amount equal to 8% of the stated
value of the remaining unexercised portion of the Series B Warrants. Holders of the Series B Warrants may not transfer them without the Companys consent until the first anniversary of issuance and, in all cases, must transfer them together
with a corresponding portion of the Series C Warrants.
If all of the Series B Warrants are exercised for cash at the initial exercise
price, the Company would receive additional gross proceeds of approximately $8.0 million. There can be no assurance that the holders of the Series B Warrant will exercise their warrants for cash, or that the Company will be able to satisfy the
conditions to a mandatory exercise in the future.
Terms of the Series C Warrants
Each Unit contains a Series C Warrant entitling the holder to purchase up to 50% of that number of shares of Common Stock actually issued upon
exercise of the holders Series B Warrant, at an initial exercise price of $0.50 per share. The Series C Warrants will be exercisable beginning on the six month anniversary after issuance and will expire five years following the initial
exercisability date. Holders of the Series C Warrants may not transfer them without the Companys consent until the first anniversary of issuance and, in all cases, must transfer them together with a corresponding portion of the Series B
Warrants. Other than as described in this paragraph, the terms of the Series C Warrants are substantially the same as the terms of the Series A Warrants.
If following full exercise of the Series B Warrants, all of the Series C Warrants are exercised for cash at the initial exercise price, the
Company would receive additional gross proceeds of approximately $4.0 million. There can be no assurance that the holders of the Series C Warrant will exercise their warrants for cash.
Terms of the Series D Warrants
Each Unit contains a Series D Warrant. The shares of Common Stock initially issuable under a Series D Warrant will be zero and such number will
be increased, if at all, to the number of shares the holder would have received at closing had the per Unit price at closing been equal to a reset price calculated on March 13, 2015, minus the number of shares received at closing,
and, in the case of an investor who received a Series E Warrant in the offering, the number of share of Common Stock underlying such Series E Warrant. The reset price will be equal to 85% of the arithmetic average of the three lowest volume-weighted
average prices of the Common Stock during the period commencing on February 23, 2015 and ending on March 13, 2015. The Series D Warrants are immediately exercisable at an exercise price of $0.0001 per share and expire on April 12,
2015, subject to extension. Pursuant to an automatic exercise feature in the Series D Warrants, on March 16, 2015, the Company is obligated to issue to the holders pursuant to a cashless exercise, without the delivery of an exercise notice by
the holders, the maximum number of shares of Common Stock the Company has authorized and available for issuance and allocated to the Series D Warrants by their terms, subject to the beneficial ownership limitation described below. The holders of the
Series D Warrants may elect to exercise them through a cashless exercise, in which case the holders will receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in the Series D
Warrant and the Company will not receive the exercise price. The Company anticipates no meaningful proceeds from the exercise of the Series D Warrants.
Terms of the Series E Warrants
An investors who, together with certain attribution parties, would beneficially own in excess of 4.99% of the number of shares of
Common Stock outstanding immediately after the closing as a result of its purchase of Units, will receive shares of Common Stock in an amount up to such 4.99% cap and a Series E Warrant to purchase the balance of the shares of Common Stock the
investor would have received at closing but for the 4.99% cap. The Series E Warrants are immediately exercisable at an exercise price of $0.0001 per share and expire on April 12, 2015, subject to extension. The holders of the Series E Warrants
may elect to exercise them through a cashless exercise, in which case the holders will receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in the Series E Warrant and the
Company will not receive the exercise price. The Company anticipates no meaningful proceeds from the exercise of the Series E Warrants.
Limitation on Exercise of the Warrants
A holder may not exercise any of the Warrants and the Company may not issue shares of Common Stock upon exercise of any of the Warrants if,
after giving effect to the exercise or issuance, the holder together with is attribution parties, would beneficially own in excess of 9.99% of the outstanding shares of Common Stock. At each holders option, the cap may be increased
or decrease to any other percentage not in excess of 9.99%, except that any increase will not be effective until the 61st day after notice to the Company.
Additional Terms of the Purchase Agreement
Under certain circumstances, if the Company is unable to issue shares upon exercise of the Warrants, for example because of the Companys
failure to maintain an effective registration statement covering the issuance of the Common Stock issuable upon exercise of the Warrants, then the Company must pay to the Institutional Investor an amount in cash equal to 1% of the sum of
(i) the aggregate purchase price of the Institutional Investors Units, and (ii) the aggregate exercise price paid by the Institutional Investor for the exercise of the Series B Warrants, on the initial day of the issuance failure and
on every 30th day thereafter until the issuance failure is cured. The Company shall also pay the reasonable fees of legal counsel of the Institutional Investor to enforce this provision.
The Company is obligated to reimburse the Institutional Investor for costs and expenses incurred in connection with the Purchase Agreement in
an amount not to exceed $170,000, which amount, at the option of the Institutional Investor, may be withheld from its purchase price at closing.
The Company has agreed to not issue any additional Warrants offered in this offering in the future so long as the Institutional Investor owns
any of the securities purchased as part of the Units or any of the shares of Common Stock underlying the Warrants. Further, during the six month period following the closing, the Company may not issue or sell any rights, warrants or options to
subscribe for or purchase Common Stock or directly or indirectly convertible into or exchangeable or exercisable for Common Stock at a price which varies or may vary with the market price of the Common Stock, unless the conversion, exchange or
exercise price of any such security cannot be less than the then applicable fixed exercise price of the Series A Warrants, the Series B Warrants and the Series C Warrants.
The Purchase Agreement prohibits the Company from issuing equity securities or securities
convertible or exercisable into equity securities and to grant certain registration rights during the period beginning on February 23, 2015 and ending on the first day after the 30th days after obtaining the shareholder approvals described
below on which there is no equity conditions failure (as defined in the Series B Warrants). The Purchase Agreement also prohibits the Company from being part of any solicitations, negotiations or discussions with regard to these matters
during portions of that time period.
The Purchase Agreement grants the Institutional Investor a participation right whereby the
Institutional Investor has the right to participate for up to 40% of any future offering of securities of the Company, other than certain excluded securities (as defined in the Series A Warrants, the Series B Warrants and the Series C
Warrants) until the two year anniversary of the closing date of the offering.
The Company is obligated to seek shareholder approval for
(i) a reverse stock split of the Common Stock to cause it to become compliant again with the NASDAQ continued listing requirements, and (ii) an amendment to its Articles of Incorporation to increase the number of our authorized shares of
Common Stock, at a shareholders meeting at or prior to our next annual meeting of shareholders, but in no event later than the date that is 75 days after the closing of this offering.
Placement Agent
WestPark Capital, Inc. acted as the placement agent for the offering (the Placement Agent) pursuant to the terms of a Placement
Agency Agreement, dated February 23, 2015 (the Placement Agency Agreement). In connection with the closing of the offering, the Company expects to pay the Placement Agent an aggregate cash fee equal to $245,000. The Company has
agreed to reimburse the Placement Agents expenses up to a maximum of $40,000.
At the closing of the offering, for an aggregate
purchase price of $100, the Company is obligated to sell to the Placement Agent a warrant to purchase up to a number of shares of our Common Stock equal to 8.0% of the aggregate number of shares of Common Stock issued at the closing and the shares
of Common Stock issuable upon exercise of the Series E Warrants. The placement agent warrant will have substantially the same terms as the Series A Warrants, as described below, other than that (i) it will become exercisable on the later of the
data that is six month after issuance or on which the Company obtains the shareholder approvals discussed above, (ii) it will expire five years after the effective date of this offering, (iii) the exercise price will not be subject to full
ratchet anti-dilution protection, and (iv) will have cashless exercise rights regardless of an effective registration statement registering, or a current prospectus being available, the resale of the shares of Common Stock underlying the
placement agent warrant. Additionally, pursuant to FINRA Rule 5110(g)(1), neither the placement agent warrant nor any shares of Common Stock issued upon exercise of the placement agent warrant may be sold, transferred, assigned, pledged, or
hypothecated, or be subject to any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of such securities by any person for a period of 180 days immediately following the date of
effectiveness or commencement of sales of this offering, except the transfer of any security: (i) by operation of law or by reason of reorganization, (ii) to any FINRA member firm participating in the offering and the officers and partners
thereof, if all securities so transferred remain subject to the lock-up restriction described above for the remainder of the time period, (iii) if the aggregate amount of our securities held by the placement agent or related person does not
exceed 1% of the securities being offered, (iv) that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and
participating members in the aggregate do not own more than 10% of the equity in the fund, or (v) the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction set forth above for the remainder
of the time period.
Additionally, the Company has agreed to indemnify the Placement Agent against certain liabilities, including
liabilities under the Securities Act of 1933, as amended, or to contribute to payments the Placement Agent may be required to make because of those liabilities.
Lock-Up Agreement
One of the closing conditions under the Purchase Agreement is that the Companys officers and directors enter into a Lock-Up Agreement
pursuant to which they will agree, for a period of six months after the closing of the
offering, not to sell or dispose of any shares of Common Stock or common stock equivalents (as defined in the Lock-Up Agreement), take certain other actions with respect to the
Companys securities or make any demand for or exercise any registration rights.
Voting Agreement
One of the closing conditions under the Purchase Agreement is that the Company and its officers, directors and currently largest shareholder,
Riverside Renewable Energy Investments, LLC (Riverside), enter into a Voting Agreement pursuant to which Riverside will agree to, at any meeting of the Companys shareholders called for this purpose or in any action by written
consent of the Companys shareholders in lieu of meeting, vote (i) for the shareholder approvals described above, and (ii) against any proposal or any other corporate action or agreement that would result in a breach of any covenant,
representation or warranty or any other obligation or agreement of the Company under the Purchase Agreement or which could result in any of the conditions to the Companys obligations under the Purchase Agreement not being fulfilled.
The descriptions of each of the Purchase Agreement, the Series A Warrants, the Series B Warrants, the Series C Warrants, the Series D
Warrants, the Series E Warrants, the Placement Agency Agreement, the Lock-Up Agreement and the Voting Agreement are qualified in their entirety by reference to the forms attached hereto as Exhibits 10.1 4.1 (consisting of a combined form for all of
the Warrants), 1.1, 10.2 and 10.3, respectively.
Disclaimers of Representations and Warranties
The representations and warranties of the Company and its subsidiaries contained in the Purchase Agreement and the Placement Agency Agreement
have been made solely for the benefit of the parties thereto. In addition, such representations and warranties (i) have been made only for purposes of such documents, (ii) in some cases, have been qualified by documents filed with, or
furnished to, the Securities and Exchange Commission by the Company before the date of the Purchase Agreement and the Placement Agency Agreement, (iii) have been qualified by confidential disclosures made to the parties to the Purchase
Agreement and the Placement Agency Agreement that may contain some nonpublic information that is not material under applicable securities laws, (iv) are subject to materiality qualifications contained therein which may differ from what may be
viewed as material by investors, (v) were made only as of the date of the Purchase Agreement and the Placement Agency Agreement or such other date as is specified in such documents, and (vi) have been included in the Purchase Agreement and
the Placement Agency Agreement for the purpose of allocating risk between the contracting parties rather than establishing matters as facts.
Accordingly, the Purchase Agreement and the Placement Agency Agreement are included with this filing only to provide investors with
information regarding the terms of such documents, and not to provide investors with any other factual information regarding the Company or its subsidiaries or their respective business. You should not rely on the representations and warranties or
any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change
after the date of the Purchase Agreement and the Placement Agency Agreement, which subsequent information may or may not be fully reflected in the Companys public disclosures. The Purchase Agreement and Placement Agency Agreement should not be
read alone, but should instead be read in conjunction with the other information regarding the Company and its subsidiaries that has been, is or will be contained in, or incorporated by reference into, the Forms 10-K, Forms 10-Q, Forms 8-K, proxy
statements, registration statements and other documents that the Company files with the Securities and Exchange Commission.
Forward-Looking Statements
This Current Report on Form 8-K includes forward-looking statements relating to matters that are not historical facts. Forward-looking
statements may be identified by the use of words such as expect, intend, believe, will, should, would or comparable terminology or by discussions of strategy. While the Company
believes its assumptions and expectations underlying forward-looking statements are reasonable, there can be no assurance that actual results will not be materially different. Risks and uncertainties that could cause materially different results
include, among others, the Companys ability to close the offering described herein and whether holders of the Warrants will exercise them for cash and other risks and uncertainties included in the Companys filings with the Securities and
Exchange Commission. The Company assumes no duty to update any forward-looking statements.
The risk factors set forth below update the risk factors contained in the
Companys Annual Report on Form 10-K for the year ended December 31, 2013 and the Companys Quarterly Reports on Form 10-Q for the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014. Unless
otherwise mentioned or unless the context requires otherwise, all references in these risk factors to we, our, us or similar references mean the Company and its subsidiaries.
Our present indebtedness and projected future borrowings could adversely affect our financial health; future cash flows may not be sufficient to meet our
obligations and we may have difficulty obtaining additional financing; and we may experience adverse effects of interest rate fluctuations
As of February 20, 2015, we had indebtedness of approximately $7.3 million. The indebtedness consisted of:
|
|
|
a revolving line of credit from Silicon Valley Bank of up to $5.5 million, with a maturity date of March 17, 2015, with approximately $3.2 million drawn; and |
|
|
|
loans in an aggregate amount of $4.1 million, including accrued interest, from Riverside Renewable Energy Investment LLC (Riverside) under the terms of the Shareholders Agreement entered into in connection
with the Alteris merger, with a maturity date of March 31, 2015. |
There can be no assurance in the future whether we
will generate sufficient cash flow from operations, future financings or other sources to meet our debt service obligations, cash requirements to fund operations or other liquidity needs. Our present indebtedness and projected future borrowings
could have important adverse consequences to us, such as:
|
|
|
making it more difficult for us to satisfy our obligations with respect to our existing indebtedness; |
|
|
|
limiting our ability to obtain additional financing without restructuring the covenants in our existing indebtedness to permit the incurrence of such financing; |
|
|
|
requiring a substantial portion of our cash flow to be used for payments on the debt and related interest, thereby reducing our ability to use cash flow to fund working capital, capital expenditures and general
corporate requirements; |
|
|
|
limiting our ability to respond to changing business, industry and economic conditions and to withstand competitive pressures, which may affect our financial condition; |
|
|
|
causing us to incur higher interest expense in the event of increases in interest rates on our borrowings that have variable interest rates or in the event of refinancing existing debt at higher interest rates;
|
|
|
|
limiting our ability to make investments, dispose of assets, pay cash dividends or repurchase stock; |
|
|
|
increasing our vulnerability to downturns in our business, our industry or the general economy and restricting us from making improvements or acquisitions or exploring business opportunities; |
|
|
|
placing us at a competitive disadvantage to competitors with less debt or greater resources; and |
|
|
|
subjecting us to financial and other restrictive covenants in our indebtedness, the non-compliance with which could result in an event of default. |
If we fail to generate sufficient cash flow or otherwise obtain capital to meet our debt service obligations, we may need to refinance all or
a portion of our debt on or before maturity. Further, our revolving line of credit from Silicon Valley Bank is due March 17, 2015 and we are currently in negotiations with Silicon Valley Bank to extend this loan. We cannot assure you that we
will be able to extend our loans from Silicon Valley Bank or refinance any of our debt on attractive terms, commercially reasonable terms or at all. Our future operating performance and our ability to service, extend or refinance our indebtedness
will be subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. Our failure to meet our debt service obligations or pay our indebtedness when it comes due may cause us to become
insolvent, which would cast doubt on our ability to continue as a going concern.
We derive the majority of the revenue from our solar energy
integration services from sales in east coast states, Hawaii and California.
We currently derive the vast majority of our revenue from solar energy integration services from
projects in east coast states, California and Hawaii. This geographic concentration exposes us to increased risks associated with the growth rates, government regulations, economic conditions, weather and other factors that may be specific to those
states to which we would be less subject if we were more geographically diversified. The growth of our business will require us to expand our operations in existing markets and to commence operations in other states. Any geographic expansion efforts
that we may make may not be successful, which would limit our growth opportunities.
The year ended December 31, 2014 is the first year for which
we are required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002.
Our independent auditor will audit our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of
2002 for the first time in connection with the year ended December 31, 2014. Our internal control over financial reporting may include a previously unidentified material weakness which would result in receiving an adverse opinion on internal
control over financial reporting from our independent registered public accounting firm. This could result in significant additional expenditures responding to the internal control audit, heightened regulatory scrutiny and potentially an adverse
effect to the price of our Common Stock. Furthermore, if we are unable to establish and maintain effective internal control over financial reporting, we may be unable to accurately or timely report our financial results or prevent fraud from
occurring. In implementing such systems and controls as required by Section 404 of the Sarbanes-Oxley Act of 2002, there is a risk that errors and misstatements could occur, resulting in a negative impact on the reliability of our financial
statements and potentially other adverse developments such as regulatory action or litigation.
Our ability to require the holders of the Series B
Warrants to exercise such warrants may have a material impact on our financial condition.
We are conducting this offering to raise
capital for our operations. We expect to receive additional funds in the future upon exercise of the Series A Warrants, the Series B Warrants and the Series C Warrants. However, there can be no assurance that the holders of these warrants will
exercise them. For example, holders of these warrants will not exercise them if the exercise price is below the market price of our Common Stock.
Further, we may require the holders of the Series B Warrants to exercise such warrants in accordance with the terms of the Series B Warrants.
Although we can require such holders to exercise the Series B Warrants, we cannot ensure that such holders actually will pay, or will be able to pay, the exercise price for the Common Stock issuable upon exercise of the Series B Warrants.
Furthermore, our ability to require the holders of the Series B Warrants to exercise such warrants is subject to satisfaction of certain conditions set forth in the Series B Warrants, including, but not limited to, that there be no equity conditions
failure during the measuring period set forth in the Series B Warrants.
If holders of the Series A Warrants, the Series B Warrants or the
Series C Warrant do not voluntarily exercise such warrants, or, in the event we mandate exercise of the Series B Warrants but holders thereof holding a substantial amount of Series B Warrants elect not to, or are unable to, pay the exercise price,
it will have a material adverse impact on our financial condition.
Our failure to realize cost savings from restructuring and optimization could
materially and adversely affect our business and operating results.
In an attempt to realize efficiencies and cost savings, we are in
the process of restructuring and optimizing our business. We may be unable to effectively complete such restructuring and optimization efforts. Furthermore, we may not realize the expected benefits from our restructuring and optimization
initiatives. Our long-term expense reduction programs may result in an increase in short-term expenses, and our efforts may lead to additional unintended consequences. As a result, our restructuring and optimization efforts could materially and
adversely affect our business and operating results.
Existing rules, regulations and policies pertaining to electricity pricing and technical
interconnection of customer-owned electricity generation and changes to these regulations and policies may deter the purchase and use of solar energy systems and negatively impact development of the solar energy industry.
The market for solar energy systems is heavily influenced by foreign, federal, state and local
government regulations and policies concerning the electric utility industry, as well as policies adopted by electric utilities. These regulations and policies often relate to electricity pricing and technical interconnection of customer-owned
electricity generation. For example, the vast majority of states have a regulatory policy known as net energy metering, or net metering which allows our customers to interconnect their on-site solar energy systems to the utility grid and offset
their utility electricity purchases by receiving a bill credit at the utilitys retail rate for energy generated by their solar energy system that is exported to the grid and not consumed on-site. In this way, the customer pays for the net
energy used or receives a credit at the retail rate if more energy is produced than consumed. Metering caps currently exist in certain jurisdictions, which limit the aggregate amount of power that may be sold by solar power generators into the
electric grid. Some utilities also restrict the amount of consumer-owned electricity generation that can be placed on a circuit and the may require special studies or equipment before such generation can be connected to the utility grid. These
regulations and policies have been modified in the past and may be modified in the future in ways that can restrict the interconnection of solar energy systems, deter purchases of solar energy systems and require investment in the research and
development of solar energy technology. For example, in 2013 and 2014, Hawaiian Electric, the electric utility on Oahu, imposed new rules and procedures for the interconnection of solar systems on circuits with a high penetration of
customer-owned electricity generation. These new rules and procedures have led to a dramatic reduction in the number of on-site solar energy systems being sold or interconnected in Oahu in 2014. Similar actions by utilities in other markets
could have a similar effect. In addition, electricity generated by solar energy systems competes primarily with expensive peak hour electricity rates rather than with the less expensive average price of electricity. Modifications to the peak hour
pricing policies of utilities, such as reducing peak hour pricing or adopting flat rate or time-of-use pricing, could require solar energy systems to achieve lower prices in order to compete with the price of utility generated electricity. Such
changes are under consideration in markets in which we operate, such as California.
From time to time, we are subject to litigation which, if
adversely determined, could cause us to incur substantial losses.
From time to time during the normal course of operating our
businesses, we are subject to various litigation claims and legal disputes. Litigation claims have also been made against us by investors in our July 2014 private placement. Some of the litigation claims may not be covered under our insurance
policies, or our insurance carriers may seek to deny coverage. As a result, we might also be required to incur significant legal fees, which may have a material adverse effect on our financial position. In addition, because we cannot accurately
predict the outcome of any action, it is possible that, as a result of current and/or future litigation, we will be subject to adverse judgments or settlements that could significantly reduce our earnings or result in losses.
A substantial portion of the PV modules used in the United States are sourced from foreign suppliers and rules and conditions affecting international trade
can have an adverse effect on the supply of PV modules and their cost.
A significant percentage of PV modules used in the United
States are imported from China or utilize solar cells made in Taiwan. In 2014 the U.S. Department of Commerce imposed tariffs on these products. Although most of the PV modules we used in 2014 were sourced from domestic manufacturers, we experienced
price increases and occasional problems with availability as a result of these tariffs. Other international trade conditions such as work slowdowns and labor strikes at port facilities or major weather events can also adversely impact the
availability and price of PV modules.
We must meet The NASDAQ Capital Market continued listing requirements or we risk delisting, which may decrease
our stock price and make it harder for our shareholders to trade our stock.
Our Common Stock is currently listed for trading on The
NASDAQ Capital Market. We must continue to satisfy NASDAQs continued listing requirements or risk delisting of our securities. Delisting would have an adverse effect on the price of our Common Stock and likely also on our business. As
previously disclosed, on December 15, 2014, we received notice from NASDAQ that we were not in compliance with the NASDAQ minimum bid-price rule. We have 180 calendar days, or until June 15, 2015, to regain compliance. If we have not
regain compliance by that date, and if certain conditions are met, we may be eligible for an additional 180 day compliance period. Further, on February 13, 2015, we publicly disclosed that, due to an impairment charge for the fourth quarter of
2014, we expect to have negative shareholders equity as of December 31, 2014, which would also constitute a violation of the NASDAQ continuing listing requirements. There can be no assurance that we will be able to regain compliance with
the NASDAQ continued listing requirements, or that our Common Stock will not be delisted from The NASDAQ Capital Market in the future. If our Common Stock is delisted from NASDAQ, it may trade on the over-the-counter market, which may be a less
liquid market. In such case, our shareholders ability to
trade, or obtain quotations of the market value of, shares of our Common Stock would be severely limited because of lower trading volumes and transaction delays. These factors could contribute to
lower prices and larger spreads in the bid and ask prices for our securities.
We rely heavily on a limited number of suppliers and vendors, to some of
which we owe significant past due balances, and if these suppliers and vendors become unwilling to deliver critical components and services, it would adversely affect our ability to operate and our financial results.
We rely on a limited number of third-party suppliers to provide the components used in our solar energy systems. We also rely on key vendors
to provide internal and external services which are critical to our operations, including installation of solar energy systems, accounting and customer relationship management software, facilities and communications. The failure of our suppliers and
vendors to supply us with products and services in a timely manner or on commercially reasonable terms could result in lost orders, delay our project schedules, limit our ability to operate and harm our financial results. We have significant
outstanding balances and are in arrears with many of our suppliers and vendors. As a result, many of these suppliers and vendors are no longer willing to provide products or services to us, have placed us on credit hold, or are requiring
payment in advance. If any of our suppliers or vendors were to fail to supply our needs on a timely basis or to cease providing us key components or services we use, we would be required to secure alternative sources of supply. We may have
difficulty securing alternative sources of supply. If this were to occur, our business would be harmed.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
|
|
|
Exhibit No. |
|
Description |
|
|
1.1 |
|
Placement Agency Agreement, dated February 23, 2015, between Real Goods Solar, Inc. and WestPark Capital, Inc. |
|
|
4.1 |
|
Combined Form of Warrants |
|
|
5.1 |
|
Opinion of Brownstein Hyatt Farber Schreck, LLP |
|
|
10.1 |
|
Form of Securities Purchase Agreement |
|
|
10.2 |
|
Form of Lock-Up Agreement |
|
|
10.3 |
|
Form of Voting Agreement |
|
|
23.1 |
|
Consent of Bronstein Hyatt Farber Schreck, LLP (contained in Exhibit 5.1 above) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
REAL GOODS SOLAR, INC. |
|
|
By: |
|
/s/ Dennis Lacey |
|
|
Dennis Lacey |
|
|
Chief Executive Officer and Acting Principal Financial Officer |
Date: February 24, 2015
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Description |
|
|
1.1 |
|
Placement Agency Agreement, dated February 23, 2015, between Real Goods Solar, Inc. and WestPark Capital, Inc. |
|
|
4.1 |
|
Combined Form of Warrants |
|
|
5.1 |
|
Opinion of Brownstein Hyatt Farber Schreck, LLP |
|
|
10.1 |
|
Form of Securities Purchase Agreement |
|
|
10.2 |
|
Form of Lock-Up Agreement |
|
|
10.3 |
|
Form of Voting Agreement |
|
|
23.1 |
|
Consent of Bronstein Hyatt Farber Schreck, LLP (contained in Exhibit 5.1 above) |
Exhibit 1.1
PLACEMENT AGENCY AGREEMENT
February 23, 2015
Ladies
and Gentlemen:
Introduction. Subject to the terms and conditions herein (this Agreement), Real Goods Solar,
Inc., a Colorado corporation (the Company), hereby agrees to sell up to an aggregate of $3,500,000 registered securities (the Securities) of the Company, including, but not limited to, shares (the
Shares) of the Companys Class A common stock, $0.0001 par value per share (the Common Stock), the Series A common stock purchase Warrants (the Series A Warrants) to purchase shares
of Common Stock, the Series B common stock purchase warrants (the Series B Warrants) to purchase shares of Common Stock, the Series C common stock purchase warrants (the Series C Warrants) to purchase shares of
Common Stock, the Series D common stock purchase warrants (the Series D Warrants) to purchase shares of Common Stock, and Series E common stock purchase warrants (the Series E Warrants together with the Series A
Warrant, Series B Warrants, the Series C Warrants and Series D Warrants, the Warrants and the Warrants together with the Shares, the Securities) to purchase shares of Common Stock directly to various investors
(each, an Investor and, collectively, the Investors) through WestPark Capital, Inc., as exclusive placement agent (the Placement Agent). The Placement Agent may retain other brokers or dealers
to act as sub-agents or selected-dealers on its behalf in connection with the Offering (as defined below).
The Company hereby confirms
its agreement with the Placement Agent as follows:
Section 1. Agreement to Act as Placement Agent.
(a) On the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the
terms and conditions of this Agreement, the Placement Agent shall be the exclusive Placement Agent in connection with the offering and sale by the Company of the Securities pursuant to the Companys registration statement on Form S-3 (File
No. 333-193718) (the Registration Statement), with the terms of such offering (the Offering) to be subject to market conditions and negotiations between the Company, the Placement Agent and the prospective
Investors. The Placement Agent will act on a reasonable best efforts basis and the Company agrees and acknowledges that there is no guarantee of the successful placement of the Securities, or any portion thereof, in the prospective Offering. Under
no circumstances will the placement Agent or any of its Affiliates (as defined below) be obligated to underwrite or purchase any of the Shares for its own account or otherwise provide any financing. The Placement Agent shall act solely
as the Companys agent and not as principal. The Placement Agent shall have no authority to bind the Company with respect to any prospective offer to purchase Shares and the Company shall have the sole right to accept offers to purchase Shares
and may reject any such offer, in whole or in part. Subject to the terms and conditions hereof, payment of the purchase price for, and delivery of, the Securities shall be made at one or more closings (each a Closing and the date
on which each Closing occurs, a Closing Date). As compensation for services rendered, on each Closing Date, the Company shall pay to the Placement Agent the fees and expenses set forth below:
(i) A cash fee equal to 7.0% of the gross proceeds received by the Company from the sale of the Securities at the closing of
the Offering (the Closing).
(ii) For and aggregate purchase price of $100, such number of Common Stock
purchase warrants (the Placement Agent Warrants) to Placement Agent or its designees at each Closing to purchase shares of Common Stock equal to 8.0% of the number of shares of Common Stock issued at the Closing and issuable under
the terms of the Series E Warrants. The Placement Agent Warrants shall have the same terms as the Series A Warrants issued to the Investors in the Offering, except that the Placement Agent Warrants will (i) not have anti-dilution adjustments,
(ii) expire five years from the effective date of the Offering, (iii) have cashless exercise rights regardless of an effective registration statement registering, or a current prospectus being available, the resale of the
shares of Common Stock underlying the Placement Agent Warrants and (iv) not be exercisable until the Company has obtained shareholder approval to increase its authorized shares of Common Stock and to conduct a reverse stock split. Additionally,
the Placement Agent Warrants shall not be transferable for six months from the date of the Offering except as permitted by Financial Industry Regulatory Authority (FINRA) Rule 5110(g)(1).
(iii) The Company also agrees to reimburse Placement Agents expenses (with supporting invoices/receipts) up to a maximum
of $40,000. The expense reimbursement shall be payable immediately to WestPark whether or not the Offering is completed.
(iv) For the purposes of clarification, the fees payable pursuant to this Section 1 shall constitute payment of the
Transaction Fee (as such term is defined in that the certain letter agreement, dated December 15, 2014, as amended, by and between the Company and the Placement Agent (the Engagement Letter) and this Offering shall not
constitute a Tail Financing pursuant to Section 6(e) of the Engagement Letter.
(b) The term of the Placement
Agents exclusive engagement will be until the completion of the Offering (the Exclusive Term); provided, however, that a party hereto may terminate the engagement with respect to itself at any time upon
10 days written notice to the other parties. Notwithstanding anything to the contrary contained herein, the provisions concerning confidentiality, indemnification and contribution contained herein and the Companys obligations contained in
the indemnification provisions will survive any expiration or termination of this Agreement, and the Companys obligation to pay fees actually earned and payable and to reimburse expenses actually incurred and reimbursable pursuant to
Section 1 hereof and which are permitted to be reimbursed under FINRA Rule 5110(f)(2)(D), will survive any expiration or termination of this Agreement. Nothing in this Agreement shall be construed to limit the ability of the Placement Agent or
its Affiliates to pursue, investigate, analyze, invest in, or engage in investment banking, financial advisory or any other business relationship with Persons (as defined below) other than the Company. As used herein (i) Persons
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind and
(ii) Affiliate means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the
Securities Act of 1933, as amended (the Securities Act).
2
Section 2. Representations, Warranties and Covenants of the Company. Each of the representations and
warranties (together with any related disclosure schedules thereto) made to the Investors in that certain Securities Purchase Agreement dated as of February 23, 2015 (the Purchase Agreement), between the Company and each Investor,
is hereby incorporated herein by reference (as though fully restated herein) and is hereby made to, and in favor of, Placement Agent. In addition, the Company hereby represents, warrants and covenants to the Placement Agent as of the date hereof,
and as of each Closing Date, as follows:
(a) Authorization; Enforcement. The Company has the requisite corporate
power and authority to enter into and to consummate the transactions contemplated by this Agreement and the Prospectus Supplement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of this
Agreement by the Company and the consummation by it of the transactions contemplated hereby and thereby and under the Prospectus Supplement have been duly authorized by all necessary action on the part of the Company and no further action is
required by the Company, the Companys Board of Directors (the Board of Directors) or the Companys stockholders in connection therewith other than in connection with the Required Approvals (as defined below). This
Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
(b) No Conflicts. The execution, delivery and performance by the Company of this Agreement and the transactions
contemplated pursuant to the Prospectus Supplement, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby to which it is a party do not and will not (i) conflict with or violate
any provision of the Companys or any Subsidiarys certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of
time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or
without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any
property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in
the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect (as defined in the Purchase Agreement).
(c) Reliance. The Company acknowledges that the Placement Agent will rely upon the accuracy and truthfulness of the
foregoing representations and warranties and hereby consents to such reliance.
3
Section 3. Delivery and Payment. Each Closing shall occur at the offices of the Ellenoff
Grossman & Schole LLP, 1345 Avenue of the Americas, New York, New York 10105 (or at such other place as shall be agreed upon by the Placement Agent and the Company) (Placement Agent Counsel). Subject to the terms and
conditions hereof, at each Closing payment of the purchase price for the Securities sold on such Closing Date shall be made by Federal Funds wire transfer, against delivery of such Securities, and such Securities shall be registered in such name or
names and shall be in such denominations, as the Placement Agent may request at least one business day before the time of purchase (as defined below).
Deliveries of the documents with respect to the purchase of the Securities, if any, shall be made at the offices of Placement Agent Counsel.
All actions taken at a Closing shall be deemed to have occurred simultaneously.
Section 4. Covenants and Agreements of the Company. The
Company further covenants and agrees with the Placement Agent as follows:
(a) Registration Statement Matters. The
Company will advise the Placement Agent promptly after it receives notice thereof of the time when any amendment to the Registration Statement has been filed or becomes effective or any supplement to any Prospectus Supplement or any amended
Prospectus Supplement has been filed and will furnish the Placement Agent with copies thereof. The Company will file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission
pursuant to Section 13(a), 14 or 15(d) of the Exchange Act subsequent to the date of any Prospectus Supplement and for so long as the delivery of a prospectus is required in connection with the Offering. The Company will advise the Placement
Agent, promptly after it receives notice thereof (i) of any request by the Commission to amend the Registration Statement or to amend or supplement any Prospectus Supplement or for additional information, and (ii) of the issuance by the
Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any order directed at any Incorporated Document, if any, or any amendment or supplement thereto or any order
preventing or suspending the use of the Base Prospectus or any Prospectus Supplement or any amendment or supplement thereto or any post-effective amendment to the Registration Statement, of the suspension of the qualification of the Securities for
offering or sale in any jurisdiction, of the institution or threatened institution of any proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or a Prospectus Supplement
or for additional information. The Company shall use its best efforts to prevent the issuance of any such stop order or prevention or suspension of such use. If the Commission shall enter any such stop order or order or notice of prevention or
suspension at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment, or will file a new registration statement and use its best efforts to have such new registration statement declared
effective as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b), 430A, 430B and 430C, as applicable, under the Securities Act, including with respect to the timely filing of
documents thereunder, and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) are received in a timely manner by the Commission.
(b) Blue Sky Compliance. The Company will cooperate with the Placement Agent and the Investors in endeavoring to qualify
the Securities for sale under the securities laws of such jurisdictions (United States and foreign) as the Placement Agent and the Investors may reasonably request and will make such applications, file such documents, and furnish such information as
may be reasonably required for that purpose, provided the Company shall not be
4
required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction where it is not now so qualified or required to file such a consent, and
provided further that the Company shall not be required to produce any new disclosure document other than a Prospectus Supplement. The Company will, from time to time, prepare and file such statements, reports and other documents as are or may be
required to continue such qualifications in effect for so long a period as the Placement Agent may reasonably request for distribution of the Securities. The Company will advise the Placement Agent promptly of the suspension of the qualification or
registration of (or any such exemption relating to) the Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such
qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment.
(c) Amendments and Supplements to a Prospectus Supplement and Other Matters. The Company will comply with the Securities
Act and the Exchange Act, and the rules and regulations of the Commission thereunder, so as to permit the completion of the distribution of the Securities as contemplated in this Agreement, the Incorporated Documents and any Prospectus Supplement.
If during the period in which a prospectus is required by law to be delivered in connection with the distribution of Securities contemplated by the Incorporated Documents or any Prospectus Supplement (the Prospectus Delivery
Period), any event shall occur as a result of which, in the judgment of the Company or in the opinion of the Placement Agent or counsel for the Placement Agent, it becomes necessary to amend or supplement the Incorporated Documents or any
Prospectus Supplement in order to make the statements therein, in the light of the circumstances under which they were made, as the case may be, not misleading, or if it is necessary at any time to amend or supplement the Incorporated Documents or
any Prospectus Supplement or to file under the Exchange Act any Incorporated Document to comply with any law, the Company will promptly prepare and file with the Commission, and furnish at its own expense to the Placement Agent and to dealers, an
appropriate amendment to the Registration Statement or supplement to the Registration Statement, the Incorporated Documents or any Prospectus Supplement that is necessary in order to make the statements in the Incorporated Documents and any
Prospectus Supplement as so amended or supplemented, in the light of the circumstances under which they were made, as the case may be, not misleading, or so that the Registration Statement, the Incorporated Documents or any Prospectus Supplement, as
so amended or supplemented, will comply with law. Before amending the Registration Statement or supplementing the Incorporated Documents or any Prospectus Supplement in connection with the Offering, the Company will furnish the Placement Agent with
a copy of such proposed amendment or supplement and will not file any such amendment or supplement to which the Placement Agent reasonably objects.
(d) Copies of any Amendments and Supplements to a Prospectus Supplement. The Company will furnish the Placement Agent,
without charge, during the period beginning on the date hereof and ending on the later of the last Closing Date of the Offering, as many copies of the Incorporated Documents and any Prospectus Supplement and any amendments and supplements thereto
(including any Incorporated Documents, if any) as the Placement Agent may reasonably request.
(e) Free Writing
Prospectus. The Company covenants that it will not, unless it obtains the prior written consent of the Placement Agent, make any offer relating to the Securities that would constitute an Company Free Writing Prospectus or that would otherwise
constitute a free writing prospectus (as defined in Rule 405 of the Securities Act) required to be filed by the Company with the Commission or retained by the Company under Rule 433 of the Securities Act.
5
In the event that the Placement Agent expressly consents in writing to any such free writing prospectus (a Permitted Free Writing Prospectus), the Company covenants that it
shall (i) treat each Permitted Free Writing Prospectus as an Company Free Writing Prospectus, and (ii) comply with the requirements of Rule 164 and 433 of the Securities Act applicable to such Permitted Free Writing Prospectus, including
in respect of timely filing with the Commission, legending and record keeping.
(f) Transfer Agent. The Company will
maintain, at its expense, a registrar and transfer agent for the Common Stock.
(g) Earnings Statement. As soon as
practicable and in accordance with applicable requirements under the Securities Act, but in any event not later than 18 months after the last Closing Date, the Company will make generally available to its security holders and to the Placement Agent
an earnings statement, covering a period of at least 12 consecutive months beginning after the last Closing Date, that satisfies the provisions of Section 11(a) and Rule 158 under the Securities Act.
(h) Periodic Reporting Obligations. During the Prospectus Delivery Period, the Company will duly file, on a timely
basis, with the Commission and the Trading Market all reports and documents required to be filed under the Exchange Act within the time periods and in the manner required by the Exchange Act.
(i) Additional Documents. The Company will enter into any subscription, purchase or other customary agreements as
the Placement Agent or the Investors deem necessary or appropriate to consummate the Offering, all of which will be in form and substance reasonably acceptable to the Placement Agent and the Investors. The Company agrees that the Placement Agent may
rely upon, and each is a third party beneficiary of, the representations and warranties, and applicable covenants, set forth in any such purchase, subscription or other agreement with Investors in the Offering.
(j) No Manipulation of Price. The Company will not take, directly or indirectly, any action designed to
cause or result in, or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities of the Company.
(k) Acknowledgment. The Company acknowledges that any advice given by the Placement Agent to the Company is solely for
the benefit and use of the Board of Directors of the Company and may not be used, reproduced, disseminated, quoted or referred to, without the Placement Agents prior written consent.
Section 5. Conditions of the Obligations of the Placement Agent. The obligations of the Placement Agent hereunder shall be subject to the accuracy
of the representations and warranties on the part of the Company set forth in Section 2 hereof, in each case as of the date hereof and as of each Closing Date as though then made, to the timely performance by each of the Company of its
covenants and other obligations hereunder on and as of such dates, and to each of the following additional conditions:
(a)
Accountants Comfort Letter. On the Closing Date, the Placement Agent shall have received, and the Company shall have caused to be delivered to the Placement Agent, a letter from EKS&H LLLP (the independent registered public
accounting firm of the Company), addressed to the Placement Agent, dated as of the date hereof, in form and substance satisfactory to the Placement Agent. The letter shall not disclose any change in the condition (financial or
6
other), earnings, operations, business or prospects of the Company from that set forth in the Incorporated Documents or the applicable Prospectus Supplement, which, in the Placement Agents
sole judgment, is material and adverse and that makes it, in the Placement Agents sole judgment, impracticable or inadvisable to proceed with the Offering of the Securities as contemplated by such Prospectus Supplement.
(b) Compliance with Registration Requirements; No Stop Order; No Objection from the FINRA. Each Prospectus Supplement
(in accordance with Rule 424(b)) and free writing prospectus (as defined in Rule 405 of the Securities Act), if any, shall have been duly filed with the Commission, as appropriate; no stop order suspending the effectiveness
of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order preventing or suspending the use of any Prospectus Supplement shall have
been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order having the effect of ceasing or suspending the distribution of the Securities or any other securities of the Company shall have been
issued by any securities commission, securities regulatory authority or stock exchange and no proceedings for that purpose shall have been instituted or shall be pending or, to the knowledge of the Company, contemplated by any securities commission,
securities regulatory authority or stock exchange; all requests for additional information on the part of the Commission shall have been complied with; and the FINRA shall have raised no objection to the fairness and reasonableness of the placement
terms and arrangements.
(c) Corporate Proceedings. All corporate proceedings and other legal matters in connection
with this Agreement, the Registration Statement and each Prospectus Supplement, and the registration, sale and delivery of the Securities, shall have been completed or resolved in a manner reasonably satisfactory to the Placement Agents
counsel, and such counsel shall have been furnished with such papers and information as it may reasonably have requested to enable such counsel to pass upon the matters referred to in this Section 5.
(d) No Material Adverse Change. Subsequent to the execution and delivery of this Agreement and prior to each Closing
Date, in the Placement Agents sole judgment after consultation with the Company, there shall not have occurred any Material Adverse Change or Material Adverse Effect.
(e) Opinion of Counsel for the Company. The Placement Agent shall have received on each Closing Date the favorable
opinion of US legal counsel to the Company, dated as of such Closing Date, including, without limitation, a negative assurance letter, addressed to the Placement Agent and in form and substance satisfactory to the Placement Agent.
(f) Officers Certificate. The Placement Agent shall have received on each Closing Date a certificate of the
Company, dated as of such Closing Date, signed by the Chief Executive Officer and Chief Financial Officer of the Company, to the effect that, and the Placement Agent shall be satisfied that, the signers of such certificate have reviewed the
Registration Statement, the Incorporated Documents, any Prospectus Supplement, and this Agreement and to the further effect that:
(i) The representations and warranties of the Company in this Agreement are true and correct, as if made on and as of such
Closing Date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to such Closing Date;
7
(ii) No stop order suspending the effectiveness of the Registration Statement or
the use of the Base Prospectus or any Prospectus Supplement has been issued and no proceedings for that purpose have been instituted or are pending or, to the Companys knowledge, threatened under the Securities Act; no order having the effect
of ceasing or suspending the distribution of the Securities or any other securities of the Company has been issued by any securities commission, securities regulatory authority or stock exchange in the United States and no proceedings for that
purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission, securities regulatory authority or stock exchange in the United States;
(iii) When the Registration Statement became effective, at the time of sale, and at all times subsequent thereto up to the
delivery of such certificate, the Registration Statement and the Incorporated Documents, if any, when such documents became effective or were filed with the Commission, contained all material information required to be included therein by the
Securities Act and the Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and in all material respects conformed to the requirements of the Securities Act and the Exchange Act and the applicable
rules and regulations of the Commission thereunder, as the case may be, and the Registration Statement and the Incorporated Documents, if any, did not and do not include any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (provided, however, that the preceding representations and warranties contained in this paragraph
(iii) shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by the Placement Agent expressly for use therein) and, since the effective date of the
Registration Statement, there has occurred no event required by the Securities Act and the rules and regulations of the Commission thereunder to be set forth in the Incorporated Documents which has not been so set forth; and
(iv) Subsequent to the respective dates as of which information is given in the Registration Statement, the Incorporated
Documents and any Prospectus Supplement, there has not been: (a) any Material Adverse Change; (b) any transaction that is material to the Company and the Subsidiaries taken as a whole, except transactions entered into in the ordinary
course of business; (c) any obligation, direct or contingent, that is material to the Company and the Subsidiaries taken as a whole, incurred by the Company or any Subsidiary, except obligations incurred in the ordinary course of business;
(d) any material change in the capital stock (except changes thereto resulting from the exercise of outstanding stock options or warrants) or outstanding indebtedness of the Company or any Subsidiary; (e) any dividend or distribution of
any kind declared, paid or made on the capital stock of the Company; or (f) any loss or damage (whether or not insured) to the property of the Company or any Subsidiary which has been sustained or will have been sustained which has a Material
Adverse Effect.
(g) Stock Exchange Listing. The Common Stock shall be registered under the Exchange Act and shall
be listed on the Trading Market, and the Company shall not have taken any action designed to terminate, or likely to have the effect of terminating, the registration of the Common Stock under the Exchange Act or delisting or suspending from
trading the Common Stock from the Trading Market, nor shall the Company have received any information suggesting that the Commission or the Trading Market is contemplating terminating such registration or listing.
8
(h) Additional Documents. On or before each Closing Date, the Placement
Agent and counsel for the Placement Agent shall have received such information and documents as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of the Securities as contemplated herein, or in order to
evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained.
If any condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Placement Agent by notice to the Company at any time on or prior to a Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section 6 (Payment of Expenses), Section 7
(Indemnification and Contribution) and Section 8 (Representations and Indemnities to Survive Delivery) shall at all times be effective and shall survive such termination.
Section 6. Payment of Expenses. To the extent incurred by the Company, the Company agrees to pay all costs, fees and expenses incurred by the
Company in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i) all expenses incident to the issuance, delivery and qualification of the
Securities (including all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Common Stock; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale
of the Securities; (iv) all fees and expenses of the Companys counsel, independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing,
shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Base Prospectus and each Prospectus Supplement, and all amendments and supplements thereto, and
this Agreement; (vi) all filing fees, reasonable attorneys fees and expenses incurred by the Company or the Placement Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of)
all or any part of the Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other country, and, if requested by the Placement Agent, preparing and printing a Blue Sky Survey, an
International Blue Sky Survey or other memorandum, and any supplements thereto, advising the Placement Agent of such qualifications, registrations and exemptions; (vii) if applicable, the filing fees incident to the review
and approval by the FINRA of the Placement Agents participation in the offering and distribution of the Securities; (viii) the fees and expenses associated with including the Securities on the Trading Market; (ix) all costs and
expenses incident to the travel and accommodation of the Companys and the Placement Agents employees on the roadshow, if any; and (x) all other fees, costs and expenses referred to in Part II of the Registration
Statement.
Section 7. Indemnification and Contribution.
(a) The Company agrees to indemnify and hold harmless the Placement Agent, its affiliates and each person controlling the
Placement Agent (within the meaning of Section 15 of the Securities Act), and the directors, officers, agents and employees of the Placement Agent, its affiliates and each such controlling person (the Placement Agent, and each such entity or
person. an Indemnified Person) from and against any losses, claims, damages, judgments, assessments, costs and other liabilities (collectively, the Liabilities), and shall reimburse each Indemnified Person for
all fees and expenses (including the reasonable fees and expenses of one counsel for all Indemnified Persons, except as otherwise expressly provided herein) (collectively, the Expenses) as they are incurred by an Indemnified
Person in investigating, preparing, pursuing or defending any Actions, whether or not any Indemnified Person is a party thereto, (i) caused by, or arising out of or in connection with, any untrue statement or alleged untrue statement of a
material fact contained in any Incorporated Document or by any omission or alleged omission to
9
state therein a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading (other than untrue statements or alleged untrue
statements in, or omissions or alleged omissions from, information relating to an Indemnified Person furnished in writing by or on behalf of such Indemnified Person expressly for use in the Incorporated Documents) or (ii) otherwise arising out
of or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Persons actions or inactions in connection with any such
advice, services or transactions; provided, however, that, in the case of clause (ii) only, the Company shall not be responsible for any Liabilities or Expenses of any Indemnified Person that are finally judicially determined to have
resulted solely from such Indemnified Persons (x) gross negligence or willful misconduct in connection with any of the advice, actions, inactions or services referred to above or (y) use of any offering materials or information
concerning the Company in connection with the offer or sale of the Securities in the Offering which were not authorized for such use by the Company and which use constitutes gross negligence or willful misconduct. The Company also agrees to
reimburse each Indemnified Person for all Expenses as they are incurred in connection with enforcing such Indemnified Persons rights under this Agreement.
(b) Upon receipt by an Indemnified Person of actual notice of an Action against such Indemnified Person with respect to which
indemnity may be sought under this Agreement, such Indemnified Person shall promptly notify the Company in writing; provided that failure by any Indemnified Person so to notify the Company shall not relieve the Company from any liability which the
Company may have on account of this indemnity or otherwise to such Indemnified Person, except to the extent the Company shall have been prejudiced by such failure. The Company shall, if requested by the Placement Agent, assume the defense of any
such Action including the employment of counsel reasonably satisfactory to the Placement Agent, which counsel may also be counsel to the Company. Any Indemnified Person shall have the right to employ separate counsel in any such action and
participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company has failed promptly to assume the defense and employ counsel or (ii) the named parties
to any such Action (including any impeded parties) include such Indemnified Person and the Company, and such Indemnified Person shall have been advised in the reasonable opinion of counsel that there is an actual conflict of interest that prevents
the counsel selected by the Company from representing both the Company (or another client of such counsel) and any Indemnified Person; provided that the Company shall not in such event be responsible hereunder for the fees and expenses of more than
one firm of separate counsel for all Indemnified Persons in connection with any Action or related Actions, in addition to any local counsel. The Company shall not be liable for any settlement of any Action effected without its written consent (which
shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the Placement Agent (which shall not be unreasonably withheld), settle, compromise or consent to the entry of any judgment in or otherwise
seek to terminate any pending or threatened Action in respect of which indemnification or contribution may be sought hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination
includes an unconditional release of each Indemnified Person from all Liabilities arising out of such Action for which indemnification or contribution may be sought hereunder. The indemnification required hereby shall be made by periodic payments of
the amount thereof during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is due and payable.
(c) In the event that the foregoing indemnity is unavailable to an Indemnified Person other than in accordance with this
Agreement, the Company shall contribute to the Liabilities and
10
Expenses paid or payable by such Indemnified Person in such proportion as is appropriate to reflect (i) the relative benefits to the Company, on the one hand, and to the Placement Agent and
any other Indemnified Person, on the other hand, of the matters contemplated by this Agreement or (ii) if the allocation provided by the immediately preceding clause is not permitted by applicable law, not only such relative benefits but also
the relative fault of the Company, on the one hand, and the Placement Agent and any other Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses relate, as well as any other relevant equitable
considerations; provided that in no event shall the Company contribute less than the amount necessary to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses in excess of the amount of fees actually
received by the Placement Agent pursuant to this Agreement. For purposes of this paragraph, the relative benefits to the Company, on the one hand, and to the Placement Agent on the other hand, of the matters contemplated by this Agreement shall be
deemed to be in the same proportion as (a) the total value paid or contemplated to be paid to or received or contemplated to be received by the Company in the transaction or transactions that are within the scope of this Agreement, whether or
not any such transaction is consummated, bears to (b) the fees paid to the Placement Agent under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the
Securities Act, as amended, shall be entitled to contribution from a party who was not guilty of fraudulent misrepresentation.
(d) The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or
tort or otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Persons actions or
inactions in connection with any such advice, services or transactions except for Liabilities (and related Expenses) of the Company that are finally judicially determined to have resulted solely from such Indemnified Persons gross negligence
or willful misconduct in connection with any such advice, actions, inactions or services.
(e) The reimbursement, indemnity
and contribution obligations of the Company set forth herein shall apply to any modification of this Agreement and shall remain in full force and effect regardless of any termination of, or the completion of any Indemnified Persons services
under or in connection with, this Agreement.
Section 8. Representations and Indemnities to Survive Delivery. The respective indemnities,
agreements, representations, warranties and other statements of the Company or any person controlling the Company, of its officers, and of the Placement Agent set forth in or made pursuant to this Agreement will remain in full force and effect,
regardless of any investigation made by or on behalf of the Placement Agent, the Company, or any of its or their partners, officers or directors or any controlling person, as the case may be, and will survive delivery of and payment for the
Securities sold hereunder and any termination of this Agreement. A successor to a Placement Agent, or to the Company, its directors or officers or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution
and reimbursement agreements contained in this Agreement.
Section 9. Notices. All communications hereunder shall be in writing and shall be
mailed, hand delivered or telecopied and confirmed to the parties hereto as follows:
If to the Placement Agent to:
WestPark Capital, Inc.
1900 Avenue of the Stars, Suite 310
Los Angeles, CA 90067
Phone: (310) 203-2902
Facsimile: (310) 843- 9304
Attention: Richard Rappaport
11
With a copy (for informational purposes only) to:
Ellenoff Grossman & Schole LLP
150 East 42nd Street
New York, New York 10017
Facsimile: (201) 401-4741
Attention: Robert Charron
If to the Company:
|
|
|
Real Goods Solar, Inc. 833 West
South Boulder Road, Louisville, CO 80027 |
Telephone: |
|
(303) 222-8541 |
Facsimile: |
|
(303) 222-8323 |
E-mail: |
|
Dennis.Lacey@rgsenergy.com |
Attention: |
|
Dennis Lacey |
With a copy (for informational purposes only) to:
Brownstein Hyatt Farber Schreck, LLP
410 Seventeenth Street,
Suite 2200
Denver, CO 80202
Telephone: (303) 223-1100
Facsimile: (303) 223-1111
E-mail:
KMacdonald@BHFS.com
Attention: Kristin M. Macdonal
Any party hereto may change the address for receipt of communications by giving written notice to the others.
Section 10. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees,
officers and directors and controlling persons referred to in Section 7 hereof, and to their respective successors, and personal representative, and no other person will have any right or obligation hereunder.
Section 11. Partial Unenforceability. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect
the validity or enforceability of any other section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor
changes (and only such minor changes) as are necessary to make it valid and enforceable.
Section 12. Governing Law; Jurisdiction; Jury Trial.
All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause the application of the laws
12
of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough
of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any
claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY
HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
Section 13. General Provisions.
(a) This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral
and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each
party whom the condition is meant to benefit. Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. Notwithstanding anything herein to the contrary, the certain
letter agreement, dated December 15, 2014, as amended, by and between the Company and the Placement Agent shall continue to be effective and the terms therein shall continue to survive and be enforceable by the Placement Agent, in accordance
with its terms.
(b) The Company acknowledges that in connection with the offering of the Securities: (i) the
Placement Agent has acted at arms length, are not agents of, and owe no fiduciary duties to the Company or any other person, (ii) the Placement Agent owes the Company only those duties and obligations set forth in this Agreement and
(iii) the Placement Agent may have interests that differ from those of the Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Placement Agent arising from an alleged breach of fiduciary
duty in connection with the offering of the Securities
[The remainder of this page has been intentionally left blank.]
13
If the foregoing is in accordance with your understanding of our agreement, please sign below
whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.
|
|
|
Very truly yours, |
|
REAL GOOD SOLAR, INC., |
a Colorado corporation |
|
|
By: |
|
/s/ Dennis Lacey |
|
|
Name: Dennis Lacey |
|
|
Title: Chief Executive Officer |
The foregoing Placement Agency Agreement is hereby confirmed and accepted as of the date first above
written.
|
|
|
WESTPARK CAPITAL, INC. |
|
|
By: |
|
/s/ Richard Rappaport |
|
|
Name: Richard Rappaport |
|
|
Title: Chief Executive Officer |
14
Exhibit 4.1
[FORM OF SERIES [A] [B] [C] [D] [E] WARRANT]
REAL GOODS SOLAR, INC.
SERIES [A] [B] [C] [D] [E] WARRANT TO PURCHASE COMMON
STOCK
Warrant
No.:
Number of Shares of
Common Stock: [INSERT IN SERIES A & E WARRANTS: ] [INSERT IN SERIES B, C & D WARRANTS: Determined in accordance with the formula set forth below.]
Date of Issuance: February [26], 2015 (Issuance Date)
Real Goods Solar, Inc., a Colorado corporation (the Company), hereby certifies that, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, [BUYER], the registered holder hereof or its permitted assigns (the Holder), is entitled, subject to the terms set forth below, to purchase from the Company, at the
Exercise Price (as defined below) then in effect, at any time or times on or after [ ]1 (the Initial Exercisability
Date), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), up to such number of fully paid and nonassessable shares of Common Stock equal to the Warrant Share Number, subject to adjustment as provided
herein (the Warrant Shares). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this
Warrant), shall have the meanings set forth in Section 17. This Warrant is one of the [INSERT IN SERIES A WARRANT: Series A] [INSERT IN SERIES B WARRANT: Series B] [INSERT IN SERIES C WARRANT: Series C]
[INSERT IN SERIES D WARRANT: Series D] [INSERT IN SERIES E WARRANT: Series E] Warrants to purchase Common Stock (the SPA Warrants) issued pursuant to Section 1 of that certain Securities Purchase Agreement,
dated as of February 23, 2015 (the Subscription Date), by and among the Company and the investors (the Buyers) referred to therein (the Securities Purchase Agreement). Capitalized terms
used herein and not otherwise defined shall have the definitions ascribed to such terms in the Securities Purchase Agreement.
1.
EXERCISE OF WARRANT.
(a) Mechanics of Exercise. Subject to the terms and conditions hereof (including, without limitation,
the limitations set forth in Section 1(f)), this Warrant may be exercised by the Holder at any time or times on or after the Initial Exercisability Date, in whole or in part, by (i) delivery of a written notice, in the form attached hereto
as Exhibit A (the Exercise Notice), of the Holders election to exercise this Warrant and (ii) (A) payment to the Company of an amount equal to the applicable Exercise Price multiplied by the number of
Warrant Shares as to which this Warrant is being exercised (the Aggregate Exercise Price) in
1 |
[INSERT IN SERIES A & C WARRANTS: Insert the date that is six (6) months immediately following the Issuance Date [August 26, 2015]] [INSERT IN SERIES B, D & E WARRANTS: the Issuance
Date] |
cash by wire transfer of immediately available funds or (B) [INSERT IN SERIES A, B & C WARRANTS: if the provisions of Section 1(d) are applicable,] by notifying the Company
that this Warrant is being exercised pursuant to a Cashless Exercise (as defined in Section 1(d)). The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. [INSERT IN SERIES A, D & E
WARRANTS: Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the
remaining number of Warrant Shares. Execution and delivery of an Exercise Notice for all of the then remaining Warrant Shares shall have the same effect as cancellation of the original of this Warrant after delivery of the Warrant Shares in
accordance with the terms hereof.] On or before the first (1st) Trading Day following the date on which the Company has received the Exercise Notice, the Company shall transmit by facsimile
an acknowledgment of confirmation of receipt of the Exercise Notice to the Holder and the Companys transfer agent (the Transfer Agent). On or before the third (3rd) Trading Day following the date on which the Company
has received the Exercise Notice, so long as the Holder delivers the Aggregate Exercise Price (or notice of a Cashless Exercise) on or prior to the second (2nd) Trading Day following the date on which the Company has received the Exercise
Notice (the Share Delivery Date) (provided that if the Aggregate Exercise Price has not been delivered by such date, the Share Delivery Date shall be one (1) Trading Day after the Aggregate Exercise Price (or notice of a
Cashless Exercise) is delivered), the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (DTC) Fast Automated Securities Transfer Program, credit such aggregate number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the Holders or its designees balance account with DTC through its Deposit / Withdrawal At Custodian system, or (Y) if the Transfer Agent is not participating in the
DTC Fast Automated Securities Transfer Program, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Companys share register in the name of the Holder or its designee, for
the number of Warrant Shares to which the Holder is entitled pursuant to such exercise. The Company shall be responsible for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant Shares via
DTC, if any. Upon delivery of the Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such
Warrant Shares are credited to the Holders DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. [INSERT IN SERIES A, D & E WARRANTS: If this Warrant is submitted in connection
with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as
practicable and in no event later than three (3) Trading Days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 7(d)) representing the right to purchase the number of Warrant Shares issuable
immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised.] No fractional Warrant Shares are to be issued upon the exercise of this Warrant, but rather the number of
Warrant Shares to be issued shall be rounded up to the nearest whole number. The Company shall pay any and all taxes (other than the Holders income taxes) which may be payable with respect to the issuance and delivery of Warrant Shares upon
exercise of this Warrant. The
- 2 -
Companys obligations to issue and deliver Warrant Shares in accordance with the terms and subject to the conditions hereof are absolute and unconditional, irrespective of any action or
inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or
termination. [INSERT IN SERIES B, C & D WARRANTS: NOTWITHSTANDING ANY PROVISION OF THIS WARRANT TO THE CONTRARY, NO MORE THAN THE MAXIMUM ELIGIBILITY NUMBER OF WARRANT SHARES SHALL BE EXERCISABLE HEREUNDER.]
(b) Exercise Price. For purposes of this Warrant, Exercise Price means
[ ]2, subject to adjustment as provided herein.
(c) Companys Failure to Timely Deliver Securities. If the Company shall fail for any reason or for no reason to issue to the
Holder on or prior to the Share Delivery Date either (I) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, a certificate for the number of shares of Common Stock to which the Holder is entitled
and register such shares of Common Stock on the Companys share register or if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, to credit the Holders balance account with DTC, for such number of
shares of Common Stock to which the Holder is entitled upon the Holders exercise of this Warrant, (II) if the Registration Statement (as defined in Section 1(d)) covering the issuance of all of the Warrant Shares that are the subject of
the Exercise Notice (the Unavailable Warrant Shares) is not available for the issuance of such Unavailable Warrant Shares and the Company fails to promptly (x) so notify the Holder and (y) deliver the Warrant Shares
electronically without any restrictive legend by crediting such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holders or its designees balance account with DTC through its Deposit /
Withdrawal At Custodian system (the event described in the immediately foregoing clause (II) is hereinafter referred as a Notice Failure and together with the event described in clause (I) above, an Exercise
Failure) or (III) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, the Company shall fail to issue and deliver a certificate to the Holder and register such shares of Common Stock on the
Companys share register or, if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit the Holders balance account with DTC for the number of shares of Common Stock to
2 |
[INSERT IN SERIES A & C WARRANTS: $0.50 [INSERT IN SERIES B WARRANT: the lower of (x) [$0.50 (x), the Fixed Exercise Price) and (y) (I) in the case of a Mandatory
Exercise (as defined below) pursuant to Section 1(h), eighty-five percent (85%) of the lowest Weighted Average Price of the Common Stock for any Trading Day during the three (3) consecutive Trading Days immediately following the date
of the applicable Mandatory Exercise Notice Date and (II) otherwise, including, without limitation, in the case of an exercise pursuant to Section 1(a), eighty-five percent (85%) of the lowest Weighted Average Price of the Common Stock for
any Trading Day during the three (3) consecutive Trading Days immediately preceding the date of the applicable Exercise Notice or other applicable date of determination, in each such case, with such Weighted Average Price appropriately adjusted
for any stock dividend, stock split, stock combination, reclassification or similar transaction during the applicable calculation period, in each case] [INSERT IN SERIES D & E WARRANTS: $0.0001] |
- 3 -
which the Holder is entitled upon the Holders exercise hereunder or pursuant to the Companys obligation pursuant to clause (ii) below, and if on or after such Trading Day the
Holder (or any other Person in respect, or on behalf, of the Holder) purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of shares of
Common Stock equal to or any portion of the number of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company (a Buy-In), then, in addition to all other remedies available to the
Holder, the Company shall, within three (3) Trading Days after the Holders request and in the Holders discretion, either (i) pay cash to the Holder in an amount equal to the Holders total purchase price (including
brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (the Buy-In Price), at which point the Companys obligation to deliver such certificate (and to issue such shares of
Common Stock) or credit such Holders balance account with DTC for such shares of Common Stock shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such shares of Common
Stock or credit such Holders balance account with DTC, as applicable, and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times
(B) any trading price of the Common Stock selected by the Holder in writing as in effect at any time during the period beginning on the date of the applicable Exercise Notice and ending on the date of such issuance and payment under this
Section 3(c). Nothing shall limit the Holders right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the
Companys failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the exercise of this Warrant as required pursuant to the terms hereof.
(d) Cashless Exercise. Notwithstanding anything contained herein to the contrary, [INSERT IN SERIES A, B & C WARRANTS:
if the Registration Statement on Form S-3 (File number 333-193718) or other applicable registration statement under the 1933 Act (the Registration Statement), covering the issuance of the Unavailable Warrant Shares is not
available for the issuance of such Unavailable Warrant Shares [INSERT ONLY IN SERIES B WARRANT: for a period of at least sixty (60) consecutive days,] the Holder may, in its sole discretion, exercise this Warrant in whole or in part and,
in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the Net Number of shares of Common Stock
determined according to the following formula (a Cashless Exercise):
For purposes of the foregoing formula:
|
A = |
the total number of shares with respect to which this Warrant is then being exercised. |
- 4 -
|
B = |
the arithmetic average of the Closing Sale Prices of the Common Stock for the five (5) consecutive Trading Days ending on the date immediately preceding the date of the Exercise Notice. |
|
C = |
the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise. |
|
D = |
the Closing Sale Price of the Common Stock on the date of the Exercise Notice. |
If Warrant
Shares are issued in a Cashless Exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the 1933 Act, the Warrant Shares shall take on the registered characteristics of the warrants being exercised, and the
holding period of the warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 1(d).
(e) Disputes. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant
Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 12.
(f) Beneficial Ownership Limitation on Exercises. Notwithstanding anything to the contrary contained herein, the Company shall not
effect the exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if
never made, to the extent that after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 9.99% (the Maximum Percentage) of the number of shares of
Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the
number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall
exclude the number of shares of Common Stock which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B) exercise or
conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including the Warrants beneficially owned by the Holder or
any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 1(f). For purposes of this Section 1(f), beneficial ownership shall be calculated in accordance with
Section 13(d) of the Securities Exchange Act of 1934, as amended (the 1934 Act). For purposes of this Warrant, in determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this
Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Companys most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current
Report on Form
- 5 -
8-K or other public filing with the Securities and Exchange Commission (the SEC), as the case may be, (y) a more recent public announcement by the Company or (3) any
other written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding (the Reported Outstanding Share Number). If the Company receives an Exercise Notice from the Holder at a time
when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that
such Exercise Notice would otherwise cause the Holders beneficial ownership, as determined pursuant to this Section 1(f), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be
purchased pursuant to such Exercise Notice (the number of shares by which such purchase is reduced, the Reduction Shares) and (ii) as soon as reasonably practicable, the Company shall return to the Holder any exercise price
paid by the Holder for the Reduction Shares. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing or by electronic mail to the Holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and
any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other
Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by
which the Holders and the other Attribution Parties aggregate beneficial ownership exceeds the Maximum Percentage (the Excess Shares) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall
not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for
the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective until the sixty-first (61st) day after
delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first
(61st) day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other
holder of SPA Warrants that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially
owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms
of this Section 1(f) to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 1(f) or to make
changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant.
- 6 -
(g) Insufficient Authorized Shares. The Company shall not issue shares upon exercise of
this Warrant if such shares are not then authorized. From the Issuance Date and prior to the date both of the Reverse Stock Split and the Authorized Shares Increase Amendment have been adopted and become effective, the Company shall initially
reserve out of its authorized and unissued Common Stock a number of shares of Common Stock for this Warrant and the Additional Warrants equal to 85,002,328 (as adjusted for any stock dividend, stock split, stock combination, reclassification or
similar transaction occurring after the Subscription Date). From and after the date the Reverse Stock Split Resolution and the Authorized Shares Increase Resolution (each, as defined in the Securities Purchase Agreement) have been obtained and both
the Reverse Stock Split and Authorized Shares Increase Amendment have been adopted and become effective and while this Warrant or any of the Additional Warrants remain outstanding, the Company shall initially reserve out of its authorized and
unissued Common Stock at least 200,000,000 shares of Common Stock (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the Subscription Date) to effect the exercise of this
Warrant and all of the Additional Warrants then outstanding or such greater number of shares of Common Stock determined by taking into account the Maximum Eligibility Number (as defined in each of the Series B Warrants, the Series C Warrants and the
Series D Warrants, without giving effect to the proviso set forth in such definitions). The number of shares of Common Stock that the Company is required form time to time to reserve from its authorized and unissued capital for the exercise of this
Warrant and all of the Additional Warrants is herein referred to as the Required Reserve Amount and the failure to have such sufficient number of authorized and unreserved shares of Common Stock is herein referred to as an
Authorized Share Failure. If at any time while this Warrant remains outstanding the Company does not have at least the Required Reserve Amount of authorized and unreserved shares of Common Stock to satisfy its obligation to
reserve for issuance upon exercise of this Warrant and the Additional Warrants, then the Company shall promptly take all action reasonably necessary to increase the Companys authorized shares of Common Stock to an amount sufficient to allow
the Company to reserve the Required Reserve Amount for this Warrant and the Additional Warrants then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized
Share Failure, but in no event later than seventy-five (75) days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting of its shareholders for the approval of an increase in the number of authorized shares of
Common Stock. In connection with such meeting, the Company shall provide each shareholder with a proxy statement and shall use its reasonable best efforts to solicit its shareholders approval of such increase in authorized shares of Common
Stock and to cause its board of directors to recommend to the shareholders that they approve such proposal. Notwithstanding the foregoing, if any such time of an Authorized Share Failure, the Company is able to obtain the written consent of a
majority of the shares of its issued and outstanding Common Stock to approve the increase in the number of authorized shares of Common Stock, the Company may satisfy this obligation by obtaining such consent and submitting for filing with the SEC an
Information Statement on Schedule 14C. In the event that upon any exercise of this Warrant, the Company does not have sufficient authorized shares to
- 7 -
deliver in satisfaction of such exercise, then unless the Holder elects to void such attempted exercise, the Holder may require in lieu of delivering the number of Warrant Shares that the Company
is unable to deliver pursuant to this Section 1(g), the Company to pay to the Holder within three (3) Trading Days of the applicable exercise, cash in an amount equal to the greatest Closing Sale Price of the Common Stock on any Trading
Day at any time during the period beginning on the date of the applicable Exercise Notice and ending on the date the Company makes the payment provided for in this sentence; provided, however, that any such cash payment shall only
apply after the date that is one hundred days (120) immediately following the Issuance Date [INSERT IN SERIES B WARRANT:; provided, further, that any such cash payment shall apply immediately following the Issuance Date if
such cash payment is triggered by a Mandatory Exercise pursuant to Section 1(h) or following a Mandatory Exercise Notice delivered to the Holder by the Company pursuant to Section 1(h)]. The initial number of shares of Common Stock
reserved for exercise of this Warrant and the Additional Warrants and each increase in the number of shares so reserved shall be allocated pro rata among the Holder and the holders of the other SPA Warrants and Additional Warrants, based on the
number of shares of Common Stock issuable upon exercise of [INSERT IN SERIES A WARRANT: this Warrant] [INSERT IN SERIES B, C, D & E WARRANTS: the Series A Warrants] (without regard to any limitations in exercise) issued to the
Holder on the Issuance Date (the Authorized Share Allocation). In the event that the Holder shall sell or otherwise transfer this Warrant or any of its other Additional Warrants, each transferee shall be allocated a pro rata
portion of such holders Authorized Share Allocation. Any shares of Common Stock reserved and allocated to any Person which ceases to hold any Warrants shall be allocated to the Holder and the remaining holders of Warrants, pro rata based on
the shares of Common Stock issuable upon exercise of the Warrants then held by such holders (without regard to any limitations on the exercise of the Warrants).
(h) [INSERT IN SERIES B WARRANT: Mandatory Exercise at the Companys Election.
(i) If at any time from and after March 30, 2015, no Equity Conditions Failure has occurred during the Equity Conditions Measuring Period
relating to the applicable Mandatory Exercise, the Company shall have the right to require the Holder and all, but not less than all, holders of the other SPA Warrants to exercise up to the Mandatory Exercise Amount as designated in the Mandatory
Exercise Notice on the Mandatory Exercise Date (each, as defined below) into fully paid, validly issued and nonassessable shares of Common Stock in accordance with Section 1(a) hereof at the Exercise Price as of the Mandatory Exercise Date
(a Mandatory Exercise). The Company may exercise its right to require exercise under this Section 1(h) by delivering a written notice thereof by facsimile or electronic mail and overnight courier to the Holder and all,
but not less than all, of the holders of the other SPA Warrants and the Transfer Agent (the Mandatory Exercise Notice and the date the Holder and all the holders of the other SPA Warrants received such notice is referred to as the
Mandatory Exercise Notice Date). The Mandatory Exercise Notice shall be irrevocable. The Mandatory Exercise Notice shall (i) state (a) the Trading Day on which the Mandatory Exercise shall occur, which Trading Day shall
be the third (3rd) Trading Day immediately following the Mandatory Exercise Notice Date (the Mandatory Exercise Date), (b) the aggregate number of SPA Warrants which
the Company has elected to be subject
- 8 -
to Mandatory Exercise from the Holder and all of the holders of the other SPA Warrants pursuant to this Section 1(h) (and analogous provisions under the other SPA Warrants) and
(c) the number of shares of Common Stock to be issued to the Holder on the Mandatory Exercise Date and (ii) certify that there has been no Equity Conditions Failure on any day during the period beginning on the first day of the Equity
Conditions Measuring Period prior to the Mandatory Exercise Notice Date through the Mandatory Exercise Date. If the Company confirmed that there was no such Equity Conditions Failure as of the Mandatory Exercise Notice Date but an Equity Conditions
Failure occurs between the Mandatory Exercise Notice Date and any time through the Mandatory Exercise Date (the Mandatory Exercise Interim Period), the Company shall provide the Holder and each holder of the other SPA Warrants a
subsequent notice to that effect. If there is an Equity Conditions Failure (which is not waived in writing by the Holder) during such Mandatory Exercise Interim Period, then the Mandatory Exercise shall be null and void with respect to all or any
part designated by the Holder of the unexercised Mandatory Exercise Amount subject to the Mandatory Exercise and the Holder shall be entitled to all the rights of a holder of this Warrant with respect to such Mandatory Exercise Amount of this
Warrant. The Company may not effect more than one (1) Mandatory Exercise under this Warrant and the other SPA Warrants during any four (4) consecutive Trading Day period. Notwithstanding anything to the contrary in this Section 1(h),
until the Mandatory Exercise has occurred, the Mandatory Exercise Amount of this Warrant subject to the Mandatory Exercise may be exercised, in whole or in part, by the Holder into shares of Common Stock pursuant to Section 1(a). All exercises
of this Warrant by the Holder after the Mandatory Exercise Notice Date shall reduce the Mandatory Exercise Amount required to be exercised on the Mandatory Exercise Date, unless the Holder otherwise indicates in the applicable Exercise Notice.
(ii) If the Company elects to cause a Mandatory Exercise pursuant to Section 1(h)(i), then it must simultaneously take the same
action in the same proportion with respect to all of the other SPA Warrants. For the avoidance of doubt, if the Company elects a Mandatory Exercise of this Warrant pursuant to Section 1(h)(i) (or similar provisions under the other SPA Warrants)
with respect to less than all of the Warrant Shares underlying the SPA Warrants then outstanding, then the Company shall require exercise of a number of SPA Warrants from the Holder and each of the holders of the other SPA Warrants equal to the
product of (i) the aggregate number of Warrant Shares which the Company has elected to cause to be exercised pursuant to Section 1(h)(i), multiplied by (ii) the fraction, the numerator of which is the sum of the aggregate number of
Warrant Shares underlying the SPA Warrant issued to such holder pursuant to the Securities Purchase Agreement and the denominator of which is the sum of the aggregate number of Warrant Shares underlying the SPA Warrants issued to all holders
pursuant to the Securities Purchase Agreement (such fraction with respect to each holder is referred to as its Exercise Allocation Percentage, and such amount with respect to each holder is referred to as its Pro Rata
Exercise Amount); provided, however, that in the event that any holders Pro Rata Exercise Amount exceeds the outstanding number of SPA Warrants such holder, then such excess Pro Rata Exercise Amount shall be allocated
amongst the remaining holders of SPA Warrants in accordance with the foregoing formula. In the event that the initial holder of any SPA Warrants shall sell or otherwise transfer any of such holders SPA Warrants, the transferee shall be
allocated a pro rata portion of such holders Exercise Allocation Percentage and Pro Rata Exercise Amount.]
- 9 -
(i) [INSERT IN SERIES D WARRANT: Automatic Exercise. On March 16, 2015, the
Company shall issue to the Holder pursuant to a Cashless Exercise pursuant to Section 1(d), without the delivery of a notice of Cashless Exercise by the Holder and without any other action on behalf of the Holder, the maximum number of shares
of Common Stock available under the Maximum Eligibility Number, subject to the provisions of Section 1(f).]
2. ADJUSTMENT OF
EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:
(a) [INSERT IN SERIES D & E WARRANTS: Intentionally omitted.] [INSERT IN SERIES A, B & C WARRANTS: Adjustment
Upon Issuance of Shares of Common Stock. If and whenever on or after the Subscription Date, the Company issues or sells, or in accordance with this Section 2 is deemed to have issued or sold, or publicly announces the issuance or sale of,
any shares of Common Stock (including the issuance or sale of shares of Common Stock owned or held by or for the account of the Company, but excluding shares of Common Stock deemed to have been issued or sold by the Company in connection with any
Excluded Securities for a consideration per share (the New Issuance Price) less than a price (the Applicable Price) equal to the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price in effect
immediately prior to such issue or sale or deemed issuance or sale (the foregoing a Dilutive Issuance), then immediately after such Dilutive Issuance, the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price then in
effect shall be reduced to an amount equal to the New Issuance Price. For purposes of determining the adjusted [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price under this Section 2(a), the following shall be applicable:
(i) Issuance of Options. If the Company grants or sells, or publicly announces the grant or sale of, any Options and the
lowest price per share for which one share of Common Stock is issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option is less than the Applicable
Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale of such Option for such price per share. For purposes of this Section 2(a)(i), the
lowest price per share for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option shall be equal
to the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of the Option, upon exercise of the Option and upon conversion, exercise or
exchange of any Convertible Security issuable upon exercise of such Option less any consideration paid or payable by the Company with respect to such one share of Common Stock upon the granting or sale of such Option, upon exercise of such Option
and upon conversion exercise or exchange of any Convertible Security issuable upon exercise of such Option.
- 10 -
No further adjustment of the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price shall be made upon the actual issuance of such shares of Common Stock or of such Convertible Securities
upon the exercise of such Options or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities.
(ii) Issuance of Convertible Securities. If the Company in any manner issues or sells, or publicly announces the
issuance or sale of, any Convertible Securities and the lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof is less than the Applicable Price, then such share of Common Stock shall
be deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale of such Convertible Securities for such price per share. For the purposes of this Section 2(a)(ii), the lowest price per share
for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof shall be equal to the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to any one share of
Common Stock upon the issuance or sale of the Convertible Security and upon conversion, exercise or exchange of such Convertible Security less any consideration paid or payable by the Company with respect to such one share of Common Stock upon the
issuance or sale of such Convertible Security and upon conversion, exercise or exchange of such Convertible Security. No further adjustment of the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price shall be made upon the actual issuance
of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities, and if any such issue or sale of such Convertible Securities is made upon exercise of any Options for which adjustment of this Warrant has been or
is to be made pursuant to other provisions of this Section 2(a), no further adjustment of the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price shall be made by reason of such issue or sale.
(iii) Change in Option Price or Rate of Conversion. If the purchase price provided for in any Options, the additional
consideration, if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any Convertible Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases
or decreases at any time, the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price in effect at the time of such increase or decrease shall be adjusted to the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price, which would have
been in effect at such time had such Options or Convertible Securities provided for such increased or decreased purchase price, additional consideration or increased or decreased conversion rate, as the case may be, at the time initially granted,
issued or sold. For purposes of this Section 2(a)(iii), if the terms of any Option or Convertible Security that was outstanding as of the Subscription Date are increased or decreased in the manner described in the immediately preceding
sentence, then such Option or Convertible Security and the shares of Common Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or decrease. No adjustment pursuant
to this Section 2(a) shall be made if such adjustment would result in an increase of the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price then in effect.
- 11 -
(iv) Calculation of Consideration Received. In case any Option is issued
in connection with the issue or sale of other securities of the Company, together comprising one integrated transaction, (x) the Options will be deemed to have been issued for the Option Value of such Options and (y) the other securities
issued or sold in such integrated transaction shall be deemed to have been issued or sold for the difference of (I) the aggregate consideration received by the Company less any consideration paid or payable by the Company pursuant to the terms
of such other securities of the Company, less (II) the Option Value. If any shares of Common Stock, Options or Convertible Securities are issued or sold or deemed to have been issued or sold for cash, the consideration other than cash received
therefor will be deemed to be the net amount received by the Company therefor. If any shares of Common Stock, Options or Convertible Securities are issued or sold for a consideration other than cash, the amount of such consideration received by the
Company will be the fair value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company will be the Closing Sale Price of such publicly traded
securities on the date of receipt. If any shares of Common Stock, Options or Convertible Securities are issued to the owners of the non-surviving entity in connection with any merger in which the Company is the surviving entity, the amount of
consideration therefor will be deemed to be the fair value of such portion of the net assets and business of the non-surviving entity as is attributable to such shares of Common Stock, Options or Convertible Securities, as the case may be. The fair
value of any consideration other than cash or publicly traded securities will be determined jointly by the Company and the Required Holders. If such parties are unable to reach agreement within ten (10) days after the occurrence of an event
requiring valuation (the Valuation Event), the fair value of such consideration will be determined within five (5) Business Days after the tenth (10th) day following
the Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Required Holders. The determination of such appraiser shall be final and binding upon all parties absent manifest error and the fees and expenses of
such appraiser shall be borne by the Company.
(v) Record Date. If the Company takes a record of the holders of
shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other distribution payable in shares of Common Stock, Options or in Convertible Securities or (B) to subscribe for or purchase shares of Common Stock,
Options or Convertible Securities, then such record date will be deemed to be the date of the issue or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other
distribution or the date of the granting of such right of subscription or purchase, as the case may be.
(vi) No
Readjustments. For the avoidance of doubt, in the event the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price has been adjusted pursuant to this Section 2(a) and the Dilutive Issuance that triggered such adjustment
- 12 -
does not occur, is not consummated, is unwound or is cancelled after the facts for any reason whatsoever, in no event shall the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price
be readjusted to the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price that would have been in effect if such Dilutive Issuance had not occurred or been consummated.]
(b) Voluntary Adjustment By Company. The Company may at any time during the term of this Warrant, with the prior written consent of the
Required Holders, reduce the then current [INSERT IN SERIES B WARRANT: Fixed] Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.
(c) Adjustment Upon Subdivision or Combination of Shares of Common Stock. If the Company at any time on or after the Subscription Date
subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the [INSERT IN SERIES B WARRANT: Fixed] Exercise Price in effect
immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Subscription Date combines (by combination, reverse stock split or
otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the [INSERT IN SERIES B WARRANT: Fixed] Exercise Price in effect immediately prior to such combination will be proportionately increased
and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 2(c) shall become effective at the close of business on the date the subdivision or combination becomes effective.
(d) [INSERT IN SERIES A, B & C WARRANTS: Other Events. If any event occurs of the type contemplated by the provisions
of this Section 2 but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features), then the Companys Board of
Directors will make an appropriate adjustment in the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price and the number of Warrant Shares, as mutually determined by the Companys Board of Directors and the Required Holders, so as to
protect the rights of the Holder; provided that no such adjustment pursuant to this Section 2(d) will increase the [INSERT ONLY IN SERIES B WARRANT: Fixed] Exercise Price or decrease the number of Warrant Shares as otherwise
determined pursuant to this Section 2.]
3. RIGHTS UPON DISTRIBUTION OF ASSETS. If the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities,
property, options, evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a Distribution), at any time after the
issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this
- 13 -
Warrant, including without limitation, the Maximum Percentage, and as if both of the Reverse Stock Split and the Authorized Shares Increase Amendment had, as of such date, been adopted and become
effective) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such
Distribution (provided, however, that to the extent that the Holders right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder
shall not be entitled to participate in such Distribution to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to such extent) and the portion of
such Distribution shall be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the
Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation).
4. PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS.
(a) Purchase Rights. In addition to any adjustments pursuant to Section 2 above, if at any time the Company grants, issues or
sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the Purchase Rights), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage, and as if both of the Reverse Stock Split and the Authorized Shares Increase Amendment had, as of such date, been adopted
and become effective) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be
determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the extent that the Holders right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties
exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase Right (and
beneficial ownership) to such extent) and such Purchase Right to such extent shall be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties
exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance) to the
same extent as if there had been no such limitation).
(b) Fundamental Transactions. The Company shall not enter into or be party
to a Fundamental Transaction unless the Successor Entity assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 4(b) pursuant to written
agreements in form and
- 14 -
substance reasonably satisfactory to the Required Holders and approved by the Required Holders, such approval not to be unreasonably withheld or delayed, prior to such Fundamental Transaction,
including agreements, if so requested by the Holder, to deliver to each holder of the SPA Warrants in exchange for such SPA Warrants a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to
this Warrant, including, without limitation, an adjusted exercise price equal to the value for the shares of Common Stock reflected by the terms of such Fundamental Transaction, and exercisable for a corresponding number of shares of capital stock
equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant and as if both of the Reverse Stock Split and the Authorized Shares Increase
Amendment had, as of such date, been adopted and become effective) prior to such Fundamental Transaction, and satisfactory to the Required Holders, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such adjustments to the number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the occurrence or consummation of such Fundamental Transaction). Upon the occurrence or consummation of any Fundamental Transaction, and it shall be a required
condition to the occurrence or consummation of any Fundamental Transaction that, the Company and the Successor Entity or Successor Entities, jointly and severally, shall succeed to, and the Company shall cause any Successor Entity or Successor
Entities to jointly and severally succeed to, and be added to the term Company under this Warrant (so that from and after the date of such Fundamental Transaction, and the provisions of this Warrant referring to the Company
shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Company and the Successor Entity or Successor Entities, jointly and severally, may exercise every right and power of the
Company prior thereto and shall assume all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the
Company in this Warrant, and, solely at the request of the Holder, if the Successor Entity and/or Successor Entities is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market, shall deliver (in
addition to and without limiting any right under this Warrant) to the Holder in exchange for this Warrant a security of the Successor Entity and/or Successor Entities evidenced by a written instrument substantially similar in form and substance to
this Warrant and exercisable for a corresponding number of shares of capital stock of the Successor Entity and/or Successor Entities (the Successor Capital Stock) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant and as if both of the Reverse Stock Split and the Authorized Shares Increase Amendment had, as of such date, been adopted and become effective) prior to
such Fundamental Transaction (such corresponding number of shares of Successor Capital Stock to be delivered to the Holder shall be equal to the greater of (A) the quotient of (i) the aggregate dollar value of all consideration (including
cash consideration and any consideration other than cash (Non-Cash Consideration), in such Fundamental Transaction, as such values are set forth in any definitive agreement for the Fundamental Transaction that has been executed at
the time of the first public announcement of the Fundamental Transaction or, if no such value is determinable from such definitive
- 15 -
agreement, as determined in accordance with Section 12 with the term Non-Cash Consideration being substituted for the term Exercise Price) that the Holder would have
been entitled to receive upon the happening of such Fundamental Transaction or the record, eligibility or other determination date for the event resulting in such Fundamental Transaction, had this Warrant been exercised immediately prior to such
Fundamental Transaction or the record, eligibility or other determination date for the event resulting in such Fundamental Transaction (without regard to any limitations on the exercise of this Warrant and as if both of the Reverse Stock Split and
the Authorized Shares Increase Amendment had, as of such date, been adopted and become effective) (the Aggregate Consideration) divided by (ii) the per share Closing Sale Price of such Successor Capital Stock on the Trading
Day immediately prior to the consummation or occurrence of the Fundamental Transaction and (B) the product of (i) the Aggregate Consideration and (ii) the highest exchange ratio pursuant to which any shareholder of the Company may
exchange Common Stock for Successor Capital Stock) (provided, however, to the extent that the Holders right to receive any such shares of publicly traded common stock (or their equivalent) of the Successor Entity would result in the Holder and
its other Attribution Parties exceeding the Maximum Percentage, if applicable, then the Holder shall not be entitled to receive such shares to such extent (and shall not be entitled to beneficial ownership of such shares of publicly traded common
stock (or their equivalent) of the Successor Entity as a result of such consideration to such extent) and the portion of such shares shall be held in abeyance for the Holder until such time or times, as its right thereto would not result in the
Holder and its other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be delivered such shares to the extent as if there had been no such limitation), and such security shall be reasonably satisfactory to
the Holder, and with an identical exercise price to the Exercise Price hereunder (such adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting after the consummation or occurrence of such
Fundamental Transaction the economic value of this Warrant that was in effect immediately prior to the consummation or occurrence of such Fundamental Transaction, as elected by the Holder solely at its option). Upon occurrence or consummation of the
Fundamental Transaction, and it shall be a required condition to the occurrence or consummation of such Fundamental Transaction that, the Company and the Successor Entity or Successor Entities shall deliver to the Holder confirmation that there
shall be issued upon exercise of this Warrant at any time after the occurrence or consummation of the Fundamental Transaction, as elected by the Holder solely at its option, shares of Common Stock, Successor Capital Stock or, in lieu of the shares
of Common Stock or Successor Capital Stock (or other securities, cash, assets or other property purchasable upon the exercise of this Warrant prior to such Fundamental Transaction), such shares of stock, securities, cash, assets or any other
property whatsoever (including warrants or other purchase or subscription rights), which for purposes of clarification may continue to be shares of Common Stock, if any, that the Holder would have been entitled to receive upon the happening of such
Fundamental Transaction or the record, eligibility or other determination date for the event resulting in such Fundamental Transaction, had this Warrant been exercised immediately prior to such Fundamental Transaction or the record, eligibility or
other determination date for the event resulting in such Fundamental Transaction (without regard to any limitations on the exercise of this Warrant and as if both of the Reverse Stock Split and the Authorized Shares Increase Amendment had, as of
such date, been adopted and become effective), as adjusted in accordance with the provisions of this Warrant. In addition to and not in substitution for any other rights
- 16 -
hereunder, prior to the occurrence or consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities, cash, assets or other
property with respect to or in exchange for shares of Common Stock (a Corporate Event), the Company shall make appropriate provision to ensure that, and any applicable Successor Entity or Successor Entities shall ensure that, and
it shall be a required condition to the occurrence or consummation of such Corporate Event that, the Holder will thereafter have the right to receive upon exercise of this Warrant at any time after the occurrence or consummation of the Corporate
Event, shares of Common Stock or Successor Capital Stock or, if so elected by the Holder, in lieu of the shares of Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of this Warrant prior to such
Corporate Event (but not in lieu of such items still issuable under Sections 3 and 4(a), which shall continue to be receivable on the Common Stock or on the such shares of stock, securities, cash, assets or any other property otherwise receivable
with respect to or in exchange for shares of Common Stock), such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights and any shares of Common Stock) which the Holder
would have been entitled to receive upon the occurrence or consummation of such Corporate Event or the record, eligibility or other determination date for the event resulting in such Corporate Event, had this Warrant been exercised immediately prior
to such Corporate Event or the record, eligibility or other determination date for the event resulting in such Corporate Event (without regard to any limitations on exercise of this Warrant and as if both of the Reverse Stock Split and the
Authorized Shares Increase Amendment had, as of such date, been adopted and become effective). Provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Holder. The provisions of this
Section 4(b) shall apply similarly and equally to successive Fundamental Transactions and Corporate Events. Notwithstanding the foregoing, the Holder may elect, in its sole discretion, by delivery of written notice to the Company, to waive this
Section 4(b) and allow the Company to enter into or be a party to a Fundamental Transaction without the assumption of this Warrant pursuant to the provisions of this Section 4(b), provided, however, that any such waiver shall
only bind the Holder with respect to this Warrant and not the Holder with respect to any other Warrant or any holder of other SPA Warrants or Additional Warrants.
(c) [INSERT IN SERIES A, B & C WARRANTS: Notwithstanding the foregoing, (i) in the event of a Fundamental Transaction, other
than one in which the Successor Entity that is a publicly traded corporation whose stock is quoted or listed for trading on an Eligible Market and which Successor Entity assumes this Warrant such that the Warrant shall be exercisable for the
publicly traded Common Stock of such Successor Entity, or (ii) either the Reverse Stock Split or the Authorized Shares Increase Amendment has not been obtained on or prior to
[ ]5 (the Share Increase Date), at the request of the Holder delivered before the thirtieth (30th) day after either the occurrence or consummation of such Fundamental Transaction or the Share Increase Date, the Company (or the Successor Entity) shall purchase this Warrant from the Holder by
paying to the Holder, within five (5) Business Days after such request (or, if later, on the effective date of the Fundamental Transaction), cash in an amount equal to
5 |
[INSERT ONLY IN SERIES B WARRANT: Insert the date that is one hundred twenty (120) days after the Issuance Date [June 26, 2015]] [INSERT ONLY IN SERIES A & C WARRANTS: the Initial Exercisability
Date] |
- 17 -
[INSERT ONLY IN SERIES A & C WARRANTS: the Black Scholes Value of the remaining unexercised portion of this Warrant on either the date of such Fundamental Transaction or the Share
Increase Date] [INSERT ONLY IN SERIES B WARRANT: 8% of the Stated Warrant Value (as defined in the definition of Warrant Share Number set forth in Section 17) of the remaining unexercised portion of this Warrant on either the
date of such Fundamental Transaction or the Share Increase Date].]
5. NONCIRCUMVENTION. The Company hereby covenants and agrees
that the Company will not, by amendment of its Articles of Incorporation or Bylaws, or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all of the provisions of this Warrant and take all action as may be required to protect the rights of the
Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take
all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the SPA
Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the SPA Warrants, the Required Reserve Amount to effect
the exercise of the SPA Warrants then outstanding (without regard to any limitations on exercise).
6. WARRANT HOLDER NOT DEEMED A
SHAREHOLDER. Except as otherwise specifically provided herein, the Holder, solely in such Persons capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the
Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Persons capacity as the Holder of this Warrant, any of the rights of a shareholder of the Company or any right to
vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or
otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities
on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 6, the
Company shall provide the Holder with copies of the same notices and other information given to the shareholders of the Company generally, contemporaneously with the giving thereof to the shareholders.
7. REISSUANCE OF WARRANTS.
(h) Transfer of Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the
Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as the Holder may request, representing the right to purchase the number of Warrant
- 18 -
Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 7(d))
to the Holder representing the right to purchase the number of Warrant Shares not being transferred.
(i) Lost, Stolen or Mutilated
Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the
Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing the right
to purchase the Warrant Shares then underlying this Warrant.
(j) Exchangeable for Multiple Warrants. This Warrant is exchangeable,
upon the surrender hereof by the Holder at the principal office of the Company, for a new warrant or warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying
this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no SPA Warrants for fractional
Warrant Shares shall be given.
(k) Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to
the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the
case of a new Warrant being issued pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new warrants issued in connection with
such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same
rights and conditions as this Warrant.
8. NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise
provided herein, such notice shall be given in accordance with Section 9(f) of the Securities Purchase Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in
reasonable detail a description of such action and the reason therefor. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment of the Exercise Price, setting
forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen (15) days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or
distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock or
(C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation; provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being
provided to the Holder. It is expressly understood and agreed that the time of exercise specified by the Holder in each Exercise Notice shall be definitive and may not be disputed or challenged by the Company.
- 19 -
9. AMENDMENT AND WAIVER. Except as otherwise provided herein, the provisions of this
Warrant may be amended or waived and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Required Holders.
10. GOVERNING LAW; JURISDICTION; JURY TRIAL. This Warrant shall be governed by and construed and enforced in accordance with, and
all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and
federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or
proceeding is improper. The Company hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to the Company at the address set forth in
Section 9(f) of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Companys obligations to
the Holder, to realize on any collateral or any other security for such obligations, or to enforce a judgment or other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A
JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.
11. CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and all the Buyers and shall not be
construed against any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.
12. DISPUTE RESOLUTION. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the
Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If the
Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three (3)
- 20 -
Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2) Business Days submit via facsimile (a) the
disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Holder and approved by the Company, such approval not to be unreasonably withheld or delayed or (b) the disputed arithmetic calculation of
the Warrant Shares to the Companys independent, outside accountant, selected by the Holder and approved by the Company, such approval not to be unreasonably withheld or delayed. The Company shall cause at its expense the investment bank or the
accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) Business Days from the time it receives the disputed determinations or calculations. Such
investment banks or accountants determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error.
13. REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in
addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder
to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any
such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any
breach, without the necessity of showing economic loss and without any bond or other security being required.
14. TRANSFER. This
Warrant and the Warrant Shares may be offered for sale, sold, transferred, pledged or assigned without the consent of the Company [INSERT IN SERIES B & C WARRANTS:; provided, however, that the Holder shall not sell, offer,
transfer, pledge or assign any portion of this Warrant prior to the one (1) year anniversary of the Issuance Date, without the Companys prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned;
provided, further, that the Holder may only sell, offer, transfer, pledge or assign any portion of this Warrant together with a corresponding portion of the Holders Other Warrant].
15. SEVERABILITY. If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a
court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of
such provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and
the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would
otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the
prohibited, invalid or unenforceable provision(s).
- 21 -
16. DISCLOSURE. Upon receipt or delivery by the Company of any notice in accordance with
the terms of this Warrant, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, nonpublic information relating to the Company or its Subsidiaries (as defined in the Securities Purchase
Agreement), the Company shall within one (1) Business Day after any such receipt or delivery publicly disclose such material, nonpublic information on a Current Report on Form 8-K or otherwise. In the event that the Company believes that a
notice contains material, nonpublic information relating to the Company or its Subsidiaries, the Company so shall indicate to such Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be
allowed to presume that all matters relating to such notice do not constitute material, nonpublic information relating to the Company or its Subsidiaries.
17. CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:
(a) 1933 Act means the Securities Act of 1933, as amended.
(b) Additional Warrants means [INSERT IN SERIES A WARRANT: the Series B Warrants, the Series C Warrants, the
Series D Warrants and the Series E Warrants, if any (each, as defined in the Securities purchase Agreement)] [INSERT IN SERIES B WARRANT: the Series A Warrants, the Series C Warrants, the Series D Warrants and the Series E Warrants, if any
(each, as defined in the Securities purchase Agreement)] [INSERT IN SERIES C WARRANT: the Series A Warrants, the Series B Warrants, the Series D Warrants and the Series E Warrants, if any (each, as defined in the Securities Purchase
Agreement)] [INSERT IN SERIES D WARRANT: the Series A Warrants, the Series B Warrants, the Series C Warrants and the Series E Warrants, if any (each, as defined in the Securities Purchase Agreement)] [INSERT IN SERIES E WARRANT: the
Series A Warrants, the Series B Warrants, the Series C Warrants and the Series D Warrants (each, as defined in the Securities Purchase Agreement)].
(c) Affiliate means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by,
or is under common control with, such Person, it being understood for purposes of this definition that control of a Person means the power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for
the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise.
(d) Attribution Parties means, collectively, the following Persons and entities: (i) any investment vehicle,
including, any funds, feeder funds or managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by the Holders investment manager or any of its Affiliates or principals, (ii) any
direct or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv) any
- 22 -
other Persons whose beneficial ownership of the Companys Common Stock would or could be aggregated with the Holders and the other Attribution Parties for purposes of
Section 13(d) of the 1934 Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.
(e) [INSERT IN SERIES A, B & C WARRANTS: Approved Stock Plan means any employee benefit plan which has been
approved by the Board of Directors of the Company, pursuant to which the Companys securities may be issued to any employee, officer, director or consultant for services provided to the Company.]
(f) Authorized Shares Increase Amendment shall have the meaning ascribe to such term in the Securities Purchase Agreement.
(g) [INSERT IN SERIES A & C WARRANTS: Black Scholes Value means the value of this Warrant based on the
Black-Scholes Option Pricing Model obtained from the OV function on Bloomberg determined as of the day immediately following the public announcement of the applicable Fundamental Transaction, or, if the Fundamental Transaction is not
publicly announced, the date the Fundamental Transaction is consummated, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of
such date of request, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the day immediately following the public announcement of the applicable Fundamental
Transaction, or, if the Fundamental Transaction is not publicly announced, the date the Fundamental Transaction is consummated, (iii) the underlying price per share used in such calculation shall be the sum of the price per share being offered
in cash, if any, plus the value of any non-cash consideration, if any, being offered in the Fundamental Transaction, (iv) a zero cost of borrow and (v) a 360 day annualization factor.]
(h) Bloomberg means Bloomberg Financial Markets.
(i) Business Day means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York
are authorized or required by law to remain closed.
(j) Closing Bid Price and Closing Sale Price
means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours
basis and does not designate the closing bid price or the closing trade price, as the case may be, then the last bid price or the last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if
the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such
security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security
as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for
- 23 -
such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the OTC Link or pink sheets by OTC
Markets Group Inc. (formerly Pink OTC Markets Inc.). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the
case may be, of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be
resolved pursuant to Section 12. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or other similar transaction during the applicable calculation period.
(k) Common Stock means (i) the Companys shares of Class A Common Stock, par value $0.0001 per share, and
(ii) any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock.
(l) Convertible Securities means any stock or securities (other than Options) directly or indirectly convertible into or
exercisable or exchangeable for shares of Common Stock.
(m) Eligible Market means the Principal Market, the NYSE MKT
LLC, The NASDAQ Global Market, The NASDAQ Global Select Market, The New York Stock Exchange, Inc., the OTC QX or the OTC QB.
(n)
[INSERT IN SERIES B WARRANT: Equity Conditions means each of the following conditions: (i) 200% of all shares of Common Stock issuable upon exercise of the Mandatory Exercise Amount that is subject to the applicable Mandatory
Exercise on the applicable Mandatory Exercise Date requiring the satisfaction of the Equity Conditions, shall be either (x) issuable without restrictive legends and shall be eligible for sale without restriction pursuant to Rule 144 of the
Securities Act (other than with respect to the volume and manner of sale limitations of Rule 144 if the Holder becomes an Affiliate of the Issuer after the Issuance Date) or Rule 3(a)(9) of the Securities Act and without the need for registration
under any applicable federal or state securities laws or (y) be subject to an effective registration statement; (ii) on each day during the Equity Conditions Measuring Period, the Common Stock is designated for quotation on the Principal
Market or any other Eligible Market and shall not have been suspended from trading on such exchange or market nor shall delisting or suspension by such exchange or market been threatened commenced or pending in writing by such exchange or market
(with a reasonable prospect of delisting occurring after giving effect to all applicable notice, appeal, compliance and hearing periods), provided, however, that after the Reverse Stock Split Date (as defined in the Securities Purchase
Agreement), delisting or suspension by such exchange or market shall not have been threatened, commenced or pending either (A) in writing by such exchange or market or (B) by falling below the then effective minimum listing maintenance
requirements of such exchange or market; (iii) during the Equity Conditions Measuring Period, the Company shall have delivered the shares of Common Stock pursuant to the terms of this Warrant, the other SPA Warrants and the Additional Warrants
to the Holder on a timely basis as set forth in Section 1(a) hereof (and analogous provisions under the other SPA
- 24 -
Warrants and the Additional Warrants); (iv) all shares of Common Stock issuable upon exercise of the Mandatory Exercise Amount that is subject to the applicable Mandatory Exercise on the
applicable Mandatory Exercise Date requiring the satisfaction of the Equity Conditions may be issued in full without violating Section 1(f) hereof (and analogous provisions under the other SPA Warrants and the Additional Warrants) and 200% of
all shares of Common Stock issuable upon exercise of the Mandatory Exercise Amount that is subject to the applicable Mandatory Exercise on the applicable Mandatory Exercise Date requiring the satisfaction of the Equity Conditions may be issued in
full without violating the rules or regulations of the Principal Market or any other applicable Eligible Market; (v) during the Equity Conditions Measuring Period, the Company shall not have failed to timely make any payments within five
(5) Business Days of when such payment is due beyond any applicable cure period pursuant to any Transaction Document; (vi) during the Equity Conditions Measuring Period, there shall not have occurred either (A) the consummation of a
Change of Control, (B) an Event of Default or Triggering Event or (C) an event that with the passage of time or giving of notice would constitute an Event of Default or Triggering Event; (vii) the Company shall have no knowledge of
any fact that would reasonably be expected to cause any shares of Common Stock issuable upon exercise of the Mandatory Exercise Amount that is subject to the applicable Mandatory Exercise requiring the satisfaction of the Equity Conditions, not to
be eligible for sale without restriction pursuant to Rule 144 of the Securities Act (other than with respect to the volume and manner of sale limitations of Rule 144 if the Holder becomes an Affiliate of the Issuer after the Issuance Date) or Rule
3(a)(9) of the Securities Act and without the need for registration (other than as required under the Registration Statement (as defined in the Securities Purchase Agreement)) under any applicable federal or state securities laws; (viii) on
each day during Equity Conditions Measuring Period, the Holder shall not be in possession of any material, nonpublic information received from the Company, any Subsidiary or its respective agent or Affiliates; (ix) 200% of the shares of Common
Stock issuable upon exercise of the Mandatory Exercise Amount that is subject to the applicable Mandatory Exercise requiring the satisfaction of the Equity Conditions are duly reserved, authorized and listed and eligible for trading without
restriction on an Eligible Market; (x) the daily dollar trading volume of the Common Stock as reported by Bloomberg for each Trading Day during the Equity Conditions Measuring Period shall be at least $100,000; and (xi) on each Trading Day
during the Equity Conditions Measuring Period, the Closing Sale Price of the Common Stock equals or exceeds $0.20.]
(o) [INSERT IN
SERIES B WARRANT: Equity Conditions Failure means that on any day during the period commencing two (2) Trading Days prior to the applicable date of determination through the applicable date of determination, the Equity
Conditions have not each been satisfied (or waived in writing by the Holder).]
(p) [INSERT IN SERIES B WARRANT: Equity
Conditions Measuring Period means the period beginning thirty (30) Trading Days prior to the applicable date of determination and ending on and including the applicable date of determination.]
(q) [INSERT IN SERIES A, B & C WARRANTS: Excluded Securities means any Common Stock issued or issuable:
(i) in connection with any Approved Stock Plan, provided, however, that no more than an aggregate of 150,000 (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction after the
- 25 -
Subscription Date) shares of Common Stock are issued or issuable to consultants hereunder as Excluded Securities, (ii) upon exercise of any Warrants issued pursuant to the Securities
Purchase Agreement and the warrants issued to the Agent (as defined in the Securities Purchase Agreement) by the Company as compensation for the transactions contemplated by the Securities Purchase Agreement (the Agent Warrants);
provided, that the terms of such Warrants and Agent Warrants are not amended, modified or changed on or after the Subscription Date without the prior written consent of the Required Holders, (iii) upon conversion or exercise of any
Options or Convertible Securities which are outstanding on the day immediately preceding the Subscription Date; provided, that the terms of such Options or Convertible Securities are not amended, modified or changed on or after the
Subscription Date; (iv) to vendors or consultants for services rendered to the Company; provided, however, that no more than an aggregate of 100,000 (as adjusted for any stock dividend, stock split, stock combination,
reclassification or similar transaction after the Subscription Date) shares of Common Stock are issued or issuable to vendors or consultants hereunder as Excluded Securities; and (v) to Silicon Valley Bank in connection with extending the
maturity date of the indebtedness evidenced by that certain Loan and Security Agreement dated as of December 19, 2011 by and among Real Goods Energy Tech, INC., Real Goods Trading Corporation, Earth Friendly Energy Group Holdings, LLC, Alteris
Renewables, INC., Earth Friendly Energy Group, LLC, Solar Works, LLC, Alteris RPS, LLC and Alteris ISI, LLC and Silicon Valley Bank; provided, however, that no more than an aggregate of 100,000 (as adjusted for any stock dividend,
stock split, stock combination, reclassification or similar transaction after the Subscription Date) shares of Common Stock are issued or issuable to the senior lender under such indebtedness hereunder as Excluded Securities.]
(r) Expiration Date means the date [INSERT IN SERIES A & C WARRANTS: that is sixty (60) months after the
Initial Exercisability Date] [INSERT IN SERIES B WARRANT: that is twelve (12) months after the later of (i) the Issuance Date and (ii) the date as of which (I) the Company obtained the Shareholder Approval (as defined in
the Securities Purchase Agreement) and (II) the Holder may sell all the Warrant Shares without restriction or limitation either (x) pursuant to Rule 144 of the Securities Act and without the requirement to be in compliance with Rule 144(c)(1)
of the Securities Act or (y) pursuant to an effective registration statement registering the Warrant Shares for issuance] [INSERT IN SERIES D & E WARRANTS: April 12, 2015, provided, however, that the Expiration Date
shall be extended by one day for each day any one of the following occurs (which for clarity and by way of example means that if two of the following occur on two different days, the Expiration Date will be extended by a total of two days):
(i) for each day there is not a sufficient number of available shares of Common Stock authorized to exercise this Warrant in full (without regard to any limitations on exercise), (ii) for each Trading Day the daily dollar trading volume of
the Common Stock reported by Bloomberg is less than $100,000, (iii) for each Business Day that is not a Trading Day and (iv) for each day the Registration Statement is not available for the issuance of the Warrant Shares], or, in each
case, if such date falls on a day other than a Business Day or on which trading does not take place on the Principal Market (a Holiday), the next day that is not a Holiday.
- 26 -
(s) Fundamental Transaction means (A) that the Company shall, directly
or indirectly, including through Subsidiaries, Affiliates or otherwise, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject Entity, or
(ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its significant subsidiaries (as defined in Rule 1-02 of Regulation S-X) to one or more
Subject Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer
that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or
party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z) such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated
with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or
(iv) consummate a share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with one or more Subject Entities whereby such Subject Entities,
individually or in the aggregate, acquire, either (x) at least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all the Subject
Entities making or party to, or Affiliated with any Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding; or (z) such number of shares of Common Stock such that the Subject Entities
become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (v) reorganize, recapitalize or reclassify its Common Stock, (B) that the Company shall,
directly or indirectly, including through Subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in the aggregate to be or become the beneficial owner (as
defined in Rule 13d-3 under the 1934 Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business
combination, reorganization, recapitalization, spin-off, scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner whatsoever, of either (x) at least 50% of the aggregate ordinary voting power
represented by issued and outstanding Common Stock, (y) at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock not held by all such Subject Entities as of the Subscription Date calculated as if
any shares of Common Stock held by all such Subject Entities were not outstanding, or (z) a percentage of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company
sufficient to allow such Subject Entities to effect a statutory short form merger or other transaction requiring other shareholders of the Company to surrender their shares of Common Stock without approval of the shareholders of the Company or
(C) directly or indirectly, including through Subsidiaries, Affiliates or otherwise, in one or more related transactions, the
- 27 -
issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this definition which may be defective or inconsistent with the
intended treatment of such instrument or transaction.
(t) Group means a group as that term is used in
Section 13(d) of the 1934 Act and as defined in Rule 13d-5 thereunder.
(u) Lead Investor means
[ ].
(v) [INSERT IN SERIES C WARRANT: Mandatory
Exercise shall have the meaning ascribed to such term in the Series B Warrants (as defined in the Securities Purchase Agreement).]
(w) [INSERT IN SERIES B WARRANT: Mandatory Exercise Amount means the Holders Pro Rata Share of such aggregate
number of SPA Warrants that the Company has elected to be subject to a Mandatory Exercise from the Holder and the holders of the other SPA warrants pursuant to Section 1(h) of this Warrant (the Aggregate Mandatory Exercise
Amount, provided that the Aggregate Mandatory Exercise Amount shall not exceed thirty-five percent (35%) of the aggregate daily volume of the Common Stock on the Principal Market or on any other Eligible Market during the three
(3) consecutive Trading Days immediately preceding the applicable Mandatory Exercise Notice Date.]
(x) [INSERT IN SERIES B
WARRANT: Maximum Eligibility Number means initially 85,002,328 (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the Subscription Date) and such number
shall be increased as of the date both of the Reverse Stock Split and the Authorized Shares Increase Amendment have been adopted and become effective, to the quotient obtained by dividing (i) the difference obtained by subtracting from
(x) $[ ]8, (y) the Aggregate Exercise Price (as defined in Section 1(a)) paid by the Holder from time to time
upon exercise, divided by (ii) the Exercise Price (as defined in Section 1(b)) at the time of the applicable Exercise Notice, Mandatory Exercise Notice Date or other applicable date of determination (as adjusted for any stock dividend,
stock split, stock combination, reclassification or similar transaction occurring after the Subscription Date); provided, that if the Maximum Eligibility Number determined pursuant to the foregoing formula would at any time exceed the maximum
number of authorized and unissued shares of Common Stock available, the Maximum Eligibility Number shall be capped at the maximum number of authorized and unissued shares of Common Stock available at such time; provided, further, that
if the Company elects to effect a Mandatory Exercise pursuant to Section 1(h) and the Holder does not deliver the Aggregate Exercise Price with respect to the applicable Mandatory Exercise Amount to the Company on or prior to the Business Day
that is immediately following the applicable Mandatory Exercise Date
8 |
Insert the Holders Pro Rata Share of $8,000,000. |
- 28 -
(the Mandatory Exercise Payment Deadline), the Maximum Eligibility Number shall be decreased on the date immediately following the applicable Mandatory Exercise Payment
Deadline, by the number of shares of Common Stock equal to the Mandatory Exercise Amount for which the Holder did not deliver the Aggregate Exercise Price to the Company on or prior to the applicable Mandatory Exercise Payment Deadline.]
(y) [INSERT IN SERIES C WARRANT: Maximum Eligibility Number means initially zero (0) and such number shall be
increased each time the Holder exercises, or the Company effects a Mandatory Exercise of, the Series B Warrants (as defined in the Securities Purchase Agreement) by an amount equal to fifty percent (50%) of the shares of Common Stock issued to
the Holder upon an exercise, including, without limitation a Mandatory Exercise, of the Series B Warrants); provided, that if the Maximum Eligibility Number determined pursuant to the foregoing formula would at any time exceed the maximum
number of authorized and unissued shares of Common Stock available, the Maximum Eligibility Number shall be capped at the maximum number of authorized and unissued shares of Common Stock available at such time.]
(z) [INSERT IN SERIES D WARRANT: Maximum Eligibility Number means initially zero (0) and such number shall be
increased on March 13, 2015 to the Warrant Share Number; provided, that if the Maximum Eligibility Number determined pursuant to the foregoing sentence would at any time exceed the maximum number of authorized and unissued shares of Common
Stock available, the Maximum Eligibility Number shall be capped at the maximum number of authorized and unissued shares of Common Stock available at such time.]
(aa) [INSERT IN SERIES A, B & C WARRANTS: Option Value means the value of an Option based on the Black and
Scholes Option Pricing model obtained from the OV function on Bloomberg determined as of (A) the Trading Day prior to the public announcement of the issuance of the applicable Option, if the issuance of such Option is publicly
announced or (B) the Trading Day immediately following the issuance of the applicable Option if the issuance of such Option is not publicly announced, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the
U.S. Treasury rate for a period equal to the remaining term of the applicable Option as of the applicable date of determination, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function
on Bloomberg as of (A) the Trading Day immediately following the public announcement of the applicable Option if the issuance of such Option is publicly announced or (B) the Trading Day immediately following the issuance of the applicable
Option if the issuance of such Option is not publicly announced, (iii) the underlying price per share used in such calculation shall be the highest Weighted Average Price of the Common Stock during the period beginning on the Trading Day prior
to the execution of definitive documentation relating to the issuance of the applicable Option and ending on (A) the Trading Day immediately following the public announcement of such issuance, if the issuance of such Option is publicly
announced or (B) the Trading Day immediately following the issuance of the applicable Option if the issuance of such Option is not publicly announced, (iv) a zero cost of borrow and (v) a 360 day annualization factor.]
- 29 -
(bb) Options means any rights, warrants or options to subscribe for or
purchase shares of Common Stock or Convertible Securities.
(cc) [INSERT IN SERIES B WARRANT: Other Warrant
means [the Series C Warrant (as defined in the Securities purchase Agreement).] [INSERT IN SERIES C WARRANT: the Series B Warrant.]
(dd) Parent Entity of a Person means an entity that, directly or indirectly, controls the applicable Person, including such
entity whose common shares or common stock or equivalent equity security is quoted or listed on an Eligible Market (or, if so elected by the Required Holders, any other market, exchange or quotation system), or, if there is more than one such Person
or such entity, the Person or such entity designated by the Required Holders or in the absence of such designation, such Person or entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.
(ee) Person means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust,
an unincorporated organization, any other entity and a government or any department or agency thereof.
(ff) Principal
Market means The NASDAQ Capital Market.
(gg) [INSERT IN SERIES B WARRANT: Pro Rata Share means a
fraction (i) the numerator of which is the number of shares of Common Stock issuable upon exercise in full (without regard to any limitations on exercise) of the Holders Series A Warrants on the Issuance Date and (ii) the denominator
of which is the aggregate number of shares of Common Stock issuable upon exercise in full (without regard to any limitations on exercise) of all Series A Warrants issued by the Company pursuant to the Securities Purchase Agreement on the Issuance
Date. In the event that the initial holder of any Series A Warrants shall sell or otherwise transfer any of such holders Series A Warrants, the transferee shall be allocated a pro rata portion of such holders Pro Rata Share.]
(hh) Required Holders means the holders of the SPA Warrants representing at least a majority of the shares of Common Stock
underlying the SPA Warrants then outstanding and shall include the Lead Investor so long as the Lead Investor and/or any of its Affiliates collectively hold at least five percent (5%) of the SPA Warrants.
(ii) [INSERT IN SERIES D WARRANT: Reset Price means 85% of the arithmetic average of the three (3) lowest
Weighted Average Prices of the Common Stock during the period commencing on the Subscription Date and ending on [March 13, 2015]10.]
10 |
Insert the date that is the fourteenth (14th) Trading Day immediately following the Subscription Date. |
- 30 -
(jj) Reverse Stock Split shall have the meaning ascribe to such term in the
Securities Purchase Agreement.
(kk) [INSERT IN SERIES B, C, D & E WARRANTS: Series A Warrants shall have the
meaning ascribe to such term in the Securities Purchase Agreement.]
(ll) [INSERT IN SERIES C WARRANT: Series B
Warrants shall have the meaning ascribe to such term in the Securities Purchase Agreement.]
(mm) Subject
Entity means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group.
(nn)
Successor Entity means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or one or more Person or Persons (or, if so
elected by the Holder, the Company or the Parent Entity) with which such Fundamental Transaction shall have been entered into.
(oo)
Trading Day means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities
market on which the Common Stock is then traded; provided that Trading Day shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common
Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00
p.m., New York time).
(pp) Warrant Share Number means [INSERT IN SERIES A WARRANT:
( )11] [INSERT IN SERIES B WARRANT: the
quotient obtained by dividing (i) the difference obtained by subtracting from (x) $[ ]12, (y) the aggregate
Aggregate Exercise Price (as defined in Section 1(a)) paid by the Holder from time to time upon exercise of this Warrant (such dollar amount set forth in this clause (i), the Stated Warrant Value), divided by (ii) the
Exercise Price (as defined in Section 1(b)) at the time of the applicable Exercise Notice, Mandatory Exercise Notice Date or other applicable date of determination] [INSERT IN SERIES C WARRANT: fifty percent (50%) of the quotient
obtained by dividing (i) the difference obtained by subtracting from (x) $[ ]13, (y) the Aggregate Exercise
Price (as defined in the Series B Warrants) paid by the Holder from time to time upon exercise of the Series B Warrant, divided by (ii) the Exercise Price (as
11 |
Insert 50% of the sum of (i) the number of Common Shares (as defined in the Securities Purchase Agreement) issued to the Holder on the Closing Date and (ii) the number of shares of Common Stock issuable to the
Holder upon exercise of the Series E Warrants (without regard to any limitations on exercise) issued to the Holder on the Closing Date, if any. |
12 |
Insert the Holders Pro Rata Share of $8,000,000. |
13 |
Insert the Holders Pro Rata Share (as defined in the Series B Warrants) of $8,000,000. |
- 31 -
defined in the Series B Warrants) at the time of the applicable Exercise Notice, Mandatory Exercise Notice Date (each, as defined in the Series B Warrants) or other applicable date of
determination] [INSERT IN SERIES D WARRANT: the number (if positive) obtained by subtracting (I) the sum of (x) the aggregate number of Common Shares (as defined in the Securities Purchase Agreement) issued pursuant to the
Securities Purchase Agreement to the initial Holder of this Warrant on the Closing Date and (y) the aggregate number of shares of Common Stock issued or issuable to the initial Holder of this Warrant upon exercise of the Series E Warrants
(without regard to any limitations on exercise) issued pursuant to the Securities Purchase Agreement to the initial Holder of this Warrant on the Closing Date, if any, from (II) the quotient determined by dividing (x) the aggregate Purchase
Price (as defined in the Securities Purchase Agreement) for the Common Shares and the Warrants paid by the initial Holder of this Warrant to the Company on the Issuance Date (without regard to any amount of the Purchase Price withheld pursuant to
Section 4(f) of the Securities Purchase Agreement, if any), by (y) the Reset Price] [INSERT IN SERIES E WARRANT:
( )14].
(qq) Warrants shall have the meaning ascribe to such term in the
Securities Purchase Agreement.
(rr) Weighted Average Price means, for any security as of any date, the dollar
volume-weighted average price for such security on the Principal Market during the period beginning at 9:30:01 a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at 4:00:00
p.m., New York time (or such other time as the Principal Market publicly announces is the official close of trading), as reported by Bloomberg through its Volume at Price function or, if the foregoing does not apply, the dollar
volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time (or such other time as such market publicly announces is the
official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as such market publicly announces is the official close of trading), as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for
such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the OTC Link or pink sheets by OTC Markets Group Inc.
(formerly Pink OTC Markets Inc.). If the Weighted Average Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as
mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 12 with the term Weighted Average
Price being substituted for the term Exercise Price. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or other similar transaction during the
applicable calculation period.
[Signature Page Follows]
14 |
Insert the number equal to the difference obtained by subtracting (I) the aggregate number of Common Shares (as defined in the Securities Purchase Agreement) issued to the Holder on the Closing Date, from (II) the
quotient determined by dividing (x) the aggregate Purchase Price (as defined in the Securities Purchase Agreement) for the Common Shares and the Warrants paid by the Holder to the Company on the Issuance Date (without regard to any amount of
the Holders Purchase Price withheld pursuant to Section 4(f) of the Securities Purchase Agreement, if any), by (y) $0.50 (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction
occurring after the Subscription Date). |
- 32 -
IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be
duly executed as of the Issuance Date set out above.
|
|
|
REAL GOODS SOLAR, INC. |
|
|
By: |
|
|
|
|
|
Name: |
|
|
Title: |
|
|
EXHIBIT A
EXERCISE NOTICE
TO BE
EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS
WARRANT TO PURCHASE COMMON STOCK
REAL GOODS SOLAR, INC.
The undersigned holder hereby exercises the right to purchase
of the shares of Common Stock (Warrant Shares) of Real Goods Solar, Inc., a Colorado corporation (the
Company), evidenced by the attached Series Warrant to purchase Common Stock No. (the Warrant). Capitalized terms
used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.
1. Form of Exercise Price. The holder
intends that payment of the Exercise Price shall be made as:
a Cash
Exercise with respect to Warrant Shares; or
a Cashless
Exercise with respect to Warrant Shares.
2. Payment of Exercise Price. In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be
issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $ to the Company in accordance with the terms of the Warrant.
3. Delivery of Warrant Shares. The Company shall deliver to the holder
Warrant Shares in accordance with the terms of the Warrant.
Please issue the Warrant Shares in the following name and to the following account:
|
|
|
Facsimile Number and Electronic Mail: |
|
|
|
|
|
Broker Name: |
|
|
|
|
Broker DTC #: |
|
|
|
|
Broker Telephone #: |
|
|
|
|
Account Number: |
|
|
(if electronic book entry transfer) |
|
|
|
Transaction Code Number: |
|
|
(if electronic book entry transfer) |
|
|
|
Date:
, |
|
|
Name of Registered Holder |
|
|
By: |
|
|
|
|
|
|
|
Name: |
|
|
Title: |
TRANSFER AGENT INSTRUCTIONS
REAL GOODS SOLAR, INC.
, 20
Computershare Trust Company, N.A.
350 Indiana Street, Suite 750
Golden, CO 80401
Telephone: [ ]
Facsimile: (303) 226-0609
Attention:
[ ]
|
Re: |
Order to Issue Common Stock of Real Goods Solar, Inc. |
Ladies and Gentlemen:
Reference is made to (A) that certain Securities Purchase Agreement, dated as of February , 2015, by and
among Real Goods Solar, Inc., a Colorado corporation (the Company), and the investors named on the Schedule of Buyers attached thereto (collectively, the Buyers) and the Companys Registration Statement on
Form S-3 (File No. 333-193718) and the Companys prospectus supplement filed on , 2015
pursuant to Rule 424 promulgated pursuant to the Securities Act of 1933, as amended (the 1933 Act) pursuant to which the Company is issuing to the Buyers and certain other investors (collectively Holders)
(i) shares of Class A common stock of the Company, par value $0.0001 per share (the Common Stock), (ii) Series A Warrants, Series B Warrants, Series C Warrants, Series D Warrants and, to certain Holders, Series E
Warrants (the Series A Warrants, Series B Warrants, Series C Warrants, Series D Warrants and Series E Warrants, collectively, the Warrants), each of which is exercisable to purchase shares of Common Stock; (B) the related
Transfer Agent Instructions, dated February , 2015 (the 2015 Instruction); (C) the exercise notice attached hereto (each an Exercise Notice); and (D) the
attached copy of a written instruction from the General Counsel of the Company (or its outside legal counsel) that a registration statement covering the issuance of the shares of Common Stock subject to this letter has been declared effective by the
Securities and Exchange Commission under the Securities Act of 1933, as amended (the Counsel Instruction).
This instruction letter
shall serve as our authorization and direction to you to issue:
|
|
|
to the recipient identified under Issue to in the Exercise Notice, |
|
|
|
such number of shares of Common Stock as set forth under Delivery of Warrant Shares, respectively, in the Exercise Notice, |
|
|
|
out of the Transfer Agent Reserve (as defined in the 2015 Instruction), |
|
|
|
by crediting the designated recipients balance account with the Depository Trust Company, identified in the Exercise Notice under Broker Name, Broker DTC#, Account Number, and
Transaction Code Number through its Deposit Withdrawal at Custodian system |
The issuance of these shares of
Common Stock have been registered pursuant to an registration statement as indicated in the attached Counsel Instruction.
[Signature
Page Follows]
Should you have any questions concerning this matter, please contact me at 303-222-8344.
|
|
|
Very truly yours, |
|
REAL GOODS SOLAR, INC. |
|
|
By: |
|
|
|
|
Name: |
|
|
Title: |
Exhibit 5.1
LEGAL OPINION
February 24, 2015
Brownstein Hyatt Farber Schreck, LLP
410 Seventeenth Street, Suite 2200
Denver, Colorado 80202-4437
T
303.223.1100 F 303.223.1111
Board of Directors
Real Goods Solar, Inc.
833 West South Boulder Road
Louisville, CO 80027
Ladies and Gentlemen:
We are acting as special counsel to Real Goods Solar, Inc., a Colorado corporation (the Company), in connection with the offering and sale by the
Company of (A) an aggregate of $ of units (the Units), each consisting of (i) one share of our Class A common stock, par value $0.0001 per share (the
Common Stock), (ii) a Series A Warrant to purchase one-half of one share of Common Stock (the Series A Warrant), (iii) a Series B Warrant to purchase shares of Common Stock for a stated amount equal to
an investors pro rata share of $8,000,000 based on the aggregate purchase price paid by such investor for Units in the offering compared to the aggregate purchase price paid by all investors for Units in the offering (the Series B
Warrants); (iv) a Series C Warrant to purchase up to 50% of that number of shares of Common Stock actually issued upon exercise of the Series B Warrant (the Series C Warrants); (v) a Series D Warrant to purchase
additional shares of Common Stock in an amount determined on a future reset date after the closing (the Series D Warrants); and, (vi) with respect to an investor who, together with certain attribution parties, would
beneficially own in excess of 4.99% of the number of shares of Common Stock outstanding immediately after the closing of this offering as a result of its purchase of Units, if applicable, a Series E Warrant to purchase the balance of the shares of
Common Stock the investor would have received at closing but for the 4.99% cap (the Series E Warrants, and, collectively with the Series A Warrants, the Series B Warrants, the Series C Warrants and the Series D Warrants, the
Warrants); and (B) up to 200,000,000 shares of Common Stock issuable upon exercise of the Warrants (the Warrant Shares). The Units, the Warrants and the Warrant Shares are collectively referred to herein as the
Securities.
The Securities have been registered pursuant to a Registration Statement on Form S-3 (Registration Number 333-193718) (the
Registration Statement) under the Securities Act of 1933, as amended (the Securities Act), a related prospectus, dated as of February 10, 2014 (the Prospectus), and a prospectus supplement, dated as of
February 24, 2015 (the Prospectus Supplement).
This opinion letter is furnished to you for filing with the Securities and Exchange
Commission pursuant to Item 601 of Regulation S-K promulgated under the Securities Act.
In reaching the
opinion stated in this letter, we have reviewed originals or copies of (i) the Registration Statement, the Prospectus and the Prospectus Supplement, (ii) the Securities Purchase Agreement under which the Securities will be issued,
(iii) the Companys Articles of Incorporation and Bylaws, (iv) resolutions of the Companys Board of Directors authorizing the issuance of the Securities, (v) the Warrants, and (vi) such other documents as we have
considered relevant.
We have assumed that, (i) all information contained in all documents that we have reviewed is correct, (ii) all signatures
on all documents that we have reviewed are genuine, (iii) all documents submitted to us as originals are true and complete, (iv) all documents submitted to us as copies are true and complete copies of the originals thereof, and
(v) each natural person signing a document has sufficient legal capacity to do so.
Based upon the foregoing, it is our opinion that, when issued and delivered in the manner and on the terms
described in the Prospectus Supplement, and, with respect to the Warrant Shares, following the exercise of the Warrants in the manner and on the terms described in the Warrants:
1. |
the Units will be validly issued, legally valid and binding obligations of the Company, |
2. |
the Warrants will be validly issued, legally valid and binding obligations of the Company, and |
3. |
the Warrant Shares, will be validly issued, fully paid and non-assessable. |
We hereby consent to the use of
this opinion letter as Exhibit 5.1 to the Registration Statement. We also consent to the reference to this firm under the caption Legal Matters in the Prospectus and the Prospectus Supplement. In giving such consent, we do not admit that
we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.
As to the foregoing matters with respect to which we express our opinion, we advise that we are admitted to practice in the States of Colorado and New York,
and do not render any opinion as to legal matters subject to or governed by laws other than the States of Colorado and New York or United States federal jurisprudence.
Very truly yours,
/s/ Brownstein Hyatt Farber Schreck, LLP
2
Exhibit 10.1
SECURITIES PURCHASE AGREEMENT
SECURITIES PURCHASE AGREEMENT (the Agreement), dated as of February 23, 2015, by and among Real Goods Solar,
Inc., a Colorado corporation, with headquarters located at 833 West South Boulder Road, Louisville, CO 80027 (the Company), and the investors listed on the Schedule of Buyers attached hereto (individually, a
Buyer and collectively, the Buyers).
RECITALS
A. The Company and the Buyers desire to enter into this transaction to purchase the Common Shares (as defined below) and the
Warrants (as defined below) pursuant to the Registration Statement (as defined below) which is currently effective, has at least $200,000,000 of initial offering price of unallocated securities available for sale as of the date hereof and has been
declared effective in accordance with the Securities Act of 1933, as amended (the 1933 Act), by the United States Securities and Exchange Commission (the SEC).
B. The Series A Warrant Shares, Series B Warrant Shares and Series C Warrant Shares (each, as defined below) shall, in each
case, be issued pursuant to the Registration Statement or another registration statement, or, if the Registration Statement or such other registration statement is not available at the time of issuance of such Warrant Shares and, in the case of the
Series B Warrants, if the Registration Statement or such other registration statement remains unavailable for a period of sixty (60) consecutive days, shall be issued solely pursuant to the cashless exercise provisions of the applicable Warrant
as securities exempt from registration pursuant to Section 3(a)(9) of the 1933 Act. The Series D Warrant Shares and the Series E Warrant Shares (each, as defined below) shall, in each case, be issued pursuant to the Registration Statement,
another registration statement or pursuant to the cashless provisions of the applicable Warrant as securities exempt from registration pursuant to Section 3(a)(9) of the 1933 Act.
C. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, at
the Closing (as defined below) (i) that aggregate number of shares of the Companys Class A common stock, par value $0.0001 per share (the Common Stock) set forth opposite such Buyers name in column
(3) of the Schedule of Buyers attached hereto (which aggregate amount for all Buyers shall be [ ]) (the Common Shares), (ii) Series A warrants, in
substantially the form attached hereto as Exhibit A (the Series A Warrants), to acquire up to that number of additional shares of Common Stock set forth opposite such Buyers name in column (4)(a) of the Schedule
of Buyers (as exercised, collectively, the Series A Warrant Shares), (iii) Series B warrants, in substantially the form attached hereto as Exhibit A (the Series B Warrants) to acquire up to that
number of additional shares of Common Stock set forth therein (as exercised, collectively, the Series B Warrant Shares), (iv) Series C warrants, in substantially the form attached hereto as Exhibit A (the
Series C Warrants) to acquire up to that number of
additional shares of Common Stock set forth therein (as exercised, collectively, the Series C Warrant Shares), (v) Series D warrants, in substantially the form attached
hereto as Exhibit A (the Series D Warrants) to acquire up to that number of additional shares of Common Stock set forth therein (as exercised, collectively, the Series D Warrant Shares) and
(vi) Series E warrants, in substantially the form attached hereto as Exhibit A (the Series E Warrants and together with the Series A Warrants, Series B Warrants, Series C Warrants and Series D Warrants, the
Warrants) to acquire up to that number of additional shares of Common Stock, as set forth opposite such Buyers name in column (4)(b) of the Schedule of Buyers (as exercised, collectively, the Series E Warrant
Shares and, together with the Series A Warrant Shares, the Series B Warrant Shares, the Series C Warrant Shares and the Series D Warrant Shares, the Warrant Shares).
D. The Common Shares, the Warrants and the Warrant Shares collectively are referred to herein as the
Securities.
NOW, THEREFORE, the Company and each Buyer hereby agree as follows:
1. PURCHASE AND SALE OF COMMON SHARES AND WARRANTS.
(a) Incorporation of Recitals. The recitals set forth above shall be incorporated into, and deemed a part of
this Agreement.
(b) Closing. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and
7 below, the Company shall issue and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the Company on the Closing Date (as defined below), (i) the number of Common Shares in an aggregate amount as is set
forth opposite such Buyers name in column (3) of the Schedule of Buyers, (ii) Series A Warrants to acquire up to that number of Series A Warrant Shares as is set forth opposite such Buyers name in column (4)(a) of the
Schedule of Buyers, (iii) Series B Warrants to acquire up to that number of additional shares of Common Stock set forth therein, (iv) Series C Warrants to acquire up to that number of additional shares of Common Stock set forth therein,
(v) Series D Warrants to acquire up to that number of additional shares of Common Stock set forth therein and (vi) Series E Warrants to acquire up to that number of additional shares of Common Stock, as set forth opposite such Buyers
name in column (4)(b) of the Schedule of Buyers (the Closing). Notwithstanding anything herein to the contrary, the Buyers acknowledge and agree that certain retail investors (the Retail Investors and,
together with the Buyers, the Purchasers) will be participating in the transactions contemplated hereunder on the same terms and conditions as set forth hereunder but such participation may be obtained verbally through sub-agents
retained by the Agent (as defined in Section 3(kk)) rather through the execution of this Agreement and settlement of such accounts may occur directly with the participating brokers. The Company hereby acknowledges and agrees that the Closing
contemplated by this Agreement shall occur upon the satisfaction of the closing conditions set forth in Section 6 and 7, regardless of whether or not the Retail Investors participate in such transactions.
(c) Purchase Price. The aggregate purchase price for the Common Shares and the Warrants to be purchased by each such
Buyer at the Closing (the Purchase Price) shall be the amount set forth opposite each Buyers name in column (5) of the Schedule of Buyers (less, in the case of
(the Lead Investor), any amounts withheld pursuant to Section 4(f)), which shall be equal to $0.50 (as
adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the date hereof) per Common Share and related Warrants to be purchased by each Buyer at the Closing.
2
(d) Closing Date. The date and time of the Closing (the Closing
Date) shall be 10:00 a.m., New York City time, on the date hereof (or such later date as is mutually agreed to by the Company and each Buyer, but in no event later than February 26, 2015) after notification of satisfaction (or waiver)
of the conditions to the Closing set forth in Sections 6 and 7 below at the offices of Schulte Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022, subject to notification of satisfaction (or waiver) of the conditions to
the Closing set forth in Sections 6 and 7 below.
(e) Form of Payment. On the Closing Date each Buyer shall pay
its Purchase Price to the Company (less, in the case of the Lead Investor, any amounts withheld pursuant to Section 4(f)) by wire transfer of immediately available funds to an escrow account established by the Company and the Agent with
Signature Bank (or such other bank mutually agreed to by the Company and the Agent), as escrow agent, in accordance with the Companys written wire instructions (the Escrow Account), which funds shall be subject to the terms
and conditions of such escrow and (ii) the Company shall deliver to each Buyer (u) the Common Shares (allocated in the amounts as such Buyer shall request) which such Buyer is then purchasing hereunder, (v) the Series A Warrants
(allocated in the amounts as such Buyer shall request) such Buyer is purchasing, (w) the Series B Warrants (allocated in the amounts as such Buyer shall request) such Buyer is purchasing, (x) the Series C Warrants (allocated in the amounts
as such Buyer shall request) such Buyer is purchasing, (y) the Series D Warrants (allocated in the amounts as such Buyer shall request) such Buyer is purchasing and (z) the Series E Warrants (allocated in the amounts as such Buyer shall
request) such Buyer is purchasing, in each case duly executed on behalf of the Company and registered in the name of such Buyer or its designee.
(f) Escrow. Notwithstanding anything herein to the contrary or in the agreement governing the Escrow Account, if the
Closing does not occur on or prior to February 26, 2015, the Company shall, at the written request of a Buyer, promptly cause such Buyers Purchase Price to be returned to such Buyer pursuant to wire instructions provided in writing by such
Buyer to the Company.
2. BUYERS REPRESENTATIONS AND WARRANTIES. Each Buyer, severally and not jointly, represents and
warrants with respect to only itself that:
(a) Organization; Authority. Such Buyer is an entity duly organized,
validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its
obligations hereunder and thereunder. The execution, delivery and performance by such Buyer of the transactions contemplated by this Agreement has been duly authorized by all necessary action on the part of such Buyer. This Agreement has been duly
executed by such Buyer, and when delivered by such Buyer in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Buyer, enforceable against it in accordance with its terms, except as such enforceability
may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors rights and remedies.
(b) No Conflicts. The execution, delivery and performance by such Buyer of this Agreement and the consummation by such
Buyer of the transactions contemplated hereby will not (i) result in a violation of the organizational documents of such Buyer or (ii) conflict
3
with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which such Buyer is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such
Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of
such Buyer to perform its obligations hereunder.
(c) No Agent Information. Such Buyer acknowledges and agrees that
neither the Agent nor any Affiliate of the Agent has provided such Buyer with any information or advice with respect to the Securities nor is such information or advice necessary or desired. In connection with the issuance of the Securities to such
Buyer, neither the Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Buyer.
(d)
Buyer Status. The Buyer is an accredited investor, as defined in Rule 501(a) promulgated under the 1933 Act, and is a qualified purchaser under Section 18 of the 1933 Act.
3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to each of the Buyers that, as of the date hereof
and as of the Closing Date:
(a) Shelf Registration Statement.
(i) The Company has prepared and filed in conformity with the requirements of the 1933 Act and the published rules and regulations
thereunder (the Rules and Regulations) adopted by the SEC a shelf registration statement on Form S-3 (No. 333-193718), which became effective on February 10, 2014, including a base prospectus, (the
Base Prospectus) relating to Common Stock, preferred stock, warrants, rights, debt securities or units of the Company that may be sold from time to time by the Company, in accordance with Rule 415 of the 1933 Act, and such
amendments thereof as may have been required to the date of this Agreement. The term Registration Statement as used in this Agreement means such registration statement, including all exhibits, financial schedules and all documents
and information deemed to be part of the Registration Statement by incorporation by reference or otherwise, as amended from time to time, including the information (if any) contained in the form of final prospectus filed with the SEC pursuant to
Rule 424(b) of the Rules and Regulations and deemed to be part thereof at the time of effectiveness pursuant to Rules 430A and 430B of the Rules and Regulations. The term Preliminary Prospectus means the Base Prospectus, together
with any preliminary prospectus supplement used or filed with the SEC pursuant to Rule 424 of the Rules and Regulations. The term Prospectus means the Base Prospectus, any Preliminary Prospectus and any amendments or further
supplements to such prospectus filed with the SEC, and including, without limitation, the final prospectus supplement (the Prospectus Supplement), filed pursuant to and within the limits described in Rule 424(b) with the SEC in
connection with the proposed sale of the Securities contemplated by this Agreement through the date of such prospectus supplement. Unless otherwise stated herein, any reference herein to the Registration Statement, any Preliminary Prospectus, the
Statutory Prospectus (as
4
hereinafter defined) and the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein, including pursuant to Item 12 of Form S-3 under the 1933
Act, which were filed under the Securities Exchange Act of 1934, as amended (the 1934 Act), on or before the date hereof or are so filed hereafter. Any reference herein to the terms amend, amendment or
supplement with respect to the Registration Statement, any Preliminary Prospectus, the Statutory Prospectus or the Prospectus shall be deemed to refer to and include any such document filed or to be filed under the 1934 Act after the
date of the Registration Statement, any such Preliminary Prospectus, Statutory Prospectus or Prospectus, as the case may be, and deemed to be incorporated therein by reference.
(ii) The Company was at the time of the filing of the Registration Statement eligible to use Form S-3. As of the date of this Agreement, the
Company is eligible to use Form S-3 under the 1933 Act and it meets the transaction requirements with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) months prior to this
offering, in accordance with General Instruction I.B.1 of Form S-3. The Company filed with the SEC the Registration Statement on such Form S-3, including a Base Prospectus, for registration under the 1933 Act of the offering and sale of the
Securities, and the Company has prepared and used a Preliminary Prospectus in connection with the offer and sale of the Securities. When the Registration Statement or any amendment thereof or supplement thereto was or is declared effective and as of
the date of the most recent amendment to the Registration Statement, it (i) complied or will comply, in all material respects, with the requirements of the 1933 Act and the Rules and Regulations and the 1934 Act and the rules and regulations of
the SEC thereunder and (ii) did not or will not, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading. When any
Preliminary Prospectus or Prospectus was first filed with the SEC (whether filed as part of the Registration Statement or any amendment thereto or pursuant to Rule 424 of the Rules) and when any amendment thereof or supplement thereto was first
filed with the SEC, such Preliminary Prospectus or Prospectus as amended or supplemented complied in all material respects with the applicable provisions of the 1933 Act and the Rules and Regulations and did not or will not, contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading. Notwithstanding the forgoing, the Company makes no representations or warranties as to
information contained in or omitted from any Preliminary Prospectus or Prospectus, in reliance upon, and in conformity with, written information furnished to the Company by or on behalf of the Buyers, specifically for use therein.
(b) Prospectus. As of the Applicable Time (as defined below) and as of the Closing Date, neither (x) the General
Use Free Writing Prospectus(es) (as defined below) issued at or prior to the Applicable Time, the Statutory Prospectus (as defined below), all considered together (collectively, the General Disclosure Package), nor (y) any
individual Limited Use Free Writing Prospectus (as defined below), when considered together with the General Disclosure Package, included, includes or will include any untrue statement of a material fact or omitted, omits or will omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no representations or warranties as to information
contained in or omitted from any Issuer Free Writing Prospectus, in reliance upon, and in conformity with, written information furnished to the Company by or on behalf of the Buyers, specifically for use therein. As used in this subsection and
elsewhere in this Agreement:
5
(i) Applicable Time means 5:30 p.m. (New York time) on the date of
this Agreement or such other time as agreed to by the Company and the Buyers.
(ii) Statutory Prospectus
as of any time means the Preliminary Prospectus included in the Registration Statement immediately prior to that time.
(iii) Issuer Free Writing Prospectus means any issuer free writing prospectus, as defined in Rule 433
under the 1933 Act, relating to the Securities in the form filed or required to be filed with the SEC or, if not required to be filed, in the form retained in the Companys records pursuant to Rule 433(g) under the 1933 Act.
(iv) General Use Free Writing Prospectus means any Issuer Free Writing Prospectus that is identified on Schedule I
to this Agreement.
(v) Limited Use Free Writing Prospectus means any Issuer Free Writing Prospectus
that is not a General Use Free Writing Prospectus.
(c) Organization. Each of the Company and its
Subsidiaries (which, for the purposes of this Agreement means any entity or joint venture which the Company, directly or indirectly, owns any of the capital stock or holds an equity or similar interest) are entities duly organized
and validly existing in good standing under the laws of the jurisdiction in which they are formed, and have requisite power and authorization to own or lease their properties and conduct their business as now being conducted and as described in the
Registration Statement, the General Disclosure Package and the Prospectus. The Companys significant Subsidiaries (as such term is defined in Rule 1-02 of Regulation S-X promulgated by the SEC) include (i) those listed in Exhibit 21.1 to
the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (the Annual Report), other than Real Goods Trading Corporation, Inc. and Real Goods Syndicated, Inc., which have liquidated their
assets since December 31, 2013, and (ii) Elemental Energy, LLC, RGS Financing, Inc., Mercury Energy, Inc., Real Goods Solar, Inc. Mercury Energy, Inc., which were acquired or formed after December 31, 2013. The Subsidiaries are
the only subsidiaries, direct or indirect, of the Company. The Subsidiaries set forth on Schedule 3(c) under the heading Significant Subsidiaries are referred to herein as the Significant Subsidiaries. The
Subsidiaries which are not Significant Subsidiaries are not significant subsidiaries as defined in Rule 1-02 of Regulation S-X. The Company and each of the Subsidiaries are duly qualified as a foreign entity to do business and is in good standing in
every jurisdiction in which its ownership of property or the nature of the conduct of their business makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected
to have a Material Adverse Effect. As used in this Agreement, Material Adverse Effect means any material adverse effect on (i) the business, properties, assets, operations, results of operations, condition (financial or
otherwise) or prospects of the Company and its Subsidiaries, individually or taken as a whole, (ii) the transactions contemplated hereby or in the other Transaction Documents, or (iii) the authority or the ability of the Company to perform
its obligations under this Agreement or the other Transaction Documents or to consummate any transactions contemplated by this
6
Agreement or the other Transaction Documents. The outstanding shares of capital stock of each of the Subsidiaries have been duly authorized and validly issued, are fully paid and non-assessable
and are owned by the Company or another Subsidiary free and clear of all liens, encumbrances and equities and claims, except as described in the Registration Statement and the Annual Report; and, except as set forth in the Registration Statement and
the Prospectus, no options, warrants or other rights to purchase, agreements or other obligations to issue or other rights to convert any obligations into shares of capital stock or ownership interests in the Subsidiaries are outstanding.
(d) Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and
perform its obligations under this Agreement, the Irrevocable Transfer Agent Instructions (as defined in Section 5(b)), the Warrants, the Lock-Up Agreements (as defined in Section 3(xx)), the Voting Agreement (as defined in
Section 4(n)) and each of the other agreements entered into by the parties hereto in connection with the transactions contemplated by this Agreement (collectively, the Transaction Documents) and to issue the Securities,
except with respect to the issuance of such number of Warrant Shares exceeding the number of authorized shares, subject to obtaining the Shareholder Approval and effecting the Reverse Stock Split and the Authorized Shares Increase Amendment (each,
as defined in Section 4(p)), in accordance with the terms hereof and thereof. The execution and delivery of the Transaction Documents by the Company and, except with respect to the issuance of such number of Warrant Shares exceeding the number
of authorized shares, subject to receiving the Shareholder Approval and effecting the Reverse Stock Split and the Authorized Shares Increase Amendment, the consummation by the Company of the transactions contemplated hereby and thereby, including,
without limitation, the issuance of the Warrants, the reservation for issuance and the issuance of the Common Shares and the reservation for issuance and the issuance of the Warrant Shares issuable upon exercise of the Warrants have been duly
authorized by the Companys Board of Directors, and, no further filing, consent, or authorization is required by the Company, its Board of Directors or its shareholders. This Agreement and the other Transaction Documents have been duly executed
and delivered by the Company, and constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be limited by general principles of
equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors rights and remedies.
(e) Issuance of Securities. The outstanding shares of Common Stock of the Company have been duly authorized and validly
issued and are fully paid and non-assessable; the Securities to be issued and sold by the Company, except with respect to the issuance of such number of Warrant Shares exceeding the number of authorized shares, subject to receiving the Shareholder
Approval and effecting the Reverse Stock Split and the Authorized Shares Increase Amendment, have been duly authorized and when issued and paid for as contemplated herein in accordance with the terms of the Transaction Documents will be free from
all taxes, liens and charges with respect to the issue thereof, validly issued, fully paid and non-assessable; and no preemptive rights of shareholders exist with respect to any of the Securities or the issue and sale thereof. As of the Closing, a
number of shares of Common Stock shall have initially been duly
7
authorized and reserved for issuance which equals 85,002,328 shares of Common Stock (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction
occurring after the date hereof) to effect the sale of the Common Shares hereunder and the exercise of all of the Warrants then outstanding (such number of shares, the Initial Required Reserve Amount). As of February 23,
2015, there are 97,657,027 shares of Common Stock authorized and unissued. Neither the offering nor sale of the Securities as contemplated by this Agreement gives rise to any rights, other than those which have been waived or satisfied, for or
relating to the registration of any shares of Common Stock. Upon exercise of the Warrants in accordance with the terms thereof the Warrant Shares will be validly issued, fully paid and nonassessable and free from all preemptive or
similar rights, taxes, liens and charges with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. Except as set forth in the Registration Statement and the Prospectus, there are no
securities or instruments issued by the Company containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities.
(f) Equity Capitalization. The Company has or will have, as the case may be, an authorized, issued and outstanding
capitalization as is set forth in the Registration Statement and the Prospectus (subject, in each case, to the issuance of shares of Common Stock upon exercise of stock options and warrants disclosed as outstanding in the Registration Statement and
the Prospectus and the grant or issuance of options or shares under existing equity compensation plans or stock purchase plans described in the Registration Statement or the Prospectus), and such authorized capital stock conforms to the description
thereof set forth in the Registration Statement and the Prospectus. Except as disclosed on Schedule 3(f) hereto, in the Registration Statement or the Prospectus (i) none of the Companys capital stock is subject to preemptive rights
or any other similar rights or any liens or encumbrances suffered or permitted by the Company; (ii) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or
securities or rights convertible into, or exercisable or exchangeable for, any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its
Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or
securities or rights convertible into, or exercisable or exchangeable for, any shares of capital stock of the Company or any of its Subsidiaries; (iii) there are no material outstanding debt securities, notes, credit agreements, credit
facilities or other agreements, documents or instruments evidencing Indebtedness (as defined below) of the Company or any of its Subsidiaries or by which the Company or any of its Subsidiaries is or may become bound; (iv) there are no financing
statements securing obligations in any material amounts, either singly or in the aggregate, filed in connection with the Company or any of its Subsidiaries; (v) there are no agreements or arrangements under which the Company or any of its
Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act; (vi) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which
8
the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries; (vii) there are no securities or instruments containing
anti-dilution or similar provisions that will be triggered by the issuance of the Securities; (viii) the Company does not have any stock appreciation rights or phantom stock plans or agreements or any similar plan or agreement; and
(ix) the Company and its Subsidiaries have no liabilities or obligations required to be disclosed in the SEC Documents but not so disclosed in the SEC Documents, other than those incurred in the ordinary course of the Companys or any of
its Subsidiarys respective businesses and which, individually or in the aggregate, do not or would not have a Material Adverse Effect. The Company has furnished or made available to the Buyers true, correct and complete copies of the
Companys Articles of Incorporation, as amended and as in effect on the date hereof (the Articles of Incorporation), and the Companys Bylaws, as amended and as in effect on the date hereof (the
Bylaws), and the terms of all securities convertible into, or exercisable or exchangeable for shares of Common Stock and the material rights of the holders thereof in respect thereto. All of the Securities conform to the
description thereof contained in the Registration Statement and the Prospectus. The form of certificates for the Common Shares and the Warrant Shares, as applicable, will conform to the corporate law of the jurisdiction of the Companys
incorporation.
(g) Disclosure.
(i) The SEC has not issued an order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the
Prospectus relating to the proposed offering of the Securities, and no proceeding for that purpose or pursuant to Section 8A of the 1933 Act has been instituted or, to the Companys Knowledge threatened by the SEC.
Knowledge in this Agreement shall refer to what any named executive officer of the Company actually knows or reasonably should know. The Registration Statement conforms, and the Prospectus and any amendments or supplements thereto
will conform to the requirements of the 1933 Act and the Rules and Regulations. The documents incorporated, or to be incorporated, by reference in the Prospectus (but not the exhibits or schedules thereto), at the time filed with the SEC conformed
in all material respects, or will conform in all respects, to the requirements of the 1934 Act, or the 1933 Act, as applicable, and the Rules and Regulations. The Registration Statement and any amendments and supplements thereto do not contain, and
on the Closing Date, will not contain any untrue statement of a material fact and do not omit, and on the Closing Date will not omit, to state a material fact required to be stated therein or necessary to make the statements therein not misleading.
The Prospectus and any amendments and supplements thereto do not contain, and on the Closing Date will not contain, any untrue statement of a material fact; and do not omit, and on the Closing Date will not omit, to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, provided, however, that the Company makes no representations or warranties as to information contained in or omitted
from the Prospectus, in reliance upon, and in conformity with, written information furnished to the Company by or on behalf of the Buyers, specifically for use therein.
(ii) Each Issuer Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the public offer and sale
of the Securities or until any earlier date that the Company notified or notifies the Buyers as described in the next sentence, did not, does not and will not include any information that conflicted, conflicts or will
9
conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein that has not been superseded or modified. If at
any time following issuance of an Issuer Free Writing Prospectus, there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus included or would include an untrue statement of a material fact or omitted
or would omit to state a material fact necessary in order to make the statements therein, in light of the circumstances, not misleading, the Company has notified or will notify promptly the Buyers so that any use of such Issuer Free Writing
Prospectus may cease until it is amended or supplemented.
(iii) The Company confirms that neither it nor any other Person acting at its
direction has provided any of the Buyers or their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, nonpublic information, which immediately after the Press Release (as defined in
Section 4(h)), has not otherwise been publically disclosed. The Company understands and confirms that each of the Buyers will rely on the foregoing representations in effecting transactions in securities of the Company. All disclosure provided
to the Buyers regarding the Company, or any of its Subsidiaries, their business and the transactions contemplated hereby furnished by or on behalf of the Company is true and correct and does not contain any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. Each press release issued by the Company or any of its Subsidiaries during the
twelve (12) months preceding the date of this Agreement did not at the time of release contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. No event or circumstance has occurred or information exists with respect to the Company or any of its Subsidiaries or its or their business, properties,
prospects, operations or financial conditions, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed. The Company acknowledges and agrees
that no Buyer makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 2. For purposes of this Agreement, Person means an
individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof.
(h) Offering Materials. The Company has not, directly or indirectly, distributed and will not distribute any offering
material in connection with the offering and sale of the Securities other than any Preliminary Prospectus, the Prospectus, any Issuer Free Writing Prospectus and other materials, if any, permitted under the 1933 Act. The Company will file with the
SEC all Issuer Free Writing Prospectuses in the time required under Rule 433(d) under the 1933 Act. The Company has satisfied or will satisfy the conditions in Rule 433 under the 1933 Act to avoid a requirement to file with the SEC any electronic
road show.
(i) Ineligible Issuer Status. At the time of filing the Registration Statement and (ii) as of the
date hereof (with such date being used as the determination date for purposes of this clause (ii)), the Company was not and is not an ineligible issuer (as defined in Rule 405 under the 1933 Act, without taking into account any
determination by the SEC pursuant to Rule 405 under the 1933 Act that it is not necessary that the Company be considered an ineligible issuer), including, without limitation, for purposes of Rules 164 and 433 under the 1933 Act with respect to the
offering of the Securities as contemplated by the Registration Statement.
10
(j) Financial Statements. The consolidated financial statements of the
Company and the Subsidiaries, together with related notes and schedules as set forth or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, present fairly in all material respects the financial
position of the Company and the consolidated Subsidiaries and the results of operations and cash flows of the Company and the consolidated Subsidiaries, at the indicated dates and for the indicated periods. Such consolidated financial statements and
related schedules have been prepared in accordance with United States generally accepted accounting principles, consistently applied throughout the periods involved (GAAP), except as disclosed therein, and all adjustments
necessary for a fair presentation of results for such periods have been made. The summary and selected consolidated financial and statistical data included or incorporated by reference in the Registration Statement, the General Disclosure Package
and the Prospectus presents fairly in all material respects the information shown therein, at the indicated dates and for the indicated periods, and such data has been compiled on a basis consistent with the financial statements presented therein
and the books and records of the Company. All disclosures, if any, contained in the Registration Statement, the General Disclosure Package and the Prospectus regarding non-GAAP financial measures (as such term is defined by the Rules and
Regulations) comply in all material respects with Regulation G of the 1934 Act and Item 10 of Regulation S-K under the 1933 Act, to the extent applicable. The Company and the Subsidiaries do not have any material liabilities or obligations,
direct or contingent (including any off-balance sheet obligations or any variable interest entities within the meaning of Financial Accounting Standards Board Interpretation No. 46), not disclosed in the Registration Statement, the
General Disclosure Package and the Prospectus. There are no financial statements (historical or pro forma) that are required to be included in the Registration Statement, the General Disclosure Package or the Prospectus that are not included as
required. No other information provided by or at the direction of the Company to the Buyers which is not included in the SEC Documents (as defined below) contains any untrue statement of a material fact or omits to state any material fact necessary
in order to make the statements therein, in the light of the circumstance under which they are or were made, not misleading.
(k) Accountants. EKS&H LLLP, who have certified certain of the financial statements filed with the SEC as part of,
or incorporated by reference in, the Registration Statement, the General Disclosure Package and the Prospectus, has represented to the Company that it is an independent registered public accounting firm with respect to the Company and the
Subsidiaries within the meaning of the 1933 Act and the applicable Rules and Regulations and the Public Company Accounting Oversight Board (United States).
(l) Weaknesses or Changes in Internal Accounting Controls. It being acknowledged that the Companys
Section 404 audit is in process at this time and the results are still pending, neither the Company nor any of the Subsidiaries has during the twelve months prior to the date hereof (i) received any notice or correspondence from any
accountant relating to any material weakness in any part of the system of internal accounting controls of the Company or any of its Subsidiaries (ii) become aware of any material weakness in its internal control over financial reporting or
change in internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Companys internal control over financial reporting.
11
(m) Sarbanes-Oxley. The Company is in compliance with all applicable
requirements of the Sarbanes-Oxley Act of 2002, as amended, and all rules and regulations promulgated thereunder, or implementing the provisions thereof (the Sarbanes-Oxley Act) that are effective as of the date hereof.
(n) Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by the Principal
Market, any court, public board, government agency, self-regulatory organization or body pending or, to the Companys Knowledge, threatened against or affecting the Company or any of its Subsidiaries, the Common Stock or any of the
Companys Subsidiaries, or any of the Companys or its Subsidiaries officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such, except as set forth in the Registration Statement, the
General Disclosure Package and the Prospectus, which is required to be disclosed by the Company in its periodic 1934 Act filings. The matters set forth in the Registration Statement, the General Disclosure Package and the Prospectus, individually or
in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
(o) Title. The
Company and its Subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them which is material to the business of the Company and its Subsidiaries, in each case
free and clear of all liens, encumbrances and defects except for liens for the benefit of Silicon Valley Bank as disclosed in the Registration Statement and the Prospectus and other Permitted Liens, which, in the case of such other Permitted Liens,
do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries. Any real property and facilities held under lease by the Company and any
of its Subsidiaries are held by them under valid, subsisting and enforceable leases conforming in all material respects to the description thereof set forth in the Registration Statement, the General Disclosure Package and the Prospectus.
(p) Taxes. The Company and each of its Subsidiaries (i) has made or filed all U.S. federal, state and foreign
income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on
such returns, reports and declarations, except those being contested in good faith, and (iii) has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns,
reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.
(q) Absence of Certain Changes. Since the respective dates as of which information is given in the Registration
Statement, the General Disclosure Package and the Prospectus, as each may be amended or supplemented, there has been no material adverse change and no material adverse development in the business, assets, properties, operations, condition (financial
or otherwise), results of operations or prospects of the Company or its
12
Subsidiaries and there has not been any material transaction entered into by the Company or the Subsidiaries (including, without limitation, (i) declaration or payment of any dividends,
(ii) sale of any assets, individually or in the aggregate, in excess of $500,000 or (iii) any capital expenditures, individually or in the aggregate, in excess of $250,000, other than transactions in the ordinary course of business and
transactions described in the Registration Statement, the General Disclosure Package and the Prospectus, as each may be amended or supplemented. The Company and the Subsidiaries have no material contingent obligations which are not disclosed in the
Companys consolidated financial statements which are included in the Registration Statement, the General Disclosure Package and the Prospectus. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to
any bankruptcy law nor does the Company have any Knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings or any actual Knowledge of any fact that would reasonably lead a creditor to do so. The Company
and its Subsidiaries, individually and on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent (as defined below). For purposes of this
Agreement, (x) Insolvent means, with respect to any Person, (i) the present fair saleable value of such Persons assets is less than the amount required to pay such Persons total Indebtedness (as defined below),
(ii) such Person is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured, (iii) such Person intends to incur or believes that it will incur debts that
would be beyond its ability to pay as such debts mature or (iv) such Person has unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted,
(y) Indebtedness of any Person means, without duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase price of property or services, including,
without limitation, capital leases in accordance with GAAP (other than trade payables entered into in the ordinary course of business consistent with past practice), (C) all reimbursement or payment obligations with respect to
letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets
or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with the proceeds of such
indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar arrangement
which, in connection with GAAP, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which the holder of such
Indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets (including accounts and contract rights) owned by any Person,
even though the Person which owns such assets or property has not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to in
clauses (A) through (G) above, and (z) Contingent Obligation means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any Indebtedness, lease, dividend or
other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the primary
13
effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will be complied with, or that the
holders of such liability will be protected (in whole or in part) against loss with respect thereto.
(r) No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and any of its Subsidiaries parties to any of the Transaction Documents and the consummation by the Company and any of its Subsidiaries of the
transactions contemplated hereby and thereby (including, without limitation, the issuance of the Common Shares and the Warrants and reservation for issuance and issuance of the Common Shares and the Warrant Shares) will not (i) except with
respect to the issuance of such number of Warrant Shares exceeding the number of authorized shares, subject to receipt of the Shareholder Approval and effecting the Reverse Stock Split and the Authorized Shares Increase Amendment, result in a
violation of its Articles of Incorporation or Bylaws, any memorandum or articles of association, articles of incorporation, certificate of formation, bylaws, any certificate of designations or other constituent documents of the Company or any of its
Subsidiaries, any capital stock of the Company or any of its Subsidiaries or the articles of association or bylaws of the Company or any of its Subsidiaries or (ii) after Complying with Nasdaq Rule 5250(e)(2), conflict with, or constitute a
default (or an event which with notice or lapse of time or both would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material agreement, indenture or instrument to
which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries or any of their respective properties is bound, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree
(including other foreign, federal and state securities laws and regulations and the rules and regulations of The NASDAQ Capital Market (the Principal Market) and including all applicable laws of the State of Colorado and any
foreign, federal and state laws, rules and regulations) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected.
(s) Contracts. There is no document, contract or other agreement required to be described in the Registration Statement
or Prospectus or to be filed as an exhibit to the Registration Statement which is not described or filed as required by the 1933 Act or the Rules and Regulations. Each description of a contract, document or other agreement in the Registration
Statement and the Prospectus accurately reflects in all material respects the terms of the underlying contract, document or other agreement. Each contract, document or other agreement described in the Registration Statement and Prospectus or listed
in the exhibits to the Registration Statement or incorporated by reference is in full force and effect and is valid and enforceable by and against the Company in accordance with its terms (except as rights to indemnity and contribution thereunder
may be limited by federal or state securities laws and matter of public policy and except as the enforceability thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of
creditors rights generally and by general equitable principle). Neither the Company nor any of its Subsidiaries nor, to the Companys Knowledge, any other party is in default in the observance or performance of any term or obligation to
be performed by it under any such agreement or any other agreement or instrument to which the Company or its Subsidiaries is a party or by which the Company or its Subsidiaries or their respective properties or businesses may be bound, and no event
has occurred which with notice or lapse of time or both would constitute such a default, in any such case in which the default or event, individually or in the aggregate, would have a Material Adverse Effect.
14
(t) Regulatory Approvals. Each approval, consent, order, authorization,
designation, declaration or filing by or with any regulatory, administrative or other governmental body necessary in connection with the execution and delivery by the Company of this Agreement and the consummation of the transactions herein
contemplated (except such additional steps as may be required by the SEC, the Financial Industry Regulatory Authority, Inc. (the FINRA) or such additional steps as may be required under state securities or Blue Sky laws) has been
obtained or made and is in full force and effect.
(u) Conduct of Business. Neither the Company nor any of its
Subsidiaries is in violation of any term of or in default under any certificate of designations of any outstanding series of preferred stock of the Company (if any), its Articles of Incorporation or Bylaws or their organizational charter or
memorandum of association or articles of incorporation or articles of association or bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation
applicable to the Company or any of its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except for possible violations which would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.
(v) Intellectual Property. The Company
and its Subsidiaries own or possess adequate rights or licenses to use all trademarks, trade names, service marks, service mark registrations, service names, original works of authorship, patents, patent rights, copyrights, inventions, licenses,
approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and registrations therefor (Intellectual Property Rights) necessary to conduct their respective businesses as now
conducted. Each of patents owned by the Company or any of its Subsidiaries is listed in the Registration Statement and the Prospectus. Except as set forth in the Registration Statement and the Prospectus, none of the Companys Intellectual
Property Rights have expired or terminated or have been abandoned or are expected to expire or terminate or are expected to be abandoned, within three years from the date of this Agreement. The Company does not have any Knowledge of any infringement
by the Company or its Subsidiaries of Intellectual Property Rights of others. There is no claim, action or proceeding being made or brought, or to the Knowledge of the Company or any of its Subsidiaries, being threatened, against the Company or any
of its Subsidiaries regarding its Intellectual Property Rights. Neither the Company nor any of its Subsidiaries is aware of any facts or circumstances which might give rise to any of the foregoing infringements or claims, actions or proceedings. The
Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights. There are no outstanding options, licenses or agreements of any kind relating to the
Intellectual Property Rights of the Company that are required to be described in the Registration Statement, the General Disclosure Package and the Prospectus and are not described therein in all material respects. The Company is not a party to or
bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Prospectus and are not described therein in all material respects. None of the
technology employed by the Company and material to the Companys business has
15
been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Companys Knowledge, any of its officers, directors or
employees or, to the Companys Knowledge, otherwise in violation of the rights of any persons; the Company has not received any written or oral communications alleging that the Company has violated, infringed or conflicted with, or, by
conducting its business as set forth in the Registration Statement, the General Disclosure Package or the Prospectus, would violate, infringe or conflict with, any of the Intellectual Property Rights of any other person or entity. The Company knows
of no material infringement by others of Intellectual Property Rights owned by or licensed to the Company.
(w)
Manipulation of Prices. The Company has not, and to its Knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result, or that could reasonably be expected to cause or result, in
the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) other than the Agent or other agents with respect to prior offerings which have been disclosed in the
Registration Statement, the General Disclosure Package or the Prospectus, sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) other than the Agent or other agents with respect to prior
offerings, paid or agreed to pay to any person any compensation for soliciting another to purchase any other securities of the Company.
(x) Investment Company Act. Neither the Company nor any Subsidiary is, and upon consummation of the sale of the
Securities, and for so long any Buyer holds any Securities, will be, an investment company, a company controlled by an investment company or an affiliated person of, or promoter or principal
underwriter for, an investment company as such terms are defined in the Investment Company Act of 1940, as amended.
(y) Internal Accounting Controls.
(i) The Company and each of its Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with managements general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset
and liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with managements general or specific authorization and (iv) the recorded accountability for assets and liabilities is
compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any difference.
(ii) The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15 under the 1934 Act) that are effective
in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC,
including, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to the Companys
management, including its principal executive officer or officers and its principal financial officer or officers, as appropriate, to allow timely decisions regarding required disclosure.
16
(z) Industry and Market Data. The statistical, industry-related and
market-related data, if any, included in the Registration Statement, the General Disclosure Package and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and such
data agree in all material respects with the sources from which they are derived.
(aa) Money Laundering Laws. The
operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the Money Laundering Laws), and no action, suit or proceeding by or before any court or governmental agency, authority or body or
any arbitrator involving the Company or any or its Subsidiaries with respect to the Money Laundering Laws is pending or, to the Companys knowledge, threatened.
(bb) Office of Foreign Assets Control. Neither the Company nor, to the Companys knowledge, any director, officer,
agent, employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (OFAC); and the Company will not directly or indirectly
use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any
U.S. sanctions administered by OFAC.
(cc) Insurance. The Company and each of its Subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. Neither the
Company nor any such Subsidiary has been refused any insurance coverage sought or applied for and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers, in each case, as may be necessary to continue its business at a cost that, individually or in the aggregate, do not or would not reasonably be expected to have a Material
Adverse Effect.
(dd) Employee Benefits. The Company and each Subsidiary is in compliance in all material respects
with all presently applicable provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (ERISA); no reportable event (as defined
in ERISA) has occurred with respect to any pension plan (as defined in ERISA) for which the Company and each Subsidiary would have any material liability; the Company and each Subsidiary has not incurred and does not expect to incur
material liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any pension plan or (ii) Sections 412 or 4971 of the Internal Revenue Code of 1986, as amended (the Code);
and each pension plan for which the Company or any Subsidiary would have any liability that is intended to be qualified under Section 401(a) of the Code is so qualified in all material respects and nothing has occurred, whether by
action or by failure to act, which would cause the loss of such qualification.
17
(ee) Employee Relations.
(i) Neither the Company nor any of its Subsidiaries is a party to any collective bargaining agreement or employs any member of a union. The
Company and its Subsidiaries believe that its relations with its employees are good. No current executive officer of the Company or any of its Subsidiaries (as defined in Rule 501(f) of the 1933 Act) has notified the Company or any such Subsidiary
that such officer intends to leave the Company or any such Subsidiary or otherwise terminate such officers employment with the Company or any such Subsidiary. No current executive officer of the Company or any of its Subsidiaries is, or is now
expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant, and the
continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters, except where such violation would not, either individually or in the
aggregate, reasonably be expected to result in a Material Adverse Effect.
(ii) The Company and its Subsidiaries are in compliance with
all federal, state, local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance would not, either
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
(ff) Transactions with
Affiliates. Except as otherwise described in Schedule 3(ff), to the Companys Knowledge, there are no affiliations or associations between any member of the FINRA and any of the Companys officers, directors or 5% or greater
securityholders, except as set forth in the Registration Statement. There are no relationships or related-party transactions involving the Company or any of the Subsidiaries or, to the Knowledge of the Company, any other person required to be
described in the Prospectus which have not been described in the Registration Statement or the Prospectus, as required.
(gg) Environmental Laws. The Company and its Subsidiaries (i) are in compliance with any and all Environmental Laws
(as hereinafter defined), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of
any such permit, license or approval where, in each of the foregoing clauses (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. The term
Environmental Laws means all federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or
subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, Hazardous
Materials) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or
demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.
18
(hh) Listing; 1934 Act Registration. The Common Stock is listed for
trading on the Principal Market. The Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the 1934 Act or the quotation of the Common Stock on the Principal Market, and
except as disclosed in Schedule 3(hh), the Company has not received any notification that the SEC or the Principal Market is contemplating terminating such registration or quotation. Without limiting the generality of the foregoing, except as
disclosed in Schedule 3(hh), the Company is not in violation of any of the rules, regulations or requirements of the Principal Market and has no Knowledge of any facts or circumstances that would reasonably lead to delisting or suspension of
the Common Stock by the Principal Market in the foreseeable future. During the two (2) years prior to the date hereof, the Common Stock has been designated for quotation on the Principal Market. During the two (2) years prior to the date
hereof, (i) trading in the Common Stock has not been suspended by the SEC or the Principal Market and (ii) the Company has received no communication, written or oral, from the SEC or the Principal Market regarding the suspension or
delisting of the Common Stock from the Principal Market. The Company and its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their
respective businesses, except where the failure to possess such certificates, authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary has received any
notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit.
(ii)
Contributions; Foreign Corrupt Practices. Neither the Company, nor any of its Subsidiaries, nor any director, officer, agent, employee or other Person acting on behalf of the Company or any of its Subsidiaries has, in the course of its
actions for, or on behalf of, the Company or any of its Subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or
indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any
unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.
(jj) No Integrated Offering. The Company has not sold or issued any securities that would be integrated with the
offering of the Securities contemplated by this Agreement pursuant to the 1933 Act, the Rules and Regulations or the interpretations thereof by the SEC. None of the Company, its Subsidiaries, any of their affiliates, and any Person acting on their
behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to require approval of shareholders of the Company for
purposes of any applicable shareholder approval provisions, including, without limitation, Nasdaq Rule 5635. None of the Company, its Subsidiaries, their affiliates and any Person acting on their behalf will take any action or steps referred to in
the preceding sentence that would cause the offering of the Securities to be integrated with other offerings for purposes of any such applicable shareholder approval provisions.
19
(kk) Brokerage Fees; Commissions. Except as set forth in any of the
Transaction Documents, the Registration Statement and the Prospectus, neither the Company nor any of its Subsidiaries is a party to any contract, agreement or understanding with any person that would give rise to a valid claim against the Company or
the Buyers for a brokerage commission, finders fee or like payment in connection with the offering and sale of the Securities. The Company shall pay, and hold the Buyer harmless against, any liability, loss or expense (including, without
limitation, attorneys fees and out-of-pocket expenses) arising in connection with any such claim. The Company acknowledges that it has engaged WestPark Capital, Inc. as placement agent (the Agent) in connection with the sale
of the Securities. Other than the Agent, neither the Company nor any of its Subsidiaries has engaged any placement agent or other agent in connection with the sale of the Securities.
(ll) Consents. Neither the Company nor any of its Subsidiaries is required to obtain any consent, authorization or order
of, or make any filing or registration with, any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its obligations under or contemplated by the
Transaction Documents, in each case in accordance with the terms hereof or thereof which have not been previously obtained or made. All consents, authorizations, orders, filings and registrations which the Company or any of its Subsidiaries is
required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the Closing Date, and the Company and its Subsidiaries are unaware of any facts or circumstances that might prevent the Company or any of its
Subsidiaries from obtaining or effecting any of the registration, application or filings pursuant to the preceding sentence. The issuance by the Company of the Securities shall not have the effect of delisting or suspending the Common Stock from the
Principal Market.
(mm) Acknowledgment Regarding Buyers Purchase of Securities. The Company acknowledges and
agrees that each Buyer is acting solely in the capacity of an arms length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby and that no Buyer is (i) an officer or director of the
Company or any of its Subsidiaries, (ii) an affiliate of the Company or any of its Subsidiaries (as defined in Rule 144) or (iii) to the Knowledge of the Company, a beneficial owner of more than 10% of the shares of
Common Stock (as defined for purposes of Rule 13d-3 of the 1934 Act). The Company further acknowledges that no Buyer is acting as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with respect to
the Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Buyer or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby
is merely incidental to such Buyers purchase of the Securities. The Company further represents to each Buyer that the Companys decision to enter into the Transaction Documents has been based solely on the independent evaluation by the
Company and its representatives.
20
(nn) Dilutive Effect. The Company understands and acknowledges that the
number of Warrant Shares issuable pursuant to the terms of the Warrants will increase in certain circumstances. The Company further acknowledges that its obligation to issue Warrant Shares upon exercise of the Warrants in accordance with this
Agreement and the Warrants is, in each case, absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company, subject to the terms of the Warrants and the other
Transaction Documents.
(oo) Application of Takeover Protections; Rights Agreement. The Company and its board of
directors have taken all necessary action, if any, in order to exempt the Companys issuance of the Securities and any Buyers ownership of the Securities from the provisions of any control share acquisition, business combination, poison
pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Articles of Incorporation of the Company or the laws of the state of its incorporation which is or could become applicable to any Buyer as
a result of the transactions contemplated by this Agreement, including, without limitation, the Companys issuance of Securities and each Buyers ownership of the Securities. Except as set forth in the Registration Statement and the
Prospectus, the Company does not have any shareholder rights plan or similar arrangement relating to accumulations of beneficial ownership of Common Stock or a change in control of the Company.
(pp) Subsidiary Rights. The Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to
limitations imposed by applicable law) to receive dividends and distributions on, all capital securities of its Subsidiaries as owned by the Company or such Subsidiary.
(qq) Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and
an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its 1934 Act filings and is not so disclosed or that otherwise would be reasonably likely to have a Material Adverse Effect.
(rr) Transfer Taxes. On the Closing Date, all stock transfer or other similar taxes (other than income or similar taxes)
which are required to be paid in connection with the sale and transfer of the Securities to be sold to each Buyer hereunder will be, or will have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have
been complied with.
(ss) Acknowledgement Regarding Buyers Trading Activity. Anything in this Agreement or
elsewhere herein to the contrary notwithstanding, it is understood and acknowledged by the Company (i) that none of the Buyers have been asked by the Company or its Subsidiaries to agree, nor has any Buyer agreed with the Company or its
Subsidiaries, to desist from purchasing or selling, long and/or short, securities of the Company, or derivative securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) that past or
future open market or other transactions by any Buyer, including, without limitation, short sales or derivative transactions, before or after the closing of this or future transactions, may negatively impact the market price of the
Companys publicly-traded securities; (iii) that any Buyer, and counter parties in derivative transactions to which any such Buyer is a party, directly or indirectly, presently may have a short position in the
Common Stock; and (iv) that such Buyer shall not be deemed to have any affiliation with or
21
control over any arms length counter-party in any derivative transaction. The Company further understands and acknowledges that (a) one or more Buyers may engage in hedging
and/or trading activities at various times during the period that the Securities are outstanding, including, without limitation, during the period that the value of the Warrant Shares deliverable with respect to Warrants are being determined and
(b) such hedging and/or trading activities (if any) could reduce the value of the existing shareholders equity interests in the Company at and after the time that the hedging and/or trading activities are being conducted. The Company
acknowledges that such aforementioned hedging and/or trading activities do not constitute a breach of this Agreement, the Warrants or any of the documents executed in connection herewith.
(tt) U.S. Real Property Holding Corporation. The Company is not, has never been, and so long as any Securities remain
outstanding, shall not become, a U.S. real property holding corporation within the meaning of Section 897 of the Code and the Company shall so certify upon any Buyers request.
(uu) Shell Company Status. The Company is not, and has never been, an issuer identified in Rule 144(i)(1).
(vv) Bank Holding Company. Neither the Company nor any of its Subsidiaries or affiliates is subject to the Bank Holding
Company Act of 1956, as amended (the BHCA) and to regulation by the Board of Governors of the Federal Reserve System (the Federal Reserve). Neither the Company nor any of its Subsidiaries or affiliates owns or
controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal
Reserve.
(ww) SEC Documents; Financial Statements. Except for the Companys current report on Form 8-K filed
on December 18, 2013, which has been amended by the amended current report on Form 8-K/A filed on August 29, 2014, during the two (2) years prior to the date hereof, the Company has timely filed all reports, schedules, forms,
statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act (all of the foregoing filed prior to the date hereof, and all exhibits included therein and financial statements, notes and
schedules thereto and documents incorporated by reference therein being hereinafter referred to as the SEC Documents). The Company has delivered to the Buyers or their respective representatives true, correct and complete copies
of the SEC Documents not available on the EDGAR system other than annual reports to security holders filed with the SEC as ARS filings, which ARS filings conformed in form and substance to the reports filed by the Company
with the SEC. As of their respective filing dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of
the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading. As of their respective filing dates, the financial statements of
22
the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect
thereto. Such financial statements have been prepared in accordance with GAAP, consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the
case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of
its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).
(xx) Lock-Up Agreements. The Company and each of the parties set forth on Exhibit F-1 hereto has executed and
delivered to the Company a lock-up agreement in the form attached hereto as Exhibit F-2 (collectively, the Lock-Up Agreements).
(yy) No Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance
has occurred or exists, or is contemplated to occur with respect to the Company, its Subsidiaries or their respective business, properties, prospects, operations or financial condition, that would be required to be disclosed by the Company under
applicable securities laws on a registration statement on Form S-1 filed with the SEC relating to an issuance and sale by the Company of its Common Stock and which has not been publicly announced.
(zz) Stock Option Plans. Except as disclosed in the Registration Statement or the Prospectus, each stock option granted
by the Company was granted (i) in accordance with the terms of the applicable stock option plan of the Company and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would
be considered granted under GAAP and applicable law. No stock option granted under the Companys stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company to
knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.
(aaa) Indebtedness and Other Contracts.
(i) Neither the Company nor any of its Subsidiaries, except as disclosed in the Registration Statement and the Prospectus or which is
otherwise Permitted Indebtedness (as defined below), (i) has any outstanding Indebtedness, individually or in the aggregate, in excess of $100,0000, (ii) is a party to any contract, agreement or instrument, the violation of which, or
default under which, by the other party(ies) to such contract, agreement or instrument could reasonably be expected to result in a Material Adverse Effect, (iii) is in violation of any term of or in default under any contract, agreement or
instrument relating to any Indebtedness, except where such violations and defaults would not result, individually or in the aggregate, in a Material Adverse Effect, or (iv) is a party to any contract, agreement or instrument relating to any
Indebtedness, the performance of which, in the judgment of the Companys officers, has or is expected to have a Material Adverse Effect. The Registration Statement and the Prospectus provide a detailed description of the material terms of any
such outstanding Indebtedness.
23
(ii) As used in this subsection and elsewhere in this Agreement:
(1) Liens means any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any
property or assets (including accounts and contract rights) owned by the Company or any of its Subsidiaries.
(2)
Permitted Indebtedness means (i) trade payables incurred in the ordinary course of business consistent with past practice, (ii) Permitted Senior Indebtedness, (iii) Indebtedness secured by Permitted Liens described
in clauses (iv) and (vi) of the definition of Permitted Liens, (iv) any synthetic lease obligations, or other obligations which are required to be treated as Indebtedness under GAAP, but are otherwise operating lease obligations,
(v) letters of credit or bonds entered into in the Companys ordinary course of business in an amount not to exceed $100,000 in the aggregate and (vi) Indebtedness to Riverside Renewable Energy Investment LLC, as disclosed in the
Registration Statement and the Prospectus.
(3) Permitted Liens means (i) any Lien for taxes not
yet due or delinquent or being contested in good faith by appropriate proceedings for which adequate reserves have been established in accordance with GAAP, (ii) any statutory Lien arising in the ordinary course of business by operation of law
with respect to a liability that is not yet due or delinquent, (iii) any Lien created by operation of law, such as materialmens liens, mechanics liens and other similar liens, arising in the ordinary course of business with respect
to a liability that is not yet due or delinquent or that are being contested in good faith by appropriate proceedings, (iv) Liens (A) upon or in any equipment acquired or held by the Company or any of its Subsidiaries to secure the
purchase price of such equipment or Indebtedness incurred solely for the purpose of financing the acquisition or lease of such equipment, or (B) existing on such equipment at the time of its acquisition, provided that the Lien is confined
solely to the property so acquired and improvements thereon, and the proceeds of such equipment, (v) Liens incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in clause
(iv) above, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or refinanced does not increase,
(vi) leases or subleases and licenses and sublicenses granted to others in the ordinary course of the Companys business, not interfering in any material respect with the business of the Company and its Subsidiaries taken as a whole,
(vii) Liens in favor of customs and revenue authorities arising as a matter of law to secure payments of custom duties in connection with the importation of goods, (viii) Liens arising from judgments, decrees or attachments,
(ix) Liens securing Permitted Senior Indebtedness as in effect on the date hereof.
(4) Permitted Senior
Indebtedness means Indebtedness incurred pursuant to that certain Loan and Security Agreement dated as of December 19, 2011 by and among Real Goods Energy Tech, INC., Real Goods Trading Corporation,
24
Earth Friendly Energy Group Holdings, LLC, Alteris Renewables, INC., Earth Friendly Energy Group, LLC, Solar Works, LLC, Alteris RPS, LLC and Alteris ISI, LLC and Silicon Valley Bank, as such
Indebtedness may be refinanced, amended or extended.
(bbb) No Additional Agreements. Neither the Company nor any of
its Subsidiaries has any agreement or understanding with any Buyer with respect to the transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents.
(ccc) No Disagreements with Accountants and Lawyers. There are no material disagreements of any kind presently existing,
or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company is current with respect to any fees owed to its accountants and lawyers which could
affect the Companys ability to perform any of its obligations under any of the Transaction Documents. In addition, on or prior to the date hereof, the Company had discussions with its accountants about its financial statements previously filed
with the SEC. Based on those discussions, the Company has no reason to believe that it will need to restate any such financial statements or any part thereof.
4. COVENANTS.
(a) Best Efforts. Each party shall use its reasonable best efforts timely to satisfy each of the covenants and the
conditions to be satisfied by it as provided in Sections 6 and 7 of this Agreement.
(b) Maintenance of Registration
Statement.
(i) For so long as any of the Warrants remain outstanding or are potentially issuable hereunder, the Company shall use its
reasonable best efforts to maintain the effectiveness of the Registration Statement for the issuance thereunder of the Registrable Securities (as defined below); provided that, if at any time while any Warrants are outstanding, the Company shall be
ineligible to utilize Form S-3 (or any successor form) for the purpose of issuance of the Registrable Securities (as defined below) the Company shall use its reasonable best efforts to promptly amend or supplement the Registration Statement or, if
necessary, file a new registration statement on such other form as may be necessary to maintain the effectiveness of the Registration Statement or such other registration statement for this purpose. For the purpose of this Agreement,
Registrable Securities means at least the sum of (i) 200,000,000 shares of Common Stock (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the date
hereof) or such greater number of shares determined by taking into account the Maximum Eligibility Number (as defined in each of the Series B Warrants, the Series C Warrants and the Series D Warrants, without giving effect to the proviso set forth
in such definitions) and (ii) any shares of capital stock of the Company issued or issuable with respect to the Common Shares, the Warrants and/or the Warrant Shares as a result of any stock split, stock dividend, recapitalization, exchange,
shareholder approval or similar event or adjustment or otherwise, without regard to any limitations on issuance, conversion or exercise thereof.
25
(ii) If, on any day after the Closing Date, issuances of all of the Registrable
Securities cannot be made upon exercise of the Warrants pursuant to the Registration Statement (including, without limitation, because of a failure to keep the Registration Statement effective, failure to file or cause to become effective any
supplements or amendments thereto or other public filings necessary, failure to disclose such information as is necessary for sales to be made pursuant to the Registration Statement, a suspension or delisting of the Common Stock on its principal
trading market or exchange, failure to register or list a sufficient number of shares of Common Stock, or ineligibility to issue such Registrable Securities under the Registration Statement pursuant to General Instruction I.B.4.) (a
Maintenance Failure) then, as partial relief for the damages to any holder of Securities (an Investor) by reason of any such delay in or reduction of its ability to receive Registrable Securities upon exercise
of the Warrants (which remedy shall not be exclusive of any other remedies available at law or in equity), the Company shall pay to each Investor an amount in cash equal to one percent (1.0%) of the sum of (x) the aggregate Purchase Price
of such Investors Common Shares and the Series E Warrants and (y) the Aggregate Exercise Price (as defined in the Series B Warrants) paid by such Investor for the exercise of the Series B Warrants of such Investor on each of the following
dates: (i) the initial day of a Maintenance Failure; and (ii) on every thirtieth (30th) day (pro-rated for periods totaling less than thirty (30) days) after the initial day after a Maintenance Failure until such Maintenance
Failure is cured. The Company shall also pay the reasonable fees of legal counsel of such Investor to enforce the provisions hereof. The payments to which an Investor shall be entitled pursuant to this Section 4(b) are referred to herein as
Registration Delay Payments. Registration Delay Payments shall be paid on the initial day of a Maintenance Failure, as applicable, and thereafter on the earlier of (I) the thirtieth (30th) day after the event or failure
giving rise to the Registration Delay Payments has occurred and (II) the third (3rd) Business Day after the event or failure giving rise to the Registration Delay Payments is cured. In the event the Company fails to make Registration Delay
Payments in a timely manner, such Registration Delay Payments shall bear interest at the rate of one and one-half percent (1.5%) per month (prorated for partial months) until paid in full.
(c) Prospectus Supplement and Blue Sky. In the manner required by law, the Company shall have delivered to the Buyers,
and as soon as practicable after the Closing, the Company shall file, the Prospectus Supplement with respect to the Securities as required under and in conformity with the 1933 Act, including Rule 424(b) thereunder. If required, the Company, on or
before the Closing Date, shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Securities for sale to the Buyers at the Closing pursuant to this Agreement under applicable
securities or Blue Sky laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Buyers on or prior to the Closing Date. The Company shall
make all filings and reports relating to the offer and sale of the Securities required under applicable securities or Blue Sky laws of the states of the United States following the Closing Date.
(d) Use of Proceeds. The Company will use the proceeds from the sale of the Securities for general corporate purposes,
for working capital purposes and/or for any scheduled repayment of any outstanding Permitted Senior Indebtedness, but not for the redemption or repurchase of any of its or its Subsidiaries equity securities.
26
(e) Listing. The Company shall promptly secure the listing of all of the
authorized Common Shares and Warrant Shares and promptly secure the listing of all of the Warrant Shares not authorized at Closing promptly upon receiving the Shareholder Approval and effecting the Reverse Stock Split and the Authorized Shares
Increase Amendment, in each case, upon each securities exchange and automated quotation system, if any, upon which the Common Stock is then listed, including the Principal Market (subject to official notice of issuance) and shall use its reasonable
best efforts to maintain, in accordance with the Transaction Documents, the listing of all Common Shares and Warrant Shares, from time to time issuable under the terms of the Transaction Documents (including, without limitation, by
(1) completing the Reverse Stock Split within five (5) Business Days of the Reverse Stock Split Resolution Date (as defined in Section 4(p)) and (2) completing the Authorized Shares Increase Amendment within five
(5) Business Days of Authorized Shares Increase Resolution Date (as defined in Section 4(p))). The Company shall maintain the authorization for quotation of the Common Stock, on the Principal Market, or if such authorization is not able to
be maintained, on another Eligible Market (as defined in the Warrants). Neither the Company nor any of its Subsidiaries shall take any action which would be reasonably expected to result in the delisting or suspension of the Common Stock on the
Principal Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section 4(e).
(f) Fees. The Company shall reimburse the Lead Investor (a Buyer) or its designee(s) (in addition to any other expense
amounts paid to any Buyer or its counsel prior to the date of this Agreement) for all costs and expenses incurred in connection with the transactions contemplated by the Transaction Documents (including all legal fees and disbursements in connection
therewith, documentation and implementation of the transactions contemplated by the Transaction Documents and due diligence in connection therewith), without the prior written approval of the Company, in an amount not to exceed $170,000, which
amount, at the option of the Buyer, may be withheld by such Buyer from its Purchase Price at the Closing to the extent not previously reimbursed by the Company. The Company shall be responsible for the payment of any placement agents fees,
financial advisory fees, or brokers commissions (other than for Persons engaged by any Buyer) relating to or arising out of the transactions contemplated hereby, including, without limitation, any fees or commissions payable to the Agent.
(g) Pledge of Securities. The Company acknowledges and agrees that the Securities may be pledged by any Investor in
connection with a bona fide margin agreement or other bona fide loan or financing arrangement that is secured by the Securities. Such pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no
Investor effecting such pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document. The Company hereby agrees,
subject to applicable securities laws, to execute and deliver such documentation as a pledgee of the Securities may reasonably request in connection with a pledge of the Securities to such pledgee by an Investor.
(h) Disclosure of Transactions and Other Material Information. The Company shall (i) on or before 9:00 a.m., New York
City time, on February 24, 2015, issue a press release reasonably acceptable to the Buyers describing the terms of the transactions contemplated by the Transaction Documents (the Press Release) and (ii) on or before 12:00
p.m., New York City time, on February 24, 2015 file a Current Report on Form 8-K reasonably acceptable to Buyers describing the terms
27
of the transactions contemplated by the Transaction Documents in the form required by the 1934 Act and attaching the material Transaction Documents (including, without limitation, this
Agreement, the form of Warrants, the form of the Voting Agreement and the form of Lock-Up Agreement) as exhibits to such filing (including all attachments), the 8-K Filing). As of immediately following the issuance of the Press
Release, no Buyer shall be in possession of any material, nonpublic information received from the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that is not disclosed in the Press
Release or in prior filings with the SEC. In addition, effective upon the issuance of the Press Release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral,
between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and any of the Buyers or any of their affiliates, on the other hand, shall terminate. The Company
understands and confirms that each of the Buyers will rely on the foregoing in effecting transactions in securities of the Company. The Company shall not, and shall cause each of its Subsidiaries and its and each of their respective officers,
directors, employees, affiliates and agents, not to, provide any Buyer with any material, nonpublic information regarding the Company or any of its Subsidiaries from and after the issuance of the Press Release without the express prior written
consent of such Buyer. If a Buyer has, or believes it has, received any such material, nonpublic information regarding the Company or any of its Subsidiaries from the Company, any of its Subsidiaries or any of their respective officers, directors,
employees, affiliates or agents, it may provide the Company with written notice thereof in which case the Company shall, within two (2) Trading Days (as defined in the Warrants) of receipt of such notice, make public disclosure of such
material, nonpublic information. In the event of a breach of the foregoing covenant by the Company, any of its Subsidiaries, or any of its or their respective officers, directors, employees, affiliates and agents, in addition to any other remedy
provided herein or in the Transaction Documents, a Buyer shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, nonpublic information without the prior approval by the
Company, its Subsidiaries, or any of its or their respective officers, directors, employees, affiliates or agents. No Buyer shall have any liability to the Company, its Subsidiaries, or any of its or their respective officers, directors, employees,
affiliates or agents for any such disclosure. To the extent the Company or any of its or their respective officers, directors, employees, affiliates or agents delivers any material, non-public information to a Buyer without such Buyers
consent, the Company hereby covenants and agrees that such Buyer shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a
duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents not to trade on the basis of, such material, non-public information. Subject to the foregoing, neither the Company, its
Subsidiaries nor any Buyer shall issue any press releases or any other public statements with respect to the transactions contemplated by the Transaction Documents; provided, however, that the Company shall be entitled, without the
prior approval of any Buyer, to make any press release or other public disclosure with respect to such transactions (i) in substantial conformity with the Press Release and 8-K Filing and contemporaneously therewith and (ii) as is required
by applicable law, regulation or any Eligible Market on which the Companys securities are then listed or quoted (provided that in the case of clause (i) each Buyer shall be consulted by the Company in connection with any such press
release or other public disclosure
28
prior to its release). Without the prior written consent of any applicable Buyer, neither the Company nor any of its Subsidiaries or affiliates shall disclose the name of such Buyer in any
filing, announcement, release or otherwise other than in connection with the Registration Statement unless such disclosure is required by law, regulation or any Eligible Market on which the Companys securities are then listed or quoted. As
used herein, Business Day means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.
(i) Additional Warrants; Variable Securities. So long as any Buyer beneficially owns any Securities, the Company will
not issue any Warrants other than to the Buyers as contemplated hereby. During the six (6) month period following the Closing, the Company shall not, in any manner, issue or sell any rights, warrants or options to subscribe for or purchase
Common Stock or directly or indirectly convertible into or exchangeable or exercisable for Common Stock at a price which varies or may vary with the market price of the Common Stock, including by way of one or more reset(s) to any fixed price unless
the conversion, exchange or exercise price of any such security cannot be less than the then applicable Exercise Price (as defined in each of the Series A Warrants, the Series B Warrants and the Series C Warrants) with respect to the Common Stock
into which any Warrant is exercisable. Notwithstanding the foregoing, the Company may issue shares of Common Stock upon conversion of Options and Convertible Securities (each as defined in Section 4(o)) which are outstanding on the day
immediately preceding the date hereof; provided that the terms of such Options or Convertible Securities are not amended, modified or changed on or after the date hereof without the prior written consent of the Required Holders;
provided, further, that the Company shall be permitted to effect an Option repricing with respect to employee options under its existing Long-Term Incentive Plan.
(j) Corporate Existence. So long as any Buyer beneficially owns any Securities, the Company shall (i) maintain its
corporate existence and (ii) not be party to any Fundamental Transaction (as defined in the Warrants) unless the Company is in compliance with the applicable provisions governing Fundamental Transactions set forth in the Warrants.
(k) Reservation of Shares. From and after the Companys receipt of the Shareholder Approval and its
effecting each of the Reverse Stock Split and the Authorized Shares Increase Amendment (such date, the Authorized Shares Increase Date), the Company shall increase the number of shares of Common Stock reserved for issuance
pursuant to the Transaction Documents such that the aggregate number of shares of Common Stock so reserved shall not be not less than 200,000,000 shares of Common Stock (as adjusted for any stock dividend, stock split, stock combination,
reclassification or similar transaction occurring after the date hereof) or such greater number of shares of Common Stock determined by taking into account the Maximum Eligibility Number (as defined in each of the Series B Warrants, the Series C
Warrants and the Series D Warrants, without giving effect to the proviso set forth in such definitions) (the Required Reserve Amount), which amount shall at all times be allocable among any of the Warrants at the sole discretion
of the Buyers or the transferees of the Securities. So long as any Buyer owns any Securities, the Company shall take all action necessary to at all times (i) until the Authorized Shares Increase Date, have authorized, and reserved for issuance
the Initial Required Reserve Amount and (ii) as of the Authorized Shares Increase Date, have authorized, and reserved for issuance the applicable Required Reserve
29
Amount. If at any time the number of shares of Common Stock authorized and reserved for issuance is not sufficient to meet (i) until the Authorized Shares Increase Date, the Initial Required
Reserve Amount and (ii) as of the Authorized Shares Increase Date, the Required Reserve Amount, then, in each case, the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including,
without limitation, calling a special meeting of shareholders to authorize additional shares to meet the Companys obligations under Section 3(e), in the case of an insufficient number of authorized shares, obtain shareholder approval of
an increase in such authorized number of shares, and voting the management shares of the Company in favor of an increase in the authorized shares of the Company to ensure that the number of authorized shares is sufficient to meet the Initial
Required Reserve Amount or the Required Reserve Amount, as applicable. Upon any increase in the number of authorized or unreserved shares of Common Stock of the Company following the date hereof, the Company shall use such increased number of
authorized shares to satisfy its obligations to keep the Initial Required Reserve Amount or the Required Reserve Amount of shares, as applicable, reserved for the Securities before reserving or using shares for any other purpose. Notwithstanding
anything to the contrary herein or in any of the Transaction Documents, until the Companys receipt of the Shareholder Approval and its effecting each of the Reverse Stock Split and the Authorized Shares Increase Amendment, (i) the Company
shall not issue any shares of Common Stock to the Agent upon exercise of the Warrants issued to the Agent by the Company as compensation for the transactions contemplated by this Agreement (the Agent Warrants) and (ii) none
of the shares reserved as part of the Initial Required Reserve Amount shall be allocated or allocable for the shares of Common Stock issuable upon exercise of the Agent Warrants. The initial number of shares of Common Stock reserved for exercise of
the Warrants and each increase in the number of shares so reserved shall be allocated pro rata among the Purchasers, based on the number of shares of Common Stock issuable upon exercise of the Series A Warrants (without regard to any limitations in
exercise) issued to each Purchaser on the Issuance Date (the Authorized Share Allocation). In the event that a Purchaser shall sell or otherwise transfer any of its Warrants, each transferee shall be allocated a pro rata portion
of such holders Authorized Share Allocation. Any shares of Common Stock reserved and allocated to any Person which ceases to hold any Warrants shall be allocated to the holders of the remaining Warrants, pro rata based on the shares of Common
Stock issuable upon exercise of the Warrants then held by such holders (without regard to any limitations on the exercise of the Warrants).
(l) Conduct of Business. The business of the Company and its Subsidiaries shall not be conducted in violation of any
law, ordinance or regulation of any governmental entity, except where such violations would not result, either individually or in the aggregate, in a Material Adverse Effect.
(m) Lock-Up. The Company shall not amend or waive any provision of the Lock-Up Agreements except to extend the term of
the lock-up period contained therein and shall enforce the provisions of the Lock-Up Agreements in accordance with their terms. If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its
best efforts to seek specific performance of the terms of such Lock-Up Agreement.
30
(n) Voting Agreement. The Company shall use its reasonable best
efforts to effectuate the transactions contemplated by the Voting Agreement substantially in the form attached hereto as Exhibit G (the Voting Agreement), executed on or prior to the Closing by the Company, Riverside
Renewable Energy Investments, LLC and the Companys officers and directors holding no less than 14.96% of the issued and outstanding Common Stock plus the number of shares of Common Stock held by the Companys officers and directors
signing the Voting Agreement (collectively, the Principal Shareholders). The Company shall not amend or waive any provision of the Voting Agreement and shall enforce the provisions of the Voting Agreement in accordance with
its terms. If any of the Principal Shareholders breaches any provision of the Voting Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms of such Voting Agreement in accordance with the terms
thereof. In addition, if the Company receives any notice from any of the Principal Shareholders pursuant to the Voting Agreement, the Company shall promptly, but in no event later than two (2) Business Days, deliver a copy of such notice
to each Buyer.
(o) Additional Issuances of Securities.
(i) For purposes of this Section 4(o), the following definitions shall apply.
(1) Convertible Securities means any stock or securities (other than Options) convertible into or
exercisable or exchangeable for shares of Common Stock.
(2) Options means any rights,
warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.
(3)
Common Stock Equivalents means, collectively, Options and Convertible Securities.
(ii) The Company shall
not, (I) from the date hereof until the first date on or after the thirtieth (30th) day following the date the Company obtains the Shareholder Approval when there is no Equity Conditions Failure (as defined in the Series B Warrants), (the
Trigger Date) (x) directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or announce any offer, sale, grant or any option to purchase or other disposition of) any of its or its
Subsidiaries equity or equity equivalent securities, including without limitation any debt, preferred stock or other instrument or security that is, at any time during its life and under any circumstances, convertible into or exchangeable or
exercisable for shares of Common Stock or Common Stock Equivalents (any such offer, sale, grant, disposition or announcement being referred to as a Subsequent Placement) or (y) grant any registration rights to any Person that
can be exercised prior to such date and (II) from the date hereof until the Company obtains Shareholder Approval, be party to any solicitations, negotiations or discussions with regard to the matters set forth in clause (I)(x) above.
(iii) From the Trigger Date until the two (2) year anniversary of the Closing Date, the Company will not, directly or indirectly, effect
any Subsequent Placement unless the Company shall have first complied with this Section 4(o)(iii).
31
(1) The Company shall deliver to each Buyer an irrevocable written notice to the
contact information as is set forth opposite such Buyers name in column (2a) of the Schedule of Buyers attached hereto (the Offer Notice) of any proposed or intended issuance or sale or exchange
(the Offer) of the securities being offered (the Offered Securities) in a Subsequent Placement, which Offer Notice shall (w) identify and describe the Offered Securities, (x) describe the price
and other terms upon which they are to be issued, sold or exchanged, and the number or amount of the Offered Securities to be issued, sold or exchanged, (y) identify the persons or entities (if known) to which or with which the Offered
Securities are to be offered, issued, sold or exchanged and (z) offer to issue and sell to or exchange with such Buyers at least forty percent (40%) of the Offered Securities, allocated among such Buyers (a) based on such Buyers
pro rata portion of the number of shares of Common Stock issuable upon exercise in full of the Series A Warrants (without regard to any limitations on exercise) purchased hereunder (the Basic Amount) and (b) with respect to
each Buyer that elects to purchase its Basic Amount, any additional portion of the Offered Securities attributable to the Basic Amounts of other Buyers as such Buyer shall indicate it will purchase or acquire should the other Buyers subscribe for
less than their Basic Amounts (the Undersubscription Amount), which process shall be repeated until the Buyers shall have an opportunity to subscribe for any remaining Undersubscription Amount.
(2) To accept an Offer, in whole or in part, such Buyer must deliver a written notice to the Company prior to the end of the
fifth (5th) Business Day after such Buyers receipt of the Offer Notice (the Offer Period), setting forth the portion of such Buyers Basic Amount that such Buyer
elects to purchase and, if such Buyer shall elect to purchase all of its Basic Amount, the Undersubscription Amount, if any, that such Buyer elects to purchase (in either case, the Notice of Acceptance). If the Basic Amounts
subscribed for by all Buyers are less than the total of all of the Basic Amounts, then each Buyer who has set forth an Undersubscription Amount in its Notice of Acceptance shall be entitled to purchase, in addition to the Basic Amounts subscribed
for, the Undersubscription Amount it has subscribed for; provided, however, that if the Undersubscription Amounts subscribed for exceed the difference between the total of all the Basic Amounts and the Basic Amounts subscribed for (the
Available Undersubscription Amount), each Buyer who has subscribed for any Undersubscription Amount shall be entitled to purchase only that portion of the Available Undersubscription Amount as the Basic Amount of such Buyer bears
to the total Basic Amounts of all Buyers that have subscribed for Undersubscription Amounts, subject to rounding by the Company to the extent its deems reasonably necessary. Notwithstanding anything to the contrary contained herein, if the Company
desires to modify or amend the terms and conditions of the Offer prior to the expiration of the Offer Period, the Company may deliver to the Buyers a new Offer Notice and the Offer Period shall expire on the third (3rd) Business Day after such Buyers receipt of such new Offer Notice.
(3) The Company shall have five (5) Business Days after the expiration of the Offer Period above to offer, issue,
sell or exchange all or any part of such Offered Securities as to which a Notice of Acceptance has not been given by the Buyers (the Refused Securities) pursuant to a definitive agreement (the Subsequent Placement
Agreement), but only to the offerees described in the Offer Notice (if so described therein) and only upon terms and conditions (including, without limitation, unit prices and interest rates) that are not more favorable to the acquiring
Person or Persons or
32
less favorable to the Company than those set forth in the Offer Notice and (ii) to publicly announce (a) the execution of such Subsequent Placement Agreement and (b) either
(x) the consummation of the transactions contemplated by such Subsequent Placement Agreement or (y) the termination of such Subsequent Placement Agreement, which, if required to ensure that the Buyers will not be in possession of material
non-public information, shall be filed with the SEC on a Current Report on Form 8-K with such Subsequent Placement Agreement and, as so required, any documents contemplated therein filed as exhibits thereto.
(4) In the event the Company shall propose to sell less than all the Refused Securities (any such sale to be in the manner and
on the terms specified in Section 4(o)(iii)(3) above), then each Buyer may, at its sole option and in its sole discretion, reduce the number or amount of the Offered Securities specified in its Notice of Acceptance to an amount that shall be
not less than the number or amount of the Offered Securities that such Buyer elected to purchase pursuant to Section 4(o)(iii)(2) above multiplied by a fraction, (i) the numerator of which shall be the number or amount of Offered
Securities the Company actually proposes to issue, sell or exchange (including Offered Securities to be issued or sold to Buyers pursuant to Section 4(o)(iii)(3) above prior to such reduction) and (ii) the denominator of which shall be the
original amount of the Offered Securities. In the event that any Buyer so elects to reduce the number or amount of Offered Securities specified in its Notice of Acceptance, the Company may not issue, sell or exchange more than the reduced number or
amount of the Offered Securities unless and until such securities have again been offered to the Buyers in accordance with Section 4(o)(iii)(1) above.
(5) Upon the closing of the issuance, sale or exchange of all or less than all of the Refused Securities, the Buyers shall
acquire from the Company, and the Company shall issue to the Buyers, the number or amount of Offered Securities specified in the Notices of Acceptance, as reduced pursuant to Section 4(o)(iii)(4) above if the Buyers have so elected, upon the
terms and conditions specified in the Offer. The purchase by the Buyers of any Offered Securities is subject in all cases to the preparation, execution and delivery by the Company and the Buyers of a purchase agreement relating to such Offered
Securities in the form executed by all of the purchasers of the Refused Securities.
(6) Any Offered Securities not
acquired by the Buyers or other persons in accordance with Section 4(o)(iii)(3) above may not be issued, sold or exchanged until they are again offered to the Buyers under the procedures specified in this Agreement.
(7) The Company and the Buyers agree that if any Buyer elects to participate in the Offer, (x) neither the Subsequent
Placement with respect to such Offer nor any other transaction documents related thereto (collectively, the Subsequent Placement Documents) shall include any term or provisions whereby any Buyer shall be required to agree to any
restrictions in trading as to any securities of the Company owned by such Buyer prior to such Subsequent Placement and (y) the Buyers shall be entitled to the same registration rights provided to the other investors in the Subsequent Placement.
33
(8) Notwithstanding anything to the contrary in this Section 4(o) and
unless otherwise agreed to by the Buyers, the Company shall either confirm in writing to the Buyers that the transaction with respect to the Subsequent Placement has been abandoned or shall publicly disclose its intention to issue the Offered
Securities, in either case in such a manner such that the Buyers will not be in possession of material non-public information, by the tenth (10th) Business Day following delivery of the Offer
Notice. If by the tenth (10th) Business Day following delivery of the Offer Notice no public disclosure regarding a transaction with respect to the Offered Securities has been made, and no
notice regarding the abandonment of such transaction has been received by the Buyers, such transaction shall be deemed to have been abandoned and the Buyers shall not be deemed to be in possession of any material, non-public information with respect
to the Company. Should the Company decide to pursue such transaction with respect to the Offered Securities, the Company shall provide each Buyer with another Offer Notice and each Buyer will again have the right of participation set forth in this
Section 4(o)(iii). The Company shall not be permitted to deliver more than one such Offer Notice to the Buyers in any 30 day period (other than the Offer Notices contemplated by the last sentence of Section 4(o)(iii)(2) of this Agreement).
(iv) The restrictions contained in subsections (ii) and (iii) of this Section 4(o) shall not apply in connection with the
issuance of any Excluded Securities (as defined in the Warrants).
(p) Shareholder Approval. The Company
shall file with the SEC and provide each shareholder of the Company with an information statement complying with the requirements of the 1934 Act and substantially in the form that has been previously reviewed and approved by the Buyers and Schulte
Roth & Zabel LLP at the expense of the Company informing such shareholders of the actions taken in accordance with the Resolutions and of the Shareholder Approval (each, as defined below). In addition to the foregoing, if required by any
governmental or regulatory agency, the Company shall provide each shareholder entitled to vote at a special or annual meeting of shareholders of the Company (the Shareholder Meeting), which shall be called at or prior to the
Companys next annual meeting of shareholders, but in no event later than the date that is seventy-five (75) days after the Closing Date (the Shareholder Meeting Deadline), a proxy statement, in a form reasonably
acceptable to the Buyers after review by Schulte Roth & Zabel LLP at the expense of the Company, not to exceed $15,000, soliciting each such shareholders affirmative vote at the Shareholder Meeting for approval of resolutions (the
Resolutions) providing for (i) a reverse stock split of the Common Stock to cause the Company to become compliant again with the maintenance and listing requirements of the Principal Market (the Reverse Stock
Split, the Resolution set forth in this clause (i) is referred to herein as the Reverse Stock Split Resolution and the date the reverse Stock Split has been obtained, the Reverse Stock Split Date)
and (ii) the amendment of the Companys Articles of Incorporation to increase the number of shares of the Companys authorized Common Stock by no less than the amount required to reserve the Required Reserve Amount pursuant to
Section 4(k) hereof (the Required Increase) (the Resolution set forth in this clause (ii) is referred to herein as the Authorized Shares Increase Resolution and the
34
date the Authorized Shares Increase Resolution has been obtained is referred to herein as the Authorized Shares Increase Resolution Date), in each case, in accordance with
applicable law, the provisions of the Articles of Incorporation and the rules and regulations of the Principal Market (such affirmative approvals being referred to herein collectively as the Shareholder Approval and the date such
approvals have been obtained, the Shareholder Approval Date), and the Company shall use its reasonable best efforts to solicit its shareholders approval of such Resolutions and to cause the Board of Directors of the Company
to recommend to the shareholders that they approve the Resolutions. The Company shall be obligated to seek to obtain the Shareholder Approval by the Shareholder Meeting Deadline. If, despite the Companys reasonable best efforts, the
Shareholder Approval is not obtained at the Shareholder Meeting, the Company shall cause an additional Shareholder Meeting to be held each calendar quarter thereafter until Shareholder Approval is obtained. Each time the Company seeks the approval
of its shareholders for the Shareholder Approval, the Companys Board of Directors shall recommend to the Companys shareholders that the shareholders vote in favor of the Shareholder Approval at the Shareholders Meeting and take all
reasonable action to solicit the approval of the shareholders for the Shareholder Approval. Each time the Company seeks the approval of its shareholders for the Shareholder Approval, the Companys Board of Directors shall recommend to the
Companys shareholders that the shareholders vote in favor of the Shareholder Approval at the Shareholders Meeting and take all reasonable action to solicit the approval of the shareholders for the Shareholder Approval. No later than five
(5) Business Days following the Authorized Shares Increase Resolution Date, the Company shall file with the Secretary of State of Colorado a certificate of amendment to the Companys Articles of Incorporation to effect the Authorized
Shares Increase Resolution such that the number of authorized shares of the Companys Common Stock is increased by no less than the Required Increase, which certificate of amendment shall provide that it shall become immediately effective upon
filing (the occurrence of such filing and the amendment filing, the Authorized Shares Increase Amendment).
(q) Warrant Share Characteristics. If Warrant Shares are issued upon exercise of the Warrants in a Cashless Exercise (as
defined in the Warrants), the Company acknowledges and agrees that in accordance with Section 3(a)(9) of the 1933 Act, the Warrant Shares shall take on the registered characteristics of the Warrants with respect to which such Warrant Shares are
being issued, and the holding period of such Warrants may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 4(q) for purposes of Section 3(a)(9) or Rule 144
of the 1933 Act.
(r) Reporting Status. Until the date on which the Buyers shall have sold all of the Warrant Shares
and none of the Warrants are outstanding (the Reporting Period), the Company shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, provided, that for the purposes of this Agreement, a
report shall not be considered untimely solely because it is filed after such reports due date, so long as it is filed within the time periods set forth in Rule 12b-25 of the 1934 Act (Rule 12b-25). Further, until such date,
the Company shall not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would no longer require or otherwise permit such termination, and the Company shall take
all commercially reasonable actions necessary to maintain its eligibility to issue Securities to the Buyers on Form S-3.
35
(s) Public Information. At any time during the period commencing
from the six (6) month anniversary of the Closing Date and ending at such time that all of the Securities, if a registration statement is not available for the resale of all of the Securities, may be sold without restriction or limitation
pursuant to Rule 144 and without the requirement to be in compliance with Rule 144(c)(1), if the Company shall (i) fail for any reason to satisfy the requirements of Rule 144(c)(1), including, without limitation, the failure to satisfy the
current public information requirement under Rule 144(c) or (ii) if the Company has ever been an issuer described in Rule 144(i)(1)(i) or becomes such an issuer in the future, and the Company shall fail to satisfy any condition set forth in
Rule 144(i)(2) (a Public Information Failure) then, as partial relief for the damages to any holder of Securities by reason of any such delay in or reduction of its ability to sell the Securities (which remedy shall not be
exclusive of any other remedies available at law or in equity), the Company shall pay to each such holder an amount in cash equal to one percent (1.0%) of the sum of (x) the aggregate Purchase Price of such Investors Common Shares
and Series E Warrants and (y) the Aggregate Exercise Price (as defined in the Series B Warrants) paid by such Investor for the exercise of the Series B Warrants of such Investor on the day of a Public Information Failure and on every thirtieth
day (pro-rated for periods totaling less than thirty days) thereafter until the earlier of (i) the date such Public Information Failure is cured and (ii) such time that such public information is no longer required pursuant to Rule 144.
The payments to which a holder shall be entitled pursuant to this Section 4(s) are referred to herein as Public Information Failure Payments. Public Information Failure Payments shall be paid on the earlier of (I) the
last day of the calendar month during which such Public Information Failure Payments are incurred and (II) the third Business Day after the event or failure giving rise to the Public Information Failure Payments is cured. In the event the Company
fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Notwithstanding the foregoing, no
payment shall be required if the Company fails to satisfy the current public information requirement set forth in Rule 144(c) during the grace period provided by Rule 12b-25, so long as the Company makes the applicable filing within the time periods
set forth in Rule 12b-25.
(t) Mandatory Exercise. Upon delivery by the Company of a Mandatory Exercise
Notice (as defined in the Series B Warrants), each Buyer shall deliver the Aggregate Exercise Price (as defined in the Series B Warrants) on the applicable Mandatory Exercise Date (as defined in the Series B Warrants) with respect to the Mandatory
Exercise Amount (as defined in the Series B Warrants) of the Series B Warrants subject to such Mandatory Exercise, so long as the Mandatory Exercise (as defined in the Series B Warrants) is effected pursuant to the terms and conditions of the
Mandatory Exercise set forth in Section 1(h) of the Series B Warrants, including, without limitation the satisfaction of the Equity Conditions (as defined in the Series B Warrants).
(u) Closing Documents. On or prior to twenty-five (25) calendar days after the Closing Date, the Company agrees to
deliver, or cause to be delivered, to each Buyer and Schulte Roth & Zabel LLP a complete closing set of the executed Transaction Documents, Securities and any other documents required to be delivered to any party pursuant to Section 7
hereof or otherwise.
(v) Series B & Series E Warrants. The Company hereby agrees that a Buyer may at any time
after the date hereof submit an Exercise Notice (as defined in each of the Series B Warrants and Series E Warrants) for the exercise of the Series B Warrants and Series E Warrants. The Series B Warrant Shares and Series E Warrant Shares shall be
required to be delivered by the Company to such Buyer on or prior to the applicable Share Delivery Date (as defined in each of the Series B Warrants and Series E Warrants, as applicable), subject to the Closing Date occurring on or prior to such
date.
36
5. REGISTER; TRANSFER AGENT INSTRUCTIONS.
(a) Register. The Company shall maintain at its principal executive offices (or such other office or agency of the
Company as it may designate by notice to each holder of Securities), a register for the Warrants in which the Company shall record the name and address of the Person in whose name the Warrants have been issued (including the name and address of each
transferee) and the number of Warrant Shares issuable upon exercise of the Warrants held by such Person. The Company shall keep the register open and available at all times during business hours for inspection of any Buyer or its legal
representatives.
(b) Transfer Agent Instructions. The Company shall issue irrevocable instructions to its transfer
agent, and any subsequent transfer agent, in a form acceptable to the Buyer (the Irrevocable Transfer Agent Instructions) to issue certificates or credit shares to the applicable balance accounts at DTC, registered in the name of
each Buyer or its respective nominee(s), for the Warrant Shares issued pursuant to the terms of the Transaction Documents in such amounts as specified from time to time by each Buyer to the Company upon exercise of the Warrants. The Company warrants
that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5(b) will be given by the Company to its transfer agent, and any subsequent transfer agent, and that the Securities shall otherwise be freely
transferable on the books and records of the Company as and to the extent provided in this Agreement and the other Transaction Documents. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to each
Buyer. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5 will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this
Section 5, that each Buyer shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity of showing economic loss and
without any bond or other security being required.
6. CONDITIONS TO THE COMPANYS OBLIGATION TO SELL.
The obligation of the Company hereunder to issue and sell the Common Shares and the related Warrants to each Buyer at the Closing is subject
to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Companys sole benefit and may be waived by the Company at any time in its sole discretion by providing each
Buyer with prior written notice thereof:
(a) Such Buyer shall have executed this Agreement and each other Transaction
Document to be executed by such Buyer, and delivered the same to the Company.
(b) Such Buyer shall have delivered its
Purchase Price to the Company (less, in the case of the Lead Investor, the amounts withheld pursuant to Section 4(f)) for the Common Shares and the related Series A Warrants, Series B Warrants, Series C Warrants, Series D Warrants and Series E
Warrants being purchased by such Buyer at the Closing by wire transfer of immediately available funds pursuant to an escrow account established by the Company and the Placement Agent with Signature Bank (or such other bank mutually agreed to by the
Company and the Agent), as escrow agent, in accordance with the Companys written wire instructions, which funds shall be subject to the terms and conditions of such escrow.
37
(c) The representations and warranties of such Buyer shall be true and correct in
all material respects (except for those representations and warranties that are qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects) as of the date when made and as of the Closing Date as though made
at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct in all material respects (except for those representations and warranties that are qualified by materiality or Material Adverse
Effect, which shall be true and correct in all respects) as of such specified date), and such Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be
performed, satisfied or complied with by such Buyer at or prior to the Closing Date.
(d) No litigation, statute, rule,
regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the
matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.
7. CONDITIONS
TO EACH BUYERS OBLIGATION TO PURCHASE.
The obligation of each Buyer hereunder to purchase the Common Shares and the related
Warrants at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for each Buyers sole benefit and may be waived by such Buyer at any time in its sole
discretion by providing the Company with prior written notice thereof:
(a) The Company shall have duly executed and
delivered to such Buyer, each of the following to which it is a party: (i) each of the Transaction Documents, (ii) the Common Shares (allocated in such amounts as such Buyer shall request), being purchased by such Buyer at the Closing
pursuant to this Agreement, (iii) the Series A Warrants (allocated in such amounts as such Buyer shall request) being purchased by such Buyer at the Closing pursuant to this Agreement, (iv) the Series B Warrants (allocated in such amounts
as such Buyer shall request) being purchased by such Buyer at the Closing pursuant to this Agreement, (v) the Series C Warrants (allocated in such amounts as such Buyer shall request) being purchased by such Buyer at the Closing pursuant to
this Agreement, (vi) the Series D Warrants (allocated in such amounts as such Buyer shall request) being purchased by such Buyer at the Closing pursuant to this Agreement and (vii) the Series E Warrants (allocated in such amounts as such
Buyer shall request) being purchased by such Buyer at the Closing pursuant to this Agreement.
(b) Such Buyer shall have
received the opinions of Brownstein Hyatt Farber Schreck, LLP, the Companys outside counsel, dated as of the Closing Date, in substantially the form of Exhibit I attached hereto.
(c) The Company shall have delivered to such Buyer a copy of the Irrevocable Transfer Agent Instructions, in the form
acceptable to such Buyer, which instructions shall have been delivered to and acknowledged in writing by the Companys transfer agent.
38
(d) The Company shall have delivered to such Buyer a certificate evidencing the
formation and good standing of the Company and each of its Significant Subsidiaries in such entitys jurisdiction of formation issued by the Secretary of State (or comparable office) of such jurisdiction, or a bring down of such good standing
from Corporation Service Company, as of a date within ten (10) days before the Closing Date.
(e) The Company shall
have delivered to such Buyer a certificate evidencing the Companys qualification as a foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which the Company conducts business, or
a bring down of such good standing from Corporation Service Company, as of a date within ten (10) days of the Closing Date.
(f) The Company shall have delivered to such Buyer a certified copy of the Articles of Incorporation of the Company and each of
its Subsidiaries as certified by the Secretary of State (or comparable office) of the jurisdiction of formation of the Company and each of its Subsidiaries within ten (10) days of the Closing Date.
(g) The Company shall have delivered to such Buyer a certificate, executed by the Secretary of the Company and dated as of the
Closing Date, as to (i) the resolutions consistent with Section 3(d) as adopted by the Companys and each of its Subsidiaries Board of Directors in a form reasonably acceptable to such Buyer, (ii) the Articles of
Incorporation of the Company and each of its Subsidiaries and (iii) the Bylaws of the Company and each of its Subsidiaries, each as in effect at the Closing, in the form attached hereto as Exhibit J.
(h) The representations and warranties of the Company shall be true and correct in all material respects (except for those
representations and warranties that are qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects) as of the date when made and as of the Closing Date as though made at that time (except for representations
and warranties that speak as of a specific date, which shall be true and correct in all material respects (except for those representations and warranties that are qualified by materiality or Material Adverse Effect, which shall be true and correct
in all respects) as of such specified date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or
complied with by the Company at or prior to the Closing Date. Such Buyer shall have received a certificate, executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the foregoing effect and as to such other matters as
may be reasonably requested by such Buyer in the form attached hereto as Exhibit K.
(i) The Company shall have
delivered to such Buyer a letter from the Companys transfer agent certifying the number of shares of Common Stock outstanding as of a date within five (5) days before the Closing Date.
(j) The Common Stock (I) shall be designated for quotation or listed on the Principal Market and (II) shall not have been
suspended, as of the Closing Date, by the SEC or the Principal Market from trading on the Principal Market, nor shall suspension by the SEC or the Principal Market have been threatened, as of the Closing Date, either (A) in writing by the SEC
or the Principal Market or (B) by falling below the minimum listing maintenance requirements of the Principal Market, other than as disclosed in the Registration Statement and Prospectus Supplement.
39
(k) The Company shall have obtained all governmental, regulatory or third party
consents and approvals, if any, necessary for the sale of the Securities and the transactions contemplated by the Transaction Documents and all payments thereunder.
(l) The Registration Statement shall be effective and available for the issuance and sale of the Securities hereunder and the
Company shall have delivered to such Buyer the Prospectus and the Prospectus Supplement as required thereunder.
(m) No
litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization
having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.
(n) The Company shall have delivered to each Buyer a Lock-Up Agreement in the form attached hereto as Exhibit F-2
executed and delivered by each of the Persons listed on Exhibit F-1 hereto.
(o) The Voting Agreement shall have
been executed and delivered to such Buyer by the Company and the Principal Shareholders.
(p) The Company shall have
delivered to such Buyer such other documents relating to the transactions contemplated by this Agreement as such Buyer or its counsel may reasonably request.
8. TERMINATION. In the event that the Closing shall not have occurred with respect to a Buyer on or before five (5) Business Days
from the date hereof due to the Companys or such Buyers failure to satisfy the conditions set forth in Sections 6 and 7 above (and the nonbreaching partys failure to waive such unsatisfied condition(s)), the nonbreaching party
shall have the option to terminate this Agreement with respect to such breaching party at the close of business on such date by delivering a written notice to that effect to each other party to this Agreement and without liability of any party to
any other party; provided, however, that if this Agreement is terminated pursuant to this Section 8, the Company shall remain obligated to reimburse the Lead Investor or its designee(s), as applicable, for the expenses described
in Section 4(f) above.
9. MISCELLANEOUS.
(a) Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and
interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that
would cause the application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan,
for the adjudication of any
40
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or
proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY
RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
(b) Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature shall be considered due execution and shall be binding upon the signatory
thereto with the same force and effect as if the signature were an original, not a facsimile signature.
(c)
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.
(d) Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or
unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or
unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the
subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the
benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as
possible to that of the prohibited, invalid or unenforceable provision(s).
(e) Entire Agreement; Amendments. This
Agreement and the other Transaction Documents supersede all other prior oral or written agreements between the Buyers, the Company, their affiliates and Persons acting on their behalf with respect to the matters discussed herein, and this Agreement,
the other Transaction Documents and the instruments referenced herein and therein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither
the Company nor any Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. Provisions of this Agreement may be amended and the observance
41
thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders who were issued on the
Closing Date a majority of the Common Shares and shall include the Lead Investor (the Required Holders). Any amendment or waiver effected in accordance with, and any amendment to this Agreement made in conformity with the
provisions of this Section 9(e) shall be binding on each Buyer and holders of Securities of the Company as applicable. No such amendment shall be effective to the extent that it applies to less than all of the Buyers of Securities. No
consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration (other than the reimbursement of legal fees) also is offered to
all of the parties to the Transaction Documents, the holders of Common Shares and holders of the Warrants. The Company has not, directly or indirectly, made any agreements with any Buyers relating to the terms or conditions of the transactions
contemplated by the Transaction Documents except as set forth in the Transaction Documents. Without limiting the foregoing, the Company confirms that, except as set forth in this Agreement, no Buyer has made any commitment or promise or has any
other obligation to provide any financing to the Company or otherwise.
(f) Notices. Any notices, consents, waivers
or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by
facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party) or by electronic mail; or (iii) one Business Day after deposit with an overnight courier service, in each case
properly addressed to the party to receive the same. The addresses, facsimile numbers and e-mail address for such communications shall be:
If to the Company:
Real Goods Solar, Inc.
833 West South Boulder Road,
Louisville, CO 80027
Telephone: (303) 222-8541
Facsimile: 1-877-835-4834
E-mail: Dennis.Lacey@rgsenergy.com
Attention: Dennis Lacey
with a copy (for informational purposes only) to:
Brownstein Hyatt Farber Schreck, LLP
410 Seventeenth Street, Suite 2200
Denver, CO 80202
Telephone: (303) 223-1100
Facsimile: (303) 223-1111
E-mail: KMacdonald@BHFS.com
Attention: Kristin M. Macdonald
42
If to the Transfer Agent:
Computershare Trust Company, N.A.
P.O. Box 30170
College Station, TX 77842-3170
Telephone: (800) 962-4284
Facsimile:
Attention: Agent
If to a Buyer, to its address, facsimile number and e-mail address set forth on the Schedule of Buyers, with copies to such Buyers representatives as
set forth on the Schedule of Buyers,
with a copy (for informational purposes only) to:
Schulte Roth & Zabel LLP
919 Third Avenue
New York, New York 10022
Telephone: (212) 756-2000
Facsimile: (212) 593-5955
Attention: Eleazer N. Klein, Esq.
E-mail: eleazer.klein@srz.com
or to such other address, facsimile number and/or email-address and/or to the attention of such other Person as the recipient party has
specified by written notice given to each other party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication,
(B) mechanically or electronically generated by the senders facsimile machine or e-mail containing the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided by an overnight courier
service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.
(g) Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their
respective successors and assigns, including any purchasers of the Warrants. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Required Holders, including by way of a
Fundamental Transaction (unless the Company is in compliance with the applicable provisions governing Fundamental Transactions set forth in the Warrants). A Buyer may assign some or all of its rights hereunder without the consent of the Company, in
which event such assignee shall be deemed to be a Buyer hereunder with respect to such assigned rights
(h) No Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except
that each Indemnitee shall have the right to enforce the obligations of the Company with respect to Section 9(k).
43
(i) Survival. Unless this Agreement is terminated under Section 8,
the representations and warranties of the Company and the Buyers contained in Sections 2 and 3, and the agreements and covenants set forth in Sections 4, 5 and 9 shall survive the Closing. Each Buyer shall be responsible only for its own
representations, warranties, agreements and covenants hereunder.
(j) Further Assurances. Each party shall do and
perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the
intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.
(k)
Indemnification. (i) In consideration of each Buyers execution and delivery of the Transaction Documents and acquiring the Securities thereunder and in addition to all of the Companys other obligations under the Transaction
Documents, the Company shall defend, protect, indemnify and hold harmless each Buyer and each other holder of the Securities and all of their shareholders, partners, members, officers, directors, employees and direct or indirect investors and any of
the foregoing Persons agents or other representatives (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the Indemnitees) from and against any
and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder
is sought), and including reasonable attorneys fees and disbursements (the Indemnified Liabilities), incurred by any Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of
any representation or warranty made by the Company in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation of the Company contained in
the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby or (c) any cause of action, suit or claim brought or made against such Indemnitee by a third party (including for these purposes a
derivative action brought on behalf of the Company) and arising out of or resulting from (i) the execution, delivery, performance or enforcement of the Transaction Documents or any other certificate, instrument or document contemplated hereby
or thereby, (ii) any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, (iii) any disclosure made by such Buyer pursuant to Section 4(h) or
(iv) the status of such Buyer or holder of the Securities as an investor in the Company, pursuant to the transactions contemplated by the Transaction Documents; provided, however, that the Company shall not shall be liable in any
such case solely to the extent that any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement or alleged untrue statement in, or omission or alleged omission from any Preliminary Prospectus, any
Registration Statement or the Prospectus, or any Issuer Free Writing Prospectus made in reliance upon and in conformity with written information furnished to the Company by or on behalf of any Buyer specifically for use therein. To the extent that
the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities that is permissible under applicable law.
44
(ii) Promptly after receipt by an Indemnitee under this Section 9(k) of
notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving an Indemnified Liability, such Indemnitee shall, if a claim for indemnification in respect thereof is to be made against any
indemnifying party under this Section 9(k), deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires,
jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnitee; provided, however, that an Indemnitee shall have the
right to retain its own counsel with the fees and expenses of not more than one counsel for such Indemnitee to be paid by the indemnifying party, if, in the reasonable opinion of the Indemnitee, the representation by such counsel of the Indemnitee
and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnitee and any other party represented by such counsel in such proceeding. Legal counsel referred to in the immediately preceding
sentence shall be selected by the Investors holding at least a majority of the Registrable Securities. The Indemnitee shall cooperate fully with the indemnifying party in connection with any negotiation or defense of any such action or Indemnified
Liabilities by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnitee that relates to such action or Indemnified Liabilities. The indemnifying party shall keep the Indemnitee fully
apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its prior written consent,
provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent of the Indemnitee, consent to entry of any judgment or enter
into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnitee of a release from all liability in respect to such Indemnified Liabilities or litigation.
Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnitee with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made.
The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnitee under this Section 9(k), except to the
extent that the indemnifying party is prejudiced in its ability to defend such action.
(iii) The indemnification required
by this Section 9(k) shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Liabilities are incurred.
(iv) The indemnity agreements contained herein shall be in addition to (x) any cause of action or similar right of the
Indemnitee against the indemnifying party or others, and (y) any liabilities the indemnifying party may be subject to pursuant to the law.
45
(v) Notwithstanding the forgoing, under no circumstances shall the Company or
its Subsidiaries, or their respective directors, officers, employees, consultants, agents or representatives, be responsible or liable for, and no Indemnitee shall be entitled to seek any consequential damages.
(l) No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties
to express their mutual intent, and no rules of strict construction will be applied against any party.
(m)
Remedies. Each Buyer and each holder of the Securities shall have all rights and remedies set forth in the Transaction Documents and all rights and remedies which such holders have been granted at any time under any other agreement or
contract and all of the rights which such holders have under any law. Any Person having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover
damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Company recognizes that in the event that it fails to perform, observe, or discharge any or all of its obligations
under the Transaction Documents, any remedy at law may prove to be inadequate relief to the Buyers. The Company therefore agrees that the Buyers shall be entitled to seek temporary and permanent injunctive relief in any such case without the
necessity of proving actual damages and without posting a bond or other security.
(n) Rescission and Withdrawal
Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) the Transaction Documents, whenever any Buyer exercises a right, election, demand or option under a Transaction Document and the
Company does not timely perform its related obligations within the periods therein provided, then such Buyer may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or
election in whole or in part without prejudice to its future actions and rights.
(o) Payment Set Aside. To the
extent that the Company makes a payment or payments to the Buyers hereunder or pursuant to any of the other Transaction Documents or the Buyers enforce or exercise their rights hereunder or thereunder, and such payment or payments or the proceeds of
such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee,
receiver or any other Person under any law (including, without limitation, any bankruptcy law, foreign, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof
originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.
(p) Independent Nature of Buyers Obligations and Rights. The obligations of each Buyer under any Transaction
Document are several and not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of any other Buyer under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Buyer pursuant hereto or
46
thereto, shall be deemed to constitute the Buyers as, and the Company acknowledges that the Buyers do not so constitute, a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Buyers are in any way acting in concert or as a group, and the Company shall not assert any such claim with respect to such obligations or the transactions contemplated by the Transaction Documents and the
Company acknowledges, and each Buyer confirms, that the Buyers are not acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. The Company acknowledges that it has independently
participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Buyer shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising
out of this Agreement or out of any other Transaction Documents, and it shall not be necessary for any other Buyer to be joined as an additional party in any proceeding for such purpose.
[Signature Page Follows]
47
IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page
to this Securities Purchase Agreement to be duly executed as of the date first written above.
|
|
|
COMPANY:
REAL GOODS SOLAR, INC. |
|
|
By: |
|
|
|
|
Name: Dennis Lacey Title: Chief
Executive Officer |
[Signature Page to Securities
Purchase Agreement]
IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page
to this Securities Purchase Agreement to be duly executed as of the date first written above.
|
|
|
BUYERS: |
|
[Lead Investor] |
|
|
By: |
|
[
] |
|
|
By: |
|
|
|
|
Name: |
|
|
Title: |
49
IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page
to this Securities Purchase Agreement to be duly executed as of the date first written above.
|
|
|
BUYERS: |
|
[OTHER BUYER] |
|
|
By: |
|
|
|
|
Name: |
|
|
Title: |
[Signature Page to Securities
Purchase Agreement]
SCHEDULE OF BUYERS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
(2) |
|
(2a) |
|
(3) |
|
|
(4)(a) |
|
|
(4)(b) |
|
|
(5) |
|
|
(6) |
Buyer |
|
Address, E-mail, Facsimile Number and Telephone Number |
|
Email and Telephone Number for Offer Notices |
|
Number of Common Shares |
|
|
Number of Series A Warrant Shares |
|
|
Number of Series E Warrant Shares |
|
|
Purchase Price |
|
|
Legal Representatives Address and Facsimile Number |
Lead Investor |
|
|
|
|
|
|
[ |
] |
|
|
[ |
] |
|
|
[ |
] |
|
$ |
[ |
] |
|
|
[Other Buyers] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EXHIBITS
|
|
|
Exhibit A |
|
Form of Series A/B/C/D/E Warrant |
Exhibit B |
|
[Reserved.] |
Exhibit C |
|
[Reserved.] |
Exhibit D |
|
[Reserved.] |
Exhibit E |
|
[Reserved.] |
Exhibit F-1 |
|
Parties to Lock-Up Agreement |
Exhibit F-2 |
|
Form of Lock-Up Agreement |
Exhibit G |
|
Form of Voting Agreement |
Exhibit H |
|
[Reserved.] |
Exhibit I |
|
Form of Opinion of Companys Outside Counsel |
Exhibit J |
|
Form of Secretarys Certificate |
Exhibit K |
|
Form of Officers Certificate |
SCHEDULES
|
|
|
Schedule I |
|
List of General Use Free Writing Prospectus |
Schedule 3(c) |
|
Significant Subsidiaries |
Schedule 3(f) |
|
Equity Capitalization |
Schedule 3(ff) |
|
Transactions with Affiliates |
Schedule 3(hh) |
|
Listing; 1934 Act Registration |
EXHIBIT A
Form of Series A/B/C/D/E Warrant
[Filed as Exhibit 4.1 to this Current Report on Form 8-K]
EXHIBIT F-1
Parties to Lock-Up Agreement
David L.
Belluck
Pavel Bousaka
Ian Bowles
Steven B. Kauffman
John Schaeffer
Robert L. Scott
Dennis Lacey
Alan Fine
EXHIBIT F-2
Form of Lock-Up Agreement
[Filed as Exhibit 10.2 to this Current Report on Form 8-K]
EXHIBIT G
Form of Voting Agreement
[Filed as Exhibit 10.3 to this Current Report on Form 8-K]
EXHIBIT I
Form of Opinion of Companys Outside Counsel
EXHIBIT J
Form of Secretarys Certificate
EXHIBIT K
Form of Officers Certificate
SCHEDULE I
List of General Use Free Writing Prospectus
None
SCHEDULE 3(c)
Significant Subsidiaries
Elemental
Energy, LLC
Real Goods Energy Tech, Inc.
RGS Financing,
Inc.
Mercury Energy, Inc.
Real Goods Solar, Inc.
Mercury Solar
Alteris Renewables, Inc.
Sunetric Management,
LLC
SCHEDULE 3(f)(ii)
Equity Capitalization
Warrant to issued
203,704 shares of Class A Common Stock issued to Silicon Valley Bank dated November 19, 2014.
SCHEDULE 3(ff)
Transactions with Affiliates
Columbia
Acorn Fund and Columbia Wanger Asset Management, LLC are affiliated with Columbia Management Investment Distributors, Inc., member FINRA.
SCHEDULE 3(hh)
Listing; 1934 Act Registration
On
December 15, 2014, Real Goods Solar, Inc. (the Company) received a letter from The Nasdaq Stock Market (NASDAQ) notifying the Company that for the last 30 consecutive business days the bid price of the Companys
Class A common stock had closed below the minimum $1.00 per share requirement for continued inclusion on NASDAQ based on Listing Rule 5550(a)(2), and describing a timetable for bringing the Company into compliance with that rule. The
Company disclosed this notification on a Form 8-K filed on December 19, 2014.
In addition the Company may not be able to continue to meet the
Shareholder Equity listing standards for the Nasdaq Capital Market and may in the future receive a delisting notification with respect to a failure to meet that standard.
Exhibit 10.2
REAL GOODS SOLAR, INC.
Form of Lock-Up Agreement
February , 2015
Real
Goods Solar, Inc.
833 West South Boulder Road,
Louisville,
CO 80027
Telephone: 303-222-8400
Re: Real Goods Solar, Inc. - Lock-Up Agreement
Dear Sirs:
This Lock-Up Agreement is being
delivered to you in connection with the Securities Purchase Agreement (the Purchase Agreement), dated as of February , 2015 by and among Real Goods Solar, Inc. (the Company), and the
investors party thereto (the Buyers), with respect to the issuance of (i) shares of Class A common stock of the Company, par value $0.0001 per share (the Common Stock), and (ii) Series A Warrants,
Series B Warrants, Series C Warrants, Series D Warrants and, to certain Buyers, Series E Warrants, each of which is exercisable to purchase shares of Common Stock. Capitalized terms used herein and not otherwise defined herein shall have the
respective meanings set forth in the Purchase Agreement.
In order to induce the Buyers to enter into the Purchase Agreement, the
undersigned agrees that, commencing on the date hereof and ending on the date that is six (6) months immediately following the Closing Date (the Lock-Up Period), the undersigned will not, and will cause all affiliates (as
defined in Rule 144 promulgated under the Securities Act of 1933, as amended) of the undersigned or any person in privity with the undersigned or any affiliate of the undersigned not to (i) sell, offer to sell, contract or agree to sell,
hypothecate, pledge, grant any option to purchase, make any short sale or otherwise dispose of or agree to dispose of, directly or indirectly, any shares of Common Stock or Common Stock Equivalents, or establish or increase a put equivalent position
or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities and Exchange Act of 1934, as amended and the rules and regulations of the Securities and Exchange Commission promulgated thereunder with
respect to any shares of Common Stock or Common Stock Equivalents owned directly by the undersigned (including holding as a custodian) or with respect to which the undersigned has beneficial ownership within the rules and regulations of the
Securities and Exchange Commission (collectively, the Undersigneds Shares), or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of any of the Undersigneds Shares, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of shares of Common Stock or other securities, in cash or otherwise, (iii) make any demand for or
exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of Common Stock or Common Stock Equivalents or (iv) publicly disclose the intention to do any of
the foregoing.
The foregoing restriction is expressly agreed to preclude the undersigned, and any affiliate of
the undersigned and any person in privity with the undersigned or any affiliate of the undersigned, from engaging in any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or
disposition of the Undersigneds Shares even if the Undersigneds Shares would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions would include, without limitation, any short sale or any
purchase, sale or grant of any right (including, without limitation, any put or call option) with respect to any of the Undersigneds Shares or with respect to any security that includes, relates to, or derives any significant part of its value
from the Undersigneds Shares.
Notwithstanding the foregoing, the undersigned may transfer the Undersigneds Shares (i) as
a bona fide gift or gifts, provided that the donee or donees thereof agree to be bound in writing by the restrictions set forth herein or (ii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of
the undersigned, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value. For purposes of this Lock-Up
Agreement, immediate family shall mean any relationship by blood, marriage or adoption, not more remote than first cousin. The undersigned now has, and, except as contemplated by the immediately preceding sentence, for the duration of
this Lock-Up Agreement will have, good and marketable title to the Undersigneds Shares, free and clear of all liens, encumbrances, and claims whatsoever. The undersigned also agrees and consents to the entry of stop transfer instructions with
the Companys transfer agent (the Transfer Agent) and registrar against the transfer of the Undersigneds Shares except in compliance with the foregoing restrictions.
In order to enforce this covenant, the Company shall impose irrevocable stop-transfer instructions preventing the Transfer Agent from
effecting any actions in violation of this Lock-Up Agreement.
The undersigned acknowledges that the execution, delivery and performance
of this Lock-Up Agreement is a material inducement to each Buyer to complete the transactions contemplated by the Purchase Agreement and that the Company shall be entitled to specific performance of the undersigneds obligations hereunder. The
undersigned hereby represents that the undersigned has the power and authority to execute, deliver and perform this Lock-Up Agreement, that the undersigned has received adequate consideration therefor and that the undersigned will indirectly benefit
from the closing of the transactions contemplated by the Purchase Agreement.
The undersigned understands and agrees that this Lock-Up
Agreement is irrevocable and shall be binding upon the undersigneds heirs, legal representatives, successors, and assigns.
This
Lock-Up Agreement may be executed in two counterparts, each of which shall be deemed an original but both of which shall be considered one and the same instrument.
This Lock-Up Agreement will be governed by and construed in accordance with the laws of the State
of New York, without giving effect to any choice of law or conflicting provision or rule (whether of the State of New York, or any other jurisdiction) that would cause the laws of any jurisdiction other than the State of New York to be applied. In
furtherance of the foregoing, the internal laws of the State of New York will control the interpretation and construction of this Lock-Up Agreement, even if under such jurisdictions choice of law or conflict of law analysis, the substantive
law of some other jurisdiction would ordinarily apply.
[Remainder of page intentionally left blank]
|
Very truly yours, |
|
|
Exact Name of Shareholder |
|
|
Authorized Signature |
|
|
Title |
|
|
|
Agreed to and Acknowledged: |
|
REAL GOODS SOLAR, INC. |
|
|
By: |
|
|
|
|
Name: |
|
|
Title: |
[Signature Page to Lock-Up
Agreement]
Exhibit 10.3
Form of
VOTING AGREEMENT
VOTING AGREEMENT, dated as of February , 2015 (this Agreement), by and among Real Goods
Solar, Inc., a Colorado corporation (the Company), and the shareholders listed on the signature pages hereto under the heading Shareholders (each, a Shareholder and collectively, the
Shareholders).
WHEREAS, the Company and certain investors (each, an Investor, and
collectively, the Investors) have entered into a Securities Purchase Agreement, dated as February , 2015 (the Securities Purchase Agreement), pursuant to which, among other things, the
Company has agreed to issue and sell to the Investors and the Investors have agreed to purchase, (i) shares of Class A common stock, par value $0.0001 per share, of the Company (the Common Stock) and (iii) up to
five (5) series of warrants which will be exercisable to purchase shares of Common Stock;
WHEREAS, as of the date hereof, the
Shareholders own collectively [ ] shares of Common Stock, which represent in the aggregate approximately
[ ]% of the total issued and outstanding capital stock of the Company; and
WHEREAS,
as a condition to the willingness of the Investors to enter into the Securities Purchase Agreement and to consummate the transactions contemplated thereby (collectively, the Transaction), the Investors have required that each
Shareholder agrees, and in order to induce the Investors to enter into the Securities Purchase Agreement, each Shareholder has agreed, to enter into this Agreement with respect to all the Common Stock now owned and which may hereafter be acquired by
the Shareholders and any other securities, if any, which such Shareholder is currently entitled to vote, or after the date hererof, becomes entitled to vote, at any meeting of shareholders of the Company (the Other Securities).
NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements contained herein, and intending to be
legally bound hereby, the parties hereto hereby agree as follows:
ARTICLE I
VOTING AGREEMENT OF THE SHAREHOLDER
SECTION 1.01. Voting Agreement. Subject to the last sentence of this Section 1.01, each Shareholder hereby agrees that at any
meeting of the shareholders of the Company, however called, and in any action by written consent of the Companys shareholders, each of the Shareholders shall vote the Common Stock and the Other Securities: (a) in favor of the Shareholder
Approval (as defined in the Securities Purchase Agreement) as described in Section 4(p) of the Securities Purchase Agreement; and (b) against any proposal or any other corporate action or agreement that would result in a breach of any
covenant, representation or warranty or any other obligation or agreement of the Company under the Securities Purchase Agreement or which could result in any of the conditions to the Companys obligations under the Securities Purchase Agreement
not being fulfilled. Each Shareholder acknowledges receipt and review of a copy of the Securities Purchase Agreement and the other Transaction Documents (as defined in the Securities Purchase Agreement). The obligations of the Shareholders under
this Section 1.01 shall terminate immediately following the occurrence of the Shareholder Approval.
ARTICLE II
REPRESENTATIONS AND WARRANTIES OF THE SHAREHOLDER
Each Shareholder hereby represents and warrants, severally but not jointly, to each of the Investors as follows:
SECTION 2.01. Authority Relative to This Agreement. Each Shareholder has all necessary legal capacity, power and authority to execute
and deliver this Agreement, to perform his or its obligations hereunder and to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by such Shareholder and constitutes a legal, valid and binding
obligation of such Shareholder, enforceable against such Shareholder in accordance with its terms, except (a) as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or
similar laws now or hereafter in effect relating to, or affecting generally the enforcement of creditors and other obligees rights, (b) where the remedy of specific performance or other forms of equitable relief may be subject to
certain equitable defenses and principles and to the discretion of the court before which the proceeding may be brought, and (c) where rights to indemnity and contribution thereunder may be limited by applicable law and public policy.
SECTION 2.02. No Conflict. (a) The execution and delivery of this Agreement by such Shareholder does not, and the performance of
this Agreement by such Shareholder shall not, (i) conflict with or violate any federal, state or local law, statute, ordinance, rule, regulation, order, judgment or decree applicable to such Shareholder or by which the Common Stock or the Other
Securities owned by such Shareholder are bound or affected or (ii) result in any breach of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, or result in the creation of a lien or encumbrance on any of the Common Stock or the Other Securities owned by such Shareholder pursuant to, any note, bond, mortgage, indenture, contract,
agreement, lease, license, permit, franchise or other instrument or obligation to which such Shareholder is a party or by which such Shareholder or the Common Stock or Other Securities owned by such Shareholder are bound.
(b) The execution and delivery of this Agreement by such Shareholder does not, and the performance of this Agreement by such Shareholder shall
not, require any consent, approval, authorization or permit of, or filing with or notification to, any governmental entity by such Shareholder.
SECTION 2.03. Title to the Stock. As of the date hereof, each Shareholder is the owner of the number of shares of Common Stock set
forth opposite its name on Appendix A attached hereto, entitled to vote, without restriction, on all matters brought before holders of capital stock of the Company, which Common Stock represent on the date hereof the percentage of the
outstanding stock and voting power of the Company set forth on such Appendix. Such Common Stock are all the securities of the Company owned, either of record or beneficially, by such Shareholder. Such Common Stock are owned free and clear of all
security interests, liens, claims, pledges, options, rights of first refusal, agreements, limitations on such Shareholders voting rights, charges and other encumbrances of any nature whatsoever. No Shareholder has appointed or granted any
proxy, which appointment or grant is still effective, with respect to the Common Stock or Other Securities owned by such shareholder.
2
ARTICLE III
COVENANTS
SECTION 3.01.
No Disposition or Encumbrance of Stock. Notwithstanding anything herein to the contrary, each Shareholder hereby covenants and agrees that, until the earlier of (i) the date the Shareholder Approval has been obtained and (ii) the
date the Company sought to obtain the Shareholder Approval for the third (3rd) time pursuant to the provisions of Section 4(p) of the Securities Purchase Agreement, except as
contemplated by this Agreement, such Shareholder shall not offer or agree to sell, transfer, tender, assign, hypothecate or otherwise dispose of, grant a proxy or power of attorney with respect to, or create or permit to exist any security interest,
lien, claim, pledge, option, right of first refusal, agreement, limitation on such Shareholders voting rights, charge or other encumbrance of any nature whatsoever (Encumbrance) with respect to the Common Stock or Other
Securities, directly or indirectly, initiate, solicit or encourage any person to take actions which could reasonably be expected to lead to the occurrence of any of the foregoing; provided, however, that any such Shareholder may
assign, sell or transfer any Common Stock or Other Securities provided that any such recipient of the Common Stock or Other Securities has delivered to the Company and each Investor a written agreement in a form reasonably satisfactory to the
Investors that the recipient shall be bound by, and the Common Stock and/or Other Securities so transferred, assigned or sold shall remain subject to this Agreement.
SECTION 3.02. Company Cooperation. The Company hereby covenants and agrees that it will not, and such Shareholder irrevocably and
unconditionally acknowledges and agrees that the Company will not (and waives any rights against the Company in relation thereto), recognize any Encumbrance or agreement on any of the Common Stock or Other Securities subject to this Agreement unless
the provisions of Section 3.01 have been complied with. The Company agrees to use its reasonable best efforts to ensure that at any time in which any Shareholder Approval is required pursuant to Section 4(p) of the Securities Purchase
Agreement, it will cause holders of Common Stock or Other Securities representing the percentage of outstanding capital stock required to vote in favor of the Transaction in order for the Company to comply with its obligations under
Section 4(p) of the Securities Purchase Agreement to become party to and bound by the terms and conditions of this Agreement and the Common Stock and Other Securities held by such holders to be subject to the terms and conditions of this
Agreement.
ARTICLE IV
MISCELLANEOUS
SECTION
4.01. Further Assurances. Each Shareholder will execute and deliver such further documents and instruments and take all further action as may be reasonably necessary in order to consummate the transactions contemplated hereby.
SECTION 4.02. Specific Performance. The parties hereto agree that irreparable damage would occur in the event any provision of this
Agreement was not performed in accordance with the terms hereof and that any Investor (without being joined by any other Investor) shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity.
Any Investor shall be entitled to its reasonable attorneys fees in any action brought to enforce this Agreement in which it is the prevailing party.
3
SECTION 4.03. Entire Agreement. This Agreement constitutes the entire agreement among the
Company and the Shareholders with respect to the subject matter hereof and supersedes all prior agreements and understandings, both written and oral, among the Company and the Shareholders with respect to the subject matter hereof.
SECTION 4.04. Amendment. The provisions of this Agreement may not be amended or waived, nor may this Agreement be terminated by the
Company other than pursuant to the provisions of Section 4.07.
SECTION 4.05. Severability. If any provision of this Agreement
is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that
it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material
change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal
obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a
valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).
SECTION 4.06. Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the
laws of any jurisdictions other than the State of New York. The parties hereby agree that all actions or proceedings arising directly or indirectly from or in connection with this Agreement shall be litigated only in the Supreme Court of the State
of New York or the United States District Court for the Southern District of New York located in New York County, New York. The parties consent to the jurisdiction and venue of the foregoing courts and consent that any process or notice of motion or
other application to any of said courts or a judge thereof may be served inside or outside the State of New York or the Southern District of New York by registered mail, return receipt requested, directed to the party being served at its address set
forth on the signature ages to this Agreement (and service so made shall be deemed complete three (3) days after the same has been posted as aforesaid) or by personal service or in such other manner as may be permissible under the rules of said
courts. Each of the Company and each Shareholder irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the venue of any such suit, action, or proceeding brought in such a court
and any claim that suit, action, or proceeding has been brought in an inconvenient forum. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
4
SECTION 4.07. Termination. Except as set forth in Section 3.01 with respect to the
Shareholders obligations set forth in Section 3.01, this Agreement shall terminate immediately following the occurrence of the Shareholder Approval.
[Signature Page Follows]
5
IN WITNESS WHEREOF, each Shareholder and the Company has duly executed this Agreement.
|
|
|
|
|
|
|
THE COMPANY: |
|
|
|
|
Real Goods Solar, Inc. |
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
|
Name: |
|
|
Title: |
|
|
|
Dated: February , 2015 |
|
|
|
|
|
|
|
|
|
Address: |
|
Real Goods Solar, Inc. 833 West South
Boulder Road, Louisville, CO 80027 |
|
|
|
|
|
|
|
SHAREHOLDERS:
[ ] |
|
|
|
|
|
|
|
Dated: February , 2015 |
|
|
|
|
|
|
Address: |
|
|
|
|
|
|
|
SHAREHOLDERS:
[ ] |
|
|
|
|
|
|
|
Dated: February , 2015 |
|
|
|
|
|
|
Address: |
APPENDIX A
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholder |
|
Common Stock Owned |
|
|
Percentage of Stock Outstanding |
|
|
Voting Percentage of Stock Outstanding |
|
Riverside Renewable Energy Investment LLC |
|
|
|
|
|
|
|
|
|
|
|
|
[ ] |
|
|
[ |
] |
|
|
[ |
]% |
|
|
[ |
]% |